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Abstract 
Mammalian cells generally require both mitogens and anchorage signals 
in order to proliferate.  Failure to receive these signals results in either cell-cycle 
arrest or cell death, known as anoikis, due to activation of anchorage-dependent 
checkpoint mechanisms.   Transformed cells alleviate these checkpoints, via 
activation of oncogenes and/or inactivation of tumour suppressors.  In contrast, 
detachment  of  normal  cells  halts  cell-cycle  progression  in  G1,  because  of 
insufficient  cyclin  D1  induction  to  overcome  the  Rb/E2F  checkpoint, 
accumulation  of  cyclin-dependent  kinase  inhibitors,  and  lack  of  cyclin  A 
production.  Because of the complexity of anchorage-dependent mechanisms 
involved,  several  changes  are  required  for  cells  to  become  anchorage 
independent: impairment of both Rb and p53 pathways, plus activation of Ras.  
These  specific  defects  are  found  in  many  human  cancers,  and  anchorage 
independence correlates strongly with tumourigenic potential.  Here I have used 
cells  expressing  SV40  LT,  with  and  without  oncogenic  Ras,  to  model  the 
changes  leading  to  anchorage  independent  proliferation.    Importantly,  cells 
expressing SV40 LT alone retain their anchorage dependence, despite Rb and 
p53 inactivation.  However, the mechanism responsible for this cell-cycle arrest 
in suspension is not known.  Using immunoprecipitation and kinase assays, I 
demonstrated  that  the  cyclin-dependent  kinase  inhibitor  p27  curbs  cell-cycle 
progression in these cells.  FACS analysis showed that surprisingly, these cells 
do not undergo a robust checkpoint arrest, but instead stall throughout the cell 
cycle, showing abnormal DNA replication.  Further investigation by metaphase 
spread  showed  the  accumulation  of  aneuploid  nuclei,  indicating  the 
development  of  genomic  instability.    This  resulted  in  a  higher  rate  of 
transformation among cells cultured without anchorage for a limited time.  This 
work demonstrates that anchorage signals enable proper activation as well as 
assembly  of  cyclin-dependent  kinase  complexes,  and  that  adhesion  is 
particularly  important  for  maintaining  orderly  cell-cycle  progression  and 
preventing genomic instability in checkpoint-deficient cells.   4 
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Chapter One – Introduction 
1.1 The cell cycle 
Cell division is a fundamental property of living things, enabling the 
reproduction of unicellular organisms such as yeasts, bacteria and amoebae, and 
the development and maintenance of multicellular organisms from humans to 
jellyfish.  The cell cycle is the process by which one cell gives rise to two cells, 
and the main aim of this complex sequence of events is to accurately reproduce 
and equally segregate genetic material between the two daughter cells.  This 
allows  coordinated  expression  from  an  identical  genome  throughout  the 
organism, and enables inheritance of genetic traits by the cellular offspring.   In 
addition, regulatory mechanisms ensure that each new cell contains the means 
to  support  itself  via  energy  production,  and  the  structural  components  to 
maintain itself as an entity.  Further mechanisms determine when and how a cell 
enters and leaves the dividing state.  For over 50 years, cell division has been 
investigated  at  the  molecular  level,  and  new  complexities  are  still  being 
revealed.   
Mutations and defects at all levels of cell cycle regulation may lead to 
uncontrolled  cell  proliferation  and  cancer.    Given  the  many  trillions  of  cell 
divisions  that  take  place  over  the  lifetime  of  a  human,  these  regulatory 
mechanisms  are  remarkably  effective  at  guarding  against  tumourigenesis.  
Nevertheless, cancer was responsible for 13% of all deaths worldwide in 2007, 
according to the World Health Organisation, and thus remains the subject of 
intense  research.    Although  there  are  differences  in  cell  cycle  regulation 
between different species and cell types, the broad similarities in the process 
and the remarkable conservation of the underlying genes and proteins involved 
has  meant  that  important  breakthroughs  in  cancer  research  have  been  made 
using model organisms as diverse as yeast, flies, frogs and mice.  This chapter 
will introduce the key aspects of cell cycle regulation relevant to the research in 
mammalian cells presented in this thesis. 
   14 
1.1.1 Phases of the cell cycle 
To describe the eukaryotic cell cycle, it has historically been divided 
into phases, at first on the basis of simple microscopic observation, and then 
further subdivided, as more biochemical processes which occur at specific times 
in the cell cycle have been described.  Initially, proliferating cells were observed 
in either ‘mitosis’, partitioning their chromosomes equally into daughter nuclei, 
or ‘interphase’, the intervening period between cell divisions.  ‘M’ phase refers 
to both segregation of the genome at mitosis, and to the physical separation of 
cytoplasm to contain the two new nuclei in separate daughter cells, known as 
cytokinesis.  Within interphase is the DNA synthesis or ‘S’ phase, where the 
genome  is  replicated.  The  exact  replication  of  the  genome  to  produce  two 
identical  copies,  and  the  inheritance  of  precisely  one  copy  of  the  genetic 
material by the two daughter cells, are the fundamental objectives of the cell 
division cycle.  The simplest cell cycles therefore consist of alternating S and M 
phases, such as the early embryonic cell divisions of the frog Xenopus laevis, 
and  the  syncytial  nuclear  divisions  that  take  place  in  the  embryo  of  the  fly 
Drosophila melanogaster (where cytokinesis is also absent).  However, these 
are special cases, when rapid divisions take place without growth in order to 
create a multicellular embryo from the large fertilised egg.  In most cases, S and 
M phases are separated from each other by two ‘gap’ phases designated G1 
(post-mitosis)  and  G2  (pre-mitosis).    This  allows  time  for  cell  growth,  to 
maintain the average size of cells in a homeostatic population.  During this time, 
extracellular  signals  from  growth  factors,  mitogens,  surrounding  cells  and 
extracellular matrix proteins are also integrated to control cell cycle progression 
and timing.  Clear separation of S and M phases means that the key processes of 
genomic duplication and division  are insulated from each other, so that cell 
division cannot occur before DNA replication is complete, and vice versa.  This 
ensures  faithful  inheritance  of  the  complete  genome  by  each  cell  and  thus 
assures the future competence of the organism.   
In  special  cases,  cell  division  occurs  without  DNA  replication,  as  in 
meiosis to produce the haploid gametes; or DNA replication occurs without cell 
division, as in the endoreduplication cycles of the placental trophoblast giant   15 
cells  in  mice.    However,  these  examples  require  specific  controls,  which 
override normal cell cycle progression.  
In addition to the equal segregation of genetic material, organelles such 
as mitochondria and Golgi must be distributed between the two daughter cells.  
This is not a passive process, and is achieved by association of the fragmented 
organelles with components of the cytoskeleton (Shima et al. 1998; Boldogh et 
al. 2001).  Other key proteins are also actively distributed between daughter 
cells, sometimes  accumulating in a polarised manner in the mother cell and 
segregating predominantly to one of the two daughter cells.  This is known as 
asymmetric  division,  which  is  especially  common  during  development  as  a 
mechanism  of  producing  cells  with  different  fates,  and  also  occurs  in  the 
production of differentiated cell types from stem cells, where one daughter is 
retained as a stem cell.   
In  a  continually  proliferating  population,  the  four  cell  cycle  phases 
repeat in a loop (Figure 1- 1), so that newly produced cells from M phase return 
to G1 and continue to S phase, then G2, and so on.  This results in a doubling of 
the  cell  population  with  each  completed  cell  cycle,  leading  to  exponential 
population  growth  under  ideal  conditions.  Conversely,  in  the  absence  of 
mitogenic factors, or the presence of inhibitory signals, newborn cells stop cell 
cycle progression, known as ‘arrest’, and may exit from the cell cycle altogether 
to a state known as ‘quiescence’ or G0.  Quiescent cells are still receptive to 
external signals even though they are not actively dividing, and the cell cycle 
arrest  is  reversible  following  re-stimulation  with  mitogens,  allowing  cells  to 
return to the cell cycle.  Importantly, early cell culture experiments using serum 
as a source of mitogens found that although serum withdrawal in early G1 phase 
led  to  quiescence,  removal  of  mitogen  signals  at  later  phases  did  not 
immediately arrest the cells, and they were able to complete one cell cycle and 
return to G1 before arresting (Temin 1971; Zetterberg and Larsson 1985).   This 
transition  from  a  mitogen-dependent  to  a  mitogen-independent  state  should 
ensure that S and M phases are always completed once started, regardless of the 
persistence of external signals, so that cells are not left with partially replicated 
or separated DNA.  The point of commitment to cell division was classically 
known as the ‘restriction point’, from which cells enter quiescence and where   16 
 
 
 
 
 
 
Figure 1- 1: Phases of the cell cycle. 
Diagram shows the relative positions of the mitotic (M), DNA synthesis (S) and gap 
(G1, G2) phases in the mammalian cell cycle. R indicates Pardee’s restriction point, 
where  cells  may  exit  the  cycle  to  the  quiescent  (G0)  state,  and  where  cell  cycle 
progression becomes mitogen-independent (see text).  Diagram adapted from review 
(Baserga 1965).   17 
they re-enter the cell cycle when stimulated with mitogens (Pardee 1974).  More 
permanent exit from the cell cycle occurs when cells cease to proliferate in 
response  to  mitogens:  for  example  in  cellular  senescence  following 
environmental  stress  (Blagosklonny  2003),  or  physiologically,  during  cell 
differentiation (Walsh and Perlman 1997).  
 
The process of mitosis can itself be subdivided into stages according to 
observable features visible under the microscope (Figure 1- 2).  These include: 
(1)  Prophase,  in  which  chromosomes  condense.    Sister 
chromatids of replicated DNA produced in S phase remain 
held  together  by  cohesin  rings.    Duplicated  centrosomes 
separate and move to opposite poles.  
(2)  Prometaphase, where the nuclear envelope breaks down and 
microtubules  form  a  ‘spindle’  from  opposite  cell  poles 
around the condensed chromosomes.  Microtubules attach to 
the central kinetochore of each chromosome. 
(3)  Metaphase,  where  chromosomes  stably  attached  to  both 
spindle poles align at the equator of the cell.  Kinetochores 
are  under  tension,  produced  by  motor  forces  on  opposing 
spindle microtubules pulling towards the poles.  
(4)  Anaphase, the separation of the chromatid pairs to opposite 
sides of the cell.  When cohesin rings are cleaved, tension is 
released, the opposing forces acting on the kinetochores pull 
the  sister  chromatids  apart,  and  they  move  towards  the 
spindle poles. 
(5)  Telophase, the reformation of nuclear envelope around each 
new  set  of  chromosomes,  and  decondensation  of  the 
chromatin.   
These stages are all continuous, not discrete steps, with the important exception 
of the metaphase to anaphase transition, which occurs suddenly and only upon 
successful bipolar attachment of every chromosome to the mitotic spindle.  This 
is a key control point in the cell cycle, and will be discussed in more detail later.   18 
  
 
 
 
 
 
Figure 1- 2: Stages of the cell cycle as seen by fluorescence microscopy. 
Stages of mitosis (prophase, prometaphase, metaphase, anaphase, and telophase) are 
shown, along with cytokinesis and interphase (see text).  Chromatin is indicated in blue 
and microtubules in green.  Illustration adapted from Wan laboratory, University of 
Pittsburgh Cancer Institute. 
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The progression from G1 to S phase to G2 to  M phase and through 
mitosis and cytokinesis must be strictly controlled in sequence to ensure that 
each cell inherits a complete, intact genome.  Two key processes drive cell cycle 
progression  forward:  phosphorylation  of  target  proteins  by  cyclin-dependent 
kinase (CDK) complexes; and protein ubiquitination, notably by the anaphase-
promoting  complex/cyclosome  (APC)  and  the  Skp1/cullin/F-box  protein 
complex  (SCF),  which  tag  proteins  for  degradation  by  the  proteasome.  The 
phosphorylation of proteins is readily reversible, and determines their activity 
and/or structural conformation, often restricting activity to a particular period of 
time.    Proteolytic  degradation,  in  contrast,  is  irreversible,  and  allows  rapid 
removal of proteins once they are no longer needed, facilitating the transition 
forward to the next stage of the cell cycle.  Both mechanisms are partly self-
regulating, in that CDK complexes are themselves controlled by CDK-mediated 
phosphorylation (Fisher and Morgan 1994; Welcker et al. 2003), and both APC 
and SCF components are themselves targets for APC-mediated ubiquitination 
(Shirayama et al. 1998; Bashir et al. 2004; Wei et al. 2004).  Additionally, the 
CDK  phosphorylation  and  APC  ubiquitination  mechanisms  are  mutually 
regulating (Zachariae et al. 1998).  Robust, irreversible switching from one cell 
cycle  stage  to  the  next  is  achieved  by  this  complex  network  of  protein 
signalling, including both positive and negative feedback loops (Novak et al. 
2007).  The following sections describe the individual proteins involved in more 
detail. 
 
1.1.2 Cyclin-CDK complexes control cell cycle progression 
1.1.2.1 Discovery of cyclin-CDK complexes 
The  key  drivers  of  cell  cycle  progression  are  the  cyclin-dependent 
kinases or CDKs, which are activated at specific times, primarily by the binding 
of protein partners known as cyclins. These were named due to their regular 
appearance and disappearance in sea urchin eggs over time, with a periodicity 
that  corresponded  to  the  timing  of  the  cell  cycle  (Evans  et  al.  1983).  
Historically, the existence of the canonical cyclin-CDK complex as a controller 
of  cell  division  was  elucidated  by  a  combination  of  data  from  yeast  (both 
Saccharomyces cerevisiae and Saccharomyces pombe) and frog oocytes (Rana   20 
pipiens and Xenopus laevis), as well as clam and sea urchin eggs.  In yeast, 
screens of temperature-sensitive mutant strains identified several ‘cell division 
control’ (cdc) mutants which failed to divide at the restrictive temperature: in 
particular, the cdc28 mutant of S. cerevisiae (Hartwell et al. 1974) and the cdc2 
mutant of S. pombe (Nurse and Thuriaux 1980).  cdc28 and cdc2 genes were 
later found to be homologous (Beach et al. 1982), and both encoded a protein 
with kinase activity (Reed et al. 1985; Simanis and Nurse 1986).  Meanwhile, 
an unknown activity present in mature oocyte cytoplasm was found to promote 
meiosis of immature frog oocytes and named ‘maturation-promoting factor’, or 
MPF (Masui and Markert 1971; Smith and Ecker 1971).  Cytoplasm from an M-
phase cell, but not an interphase cell, induced M-phase entry when injected into 
an immature oocyte.  A similar factor causing frog oocyte maturation was found 
to be present in mitotic human cells (Sunkara et al. 1979).  Following the initial 
discovery of cyclins A and B in sea urchin oocytes (Evans et al. 1983), cyclin A 
was cloned from clam embryos, and the mRNA was found to trigger M phase 
entry  in  Xenopus  oocytes  (Swenson  et  al.  1986).    MPF  was  purified  from 
Xenopus oocytes and found to be composed of two subunits of approximately 
34  and  45kDa  (Lohka  et  al.  1988),  which  were  later  discovered  to  be 
homologous to cdc2 kinase and cyclin B respectively, by binding to antibodies 
against  those  proteins  (Gautier  et  al.  1988;  Gautier  et  al.  1990).   The  clam 
homologue  of  cdc2  was  found  to  bind  both  cyclins  A  and  B,  and  both 
complexes had cell cycle-dependent kinase activity (Draetta et al. 1989).   These 
discoveries established the concept of the cyclin-dependent kinase complex in 
regulating cell division.  Several cyclin and CDK proteins homologous to those 
already found in clam, sea urchin, Xenopus and yeast were rapidly found in 
several species, including humans.  The level of homology between species is 
such that human CDK1 can rescue a yeast cdc2 mutant, as seen below.  Proteins 
are listed according to the mammalian nomenclature, for clarity.   21 
 
Protein  Organism  Discovery   References 
Cyclin B  Yeast  
(S. pombe) 
As  ‘cdc13’,  mutant  genetically 
associated with cdc2; similar to 
clam cyclin; involved in mitosis 
(Hagan et al. 
1988) 
Cyclin B1 
& B2 
Xenopus  Xenopus  oocyte  cDNA  library 
probed with sea urchin cyclin B 
cDNA 
(Minshull et al. 
1989) 
Cyclin B  Human  HeLa cell cDNA library probed 
with  consensus  sequence  from 
clam,  sea  urchin,  frog,  fly  and 
yeast  cyclins;  association  with 
human cdc2 homologue (CDK1) 
(Pines and Hunter 
1989) 
Cyclin A  Fly 
(Drosophila 
melanogaster) 
cDNA  library  probed  by 
consensus sequence of clam and 
sea  urchin  cyclin;  cell  cycle-
dependent degradation  
(Lehner and 
O'Farrell 1989) 
Cyclin A  Human  cDNA  of  gene  locus  disrupted 
by  HBV  integration  in  liver 
cancer;  homology  to  clam  and 
fly cyclin A 
(Wang et al. 
1990) 
Cyclin D  Yeast 
(S. cerevisiae) 
As ‘CLN1 and CLN2’, rescued 
cdc28 mutation; homology with 
cyclins; act in G1 phase 
(Hadwiger et al. 
1989) 
Cyclin D1  Human  Human cDNA complementation 
of CLN-deficient yeast; relation 
to A and B-type cyclins 
(Lew et al. 1991; 
Xiong et al. 
1991) 
Cyclin E  Human   Rescue  of  CLN-deficient  yeast; 
homology  to  A  and  B  cyclins; 
genetic  interaction  with  human 
CDK2 in yeast 
(Koff et al. 1991; 
Lew et al. 1991)   22 
Protein  Organism  Discovery   References 
CDK1  Human  Human cDNA library 
complementation with cdc2 
mutant yeast; binds cdc2 
antibody 
(Draetta et al. 
1987; Lee and 
Nurse 1987) 
CDK2  Xenopus  As ‘Eg1’ in cDNA screen for 
proteins synthesised in oocytes 
but not embryos; homology to 
cdc2 
(Paris et al. 1991) 
CDK2  Human  Complementation of cdc28 
mutant; homology to cdc2 and 
Eg1 
(Elledge and 
Spottswood 1991; 
Ninomiya-Tsuji 
et al. 1991) 
CDK2  Human  Clone of human cdc2-related 
gene; homology with Eg1; binds 
cyclin A 
(Tsai et al. 1991) 
CDK4  Human  cDNA screen for protein-serine 
kinases in HeLa cells; homology 
to cdc2 and cdc28 
(Hanks 1987) 
CDK4  Mouse  As ‘p34PSK-J3’, catalytic 
subunit of D-type cyclins 
(Matsushime et 
al. 1992) 
CDK6  Human  Protein kinase homologous to 
cdc2; binds D cyclins in human 
cells 
(Meyerson et al. 
1992; Meyerson 
and Harlow 
1994) 
 
In all, 20 ‘CDK’ proteins and 29 ‘cyclin’ genes were identified from 
human sequence data as having sequences similar to known cyclins and CDKs, 
although just a few of these have proven activity directly linked to cell cycle 
progression: cyclins A, B, D, E and H, and CDKs 1, 2, 4, 6, and 7 (Malumbres 
and Barbacid 2005).   
Cyclins were found to bind their CDK partners via a conserved, 150 
amino-acid ‘cyclin box’ sequence identified by point mutation of amino acid   23 
residues in cyclin A (Kobayashi et al. 1992).   Although the CDKs may bind 
promiscuously  to  different  cyclins  under  certain  conditions,  they 
characteristically bind particular cyclin partners: CDK1 with either cyclin A or 
cyclin B, CDK2 with either cyclin E or cyclin A, and both CDK4 and CDK6 
with the D-type cyclins (Draetta et al. 1989; Pines and Hunter 1989; Tsai et al. 
1991;  Koff  et  al.  1992;  Matsushime  et  al.  1992;  Rosenblatt  et  al.  1992; 
Meyerson and Harlow 1994).  In most cases, CDKs are inactive in the absence 
of cyclin binding, but binding to cyclin alone is not sufficient for full activation 
(Desai et al. 1992; Connell-Crowley et al. 1993).  CDK activation is controlled 
by  a  combination  of  three  mechanisms:  cyclin  binding,  phosphorylation  on 
specific residues, and binding of CDK inhibitors (CDKIs). 
 
1.1.2.2 Control of CDK activity by cyclin binding and proteolysis 
  Cyclin  binding  is  considered  to  be  the  primary  mode  of  CDK 
regulation, since the conformational change in the CDK it induces is necessary 
for access to the regulatory phosphorylation residues (Jeffrey et al. 1995).  The 
presence of the cyclin subunit therefore defines the period during which the 
CDK complex is competent for activation, and regulation of cyclin levels allows 
cyclical regulation of CDK activity.  Cyclin levels are mostly regulated in a cell 
cycle-dependent manner, by both transcriptional and degradative mechanisms 
(Figure 1- 3).  Cyclin degradation especially is important for transitions between 
phases of the cell cycle, in particular the exit from mitosis, as described later in 
this section.   
Cyclin E accumulates from mid-G1 to reach maximum levels at the G1-
S phase transition, and then declines on S phase entry, at both the mRNA and 
protein  level  (Koff  et  al.  1992).    Cyclin  A  and  B  mRNAs  also  oscillate 
mirroring the protein levels, with cyclin A levels peaking at the beginning of 
mitosis, whereas cyclin B levels peak slightly later, at the metaphase-anaphase 
transition (Pines and Hunter 1990; Whitfield et al. 1990).  Accumulation of 
cyclin A starts before that of B, at the start of DNA replication, while cyclin B 
levels begin to rise in mid-S phase.  Both have similar CCAAT sequences in 
their promoter and are regulated by the CCAAT-binding transcription factors 
CBP (Cyclin A), which is dependent on cell adhesion, and NFY (Cyclins A and    24 
 
 
 
 
 
 
 
Figure 1- 3: Expression of the cyclins. 
Cartoon indicates order of activation of the cyclin-CDK pairs (L-R) during one cell 
cycle.  (NB. Level and duration of activation is not shown.)  
Graph shows approximate expression patterns of the cyclins throughout a model cell 
cycle, starting with return from quiescence (G0).  G1, S, G2, M denote gap 1, DNA 
synthesis, gap 2 and mitotic phases respectively.  For clarity, different cyclin isoforms 
(D1,  D2  etc.)  are  not  included.    Note  that  the  protein  level  does  not  necessarily 
correspond to the level of associated kinase activity: for example, cyclin B-CDK1 is 
only  activated  at  the  beginning  of  mitosis  by  cdc25  dephosphorylation,  despite  the 
protein complex being present in G2 phase.  Adapted from Sherr 1996.   25 
B).    Interestingly,  transactivation  by  NFY  increases  during  S  phase  as  it  is 
activated by cyclin E/A-CDK2, which may explain the later rise in cyclin B 
transcription  (Henglein  et  al.  1994;  Katula  et  al.  1997;  Krämer  et  al.  1997; 
Bolognese  et  al.  1999;  Erlandsson  et  al.  2000).    Unusually,  cyclin  B 
transcription  continues  during  mitosis,  with  the  NFY  transcription  factor 
remaining bound to the active promoter in HeLa cells (Sciortino et al. 2001).  
This is very rare, since almost all RNA PolII-transcribed genes are inactive in M 
phase.  Cyclin E and A genes also have promoter binding sites for E2F-family 
transcription factors, which are themselves repressed by the key Rb family of 
tumour  suppressor  proteins.    Overexpression  of  cyclin  E  overcomes  Rb-
mediated repression of the cyclin A promoter, and ectopic cyclin A expression 
can reverse Rb-mediated G1 arrest, evidence that both cyclins are downstream 
of Rb control (Ohtani et al. 1995; Schulze et al. 1995; Knudsen et al. 1999).  
Control of the cell cycle by Rb and E2F will be described more fully in the next 
section.    A  further  cell  cycle-dependent  element/cell  cycle  genes  homology 
region (CDE-CHR) is also found in the cyclin A promoter, in common with the 
CDK1 gene.  CDF-1 binding to the CDE-CHR represses cyclin A transcription 
during G0 and G1 phases. (Zwicker et al. 1995; Liu et al. 1997b).   
The  only  cyclin  involved  in  the  cell  cycle  whose  expression  is  not 
dependent on cell-cycle phase is the cyclin D family. Induction of cyclin D 
mRNA  is  controlled  coordinately  by  signalling  from  mitogens  and  the 
extracellular matrix, to regulate cell cycle entry from quiescence, acting as a so-
called ‘mitogen sensor’ – mRNA levels are stable in continuously-cycling cells 
(Won et al. 1992; Müller et al. 1994; Böhmer et al. 1996; Aktas et al. 1997; 
Roovers et al. 1999; D'Amico et al. 2000; Zhao et al. 2001; Zhao et al. 2003).  
Cyclin  D  protein  levels  during  the  cell  cycle  are  therefore  controlled  by 
ubiquitin-mediated degradation, and the protein turnover is fast to allow for a 
rapid response to mitogen withdrawal and/or loss of anchorage signals.  Cyclin 
D1 has a very short half-life of less than 30 minutes when complexed with CDK 
and less than 15 minutes when free (Matsushime et al. 1991; Matsushime et al. 
1992;  Bates  et  al.  1994;  Diehl  et  al.  1997).    The  phosphoinositide-3-kinase 
(PI3K)  pathway  antagonises  glycogen  synthase  kinase  (GSK)-3  beta 
phosphorylation of cyclin D1 on T286, which would mark it for proteolysis   26 
(Diehl  et  al.  1998).    This  may  explain  why  two  ‘pulses’  of  signalling  are 
necessary  and  sufficient  to  commit  quiescent  cells  to  the  cycle.    The  first 
stimulates induction of cyclin D mRNA via the MAPK pathway; the second 
prevents the GSK-3 beta tagging the cyclin D protein for destruction, via the 
PI3K pathway (Jones and Kazlauskas 2001; Blagosklonny and Pardee 2002).   
GSK-3  beta  is  also  implicated  in  targeting  cyclin  E  for  proteolysis, 
phosphorylating it on Thr380 (Welcker et al. 2003).  It was initially thought that 
this was  an autophosphorylation  site for cyclin  E-CDK2, based on mutation 
analysis of cyclin E stability and measurements of CDK2 activity (Won and 
Reed 1996), but the CDK2 target site is in fact Ser384, which binds the prolyl 
isomerase PIN1 and is recognised by the Cdc4 subunit of the SCF ubiquitin 
ligase  complex,  and  may  also  affect  cyclin  E  localisation.    Thr62 
phosphorylation  by  CDK2  has  been  shown  to  promote  ubiquitin-mediated 
proteolysis  of  cyclin  E  by  positively  regulating  Thr380  phosphorylation 
(Strohmaier et al. 2001; Ye et al. 2004; Yeh et al. 2006).  When in complex with 
CDK2, Thr380-phosphorylated cyclin E is recognised by the Fbw7 subunit of 
the  SCF  ubiquitin  ligase  complex.    CDK2  binding  prevents  recognition  by 
Cullin-3, which targets free cyclin E for destruction.  Any modification that 
disrupts  cyclin  E/CDK2  binding  may  therefore  indirectly  lead  to  cyclin  E 
proteolysis (Clurman et al. 1996; Singer et al. 1999).  More recent work has 
shown that the two cyclin E-recognising E3 ligases, Cdc4 and Fbw7, dimerise, 
and  that  this  enhances  turnover  of  cyclin  E  doubly  phosphorylated  at  both 
Thr380 and Ser384 (Hao et al. 2007).  Autophosphorylation of cyclin E by the 
cyclin E-CDK2 complex, leading to its degradation, is an important negative 
feedback loop limiting cyclin E expression.  If cyclin E is overexpressed or 
unable to be degraded, it results in S phase abnormalities and increases the 
likelihood of genomic instability and malignancy (Strohmaier et al. 2001; Yeh 
et al. 2006).  
Ubiquitin-mediated proteolysis of cyclins A and B is mediated by the 
APC complex, rather than SCF as for cyclins D and E.  This cyclin removal is 
required for cell cycle progression: in the absence of cyclin B degradation, cells 
are unable to complete anaphase and cannot exit mitosis (Wolf et al. 2006).  
Even before the discovery of the APC, it was clear that destruction of cyclin B   27 
was necessary for cell division, and that it occurred by a ubiquitin-dependent 
mechanism  (Murray  et  al.  1989;  Glotzer  et  al.  1991).    Several  genetic 
components required for cyclin B proteolysis were discovered in yeast (Irniger 
et  al.  1995),  and  the  multisubunit  APC  complex  was  purified  from  oocyte 
extracts of clam and Xenopus (King et al. 1995; Sudakin et al. 1995), pointing to 
an intricate system of protein regulation.  Indeed, new APC functions are still 
being  revealed  (Diamond  et  al.  2009;  Kim  et  al.  2009a).    Cells  arrested  in 
prometaphase  with  the  microtubule  poison  colchicine  were  able  to  degrade 
cyclin A, but not cyclin B (Hunt et al. 1992), so it was a surprise when they 
were both found to be targeted by the same complex.  Cyclin A levels decline 
just  after  nuclear  envelope  breakdown,  and  the  protein  is  degraded  before 
anaphase, unlike cyclin B which is present at high levels until the metaphase-
anaphase transition (den Elzen and Pines 2001; Geley et al. 2001). The mitotic 
cyclins both contain an N-terminal ‘destruction box’ which is recognised and 
bound by the APC (Glotzer et al. 1991; Luca et al. 1991; Sudakin et al. 1995; 
Meyn et al. 2002; Yamano et al. 2004).   
Substrate recognition is mediated by the two APC activating subunits, 
Cdc20 and Cdh1, which have homologues in yeast, Drosophila, Xenopus and 
humans (Dawson et al. 1995; Visintin et al. 1997; Kitamura et al. 1998; Kramer 
et al. 1998; Lorca et al. 1998).  Interestingly, APC targeting is controlled by 
CDK1 and Polo-like kinase phosphorylation on the complex itself (Sudakin et 
al. 1995; Kotani et al. 1998; Golan et al. 2002), in contrast to the SCF complex, 
where  target  recognition  requires  specific  phosphorylations  on  the  substrate 
cyclins (see above).  Phosphorylation of APC
Cdc20 promotes its activation, while 
phosphorylation of Cdh1 inhibits APC
Cdh1 activity, and this difference helps to 
separate  the  proteolysis  of  different targets  into  two  phases.    The  two  APC 
activating subunits recognise different sets of target proteins and ensure that 
they are degraded sequentially: APC
Cdc20 is active in metaphase, followed by 
APC
Cdh1  activation  in  telophase  (Kramer  et  al.  2000).    APC
Cdh1  activity 
continues  past  mitosis  and  into  the  following  G1  phase,  which  prevents 
reaccumulation of cyclins A and B until after the G1-S phase transition (Amon 
et al. 1994; Irniger and Nasmyth 1997; Bastians et al. 1999).  The APC complex   28 
is finally inactivated in late G1 by ubiquitinating its own E2 ubiquitin ligase, 
UbcH10 (Rape and Kirschner 2004).   
As well as targeting mitotic cyclins for proteolysis, a key role of the 
APC  is  in  triggering  the  metaphase-to-anaphase  transition,  by  causing  the 
separation  of  chromatid  pairs  to  opposite  poles.    It  was  first  thought  that 
destruction of cyclin B was sufficient for triggering anaphase, but these events 
were later found to be separable (Holloway et al. 1993; Surana et al. 1993).  
This observation was explained when APC
Cdc20 was found to target securin at 
the  metaphase-anaphase  transition,  while  cyclin  B  was  targeted  by  APC
Cdh1 
(Schwab  et  al.  1997;  Visintin  et  al.  1997).    The  destruction  of  securin 
(Pds1/Cut2)  proteins,  as  a  result  of  APC  activity,  activates  separase 
(Esp1/Cut1), a protease which cleaves the cohesin (Scc1) rings holding sister 
chromatids  together  and  allows  them  to  be  ‘pulled’  apart  by  the  spindle 
microtubules attached to their kinetochores (Ciosk et al. 1998; Uhlmann et al. 
1999).  This crucial event, and its initiation by the APC, is regulated by the 
spindle checkpoint, which will be discussed in section 1.1.3.3.  Cyclin B and 
securin  are  thought  to  be the  only  essential  targets  of  the  APC,  since  yeast 
lacking the complex can divide if securin is deleted and a cyclin B inhibitor is 
overexpressed (Thornton and Toczyski 2003).   
The degradation of cyclin B results in the rapid loss of CDK1 activity, 
which induces mitotic exit and cytokinesis.  Experiments using inhibitors have 
dissected the relative importance of cyclin B removal and loss of CDK1 activity 
in the completion of mitosis (Potapova et al. 2006).  Chemical inhibition of 
CDK1  activity  in  mitosis  was  sufficient  to  allow  mitotic  exit,  even  in  the 
presence of cyclin B.  If CDK1 inhibitors were washed out while cyclin B was 
still  present,  cells  reverted  to  M  phase,  surprisingly  even  re-fusing  after 
cytokinesis.    Proteolytic  removal  of  cyclin  B  therefore  ensures  irreversible 
CDK1 inhibition and forward progression to G1.  The coordinated degradation 
of  securin  and  cyclin  B  is  also  crucial  for  completion of  mitosis:  if  CDK1 
inhibition  occurs  without  cohesin  cleavage,  cytokinesis  will  occur  without 
chromatid segregation, trapping chromatin between the two cells and resulting 
in catastrophic damage to genetic material (Potapova et al. 2006). 
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1.1.2.3 Control of CDK activity by phosphorylation 
In addition to the extensive mechanisms regulating the expression and 
degradation of the cyclins, CDK complexes (Figure 1- 3) are both positively and 
negatively  regulated  by  phosphorylation.    Since  regulation  by  protein 
phosphorylation  is  virtually  instantaneous,  this  establishes  fast,  ‘switch-like’ 
controls  on  CDK  activity,  and  enables  robust  entry  into  distinct  cell  cycle 
phases.   
CDK7  binds  cyclin  H  to  form  the  ‘CDK-activating  kinase’  (CAK) 
holoenzyme (Fisher and Morgan 1994), which phosphorylates the other CDKs 
on a conserved threonine residue on the “T-loop” (Thr 160/161/172) to allow 
protein substrate access to the ATP binding site of the enzyme (Gu et al. 1992; 
Solomon  et  al.  1992;  De  Bondt  et  al.  1993;  Kato  et  al.  1994).    Negative 
regulation  of  CDKs  by  phosphorylation  occurs  notably  at  the  Thr14/Tyr15 
residue  on  CDK1  and  CDK2  (Gu  et  al.  1992).    The  Tyr15  inhibitory 
phosphorylation  is  catalysed  by  Wee1  kinase,  and  removed  by  CDC25 
phosphatase (Gautier et al. 1991; Parker and Piwnica-Worms 1992).  A second, 
dual-specificity  kinase,  Myt1,  can  phosphorylate  both  Thr14  and  Tyr15 
inhibitory positions in Xenopus cdc2, and is conserved in humans (Mueller et al. 
1995; Liu et al. 1997a).  Activation of the cyclin B-CDK1 complex depends on 
the balance of kinase and phosphatase activity in the cell at the G2/M phase 
transition (Atherton-Fessler et al. 1994), and following cyclin B degradation at 
mitotic exit, CDK1 is phosphorylated to lock it into the inhibited state for G1 
phase (Potapova et al. 2009). Whether other CDKs such as CDK4 are regulated 
by inhibitory phosphorylation is controversial.  An inhibitory phosphorylation 
has been detected on CDK4 at a similar Tyr17 position, but it is induced under 
conditions of quiescence or arrest, rather than being necessary for normal cell 
cycle progression (Terada et al. 1995; Iavarone and Massagué 1997; Jinno et al. 
1999).    A  CDC25  phosphatase  was  found  to  be  responsible  for  the  Tyr17 
dephosphorylation, but the kinase is not Wee1 or Myt1 (Watanabe et al. 1995; 
Booher et al. 1997).  The function of this phosphorylation seems to be less 
important than the Tyr15 phosphorylation on CDK1 and CDK2, since mutation 
of Tyr17 did not significantly affect cyclin D-CDK4 activity (Coleman et al. 
1997).    30 
1.1.2.4 Control of CDK activity by inhibitors 
The third mechanism of regulating cyclin-dependent kinase activity is 
the binding of protein inhibitors to the CDK complexes.  There are two main 
groups of CDK inhibitors (CDKI): the inhibitors of CDK4 (INK4) family and 
the CDK-interacting protein/ kinase inhibitory protein (Cip/Kip) family.  The 
INK4 family inhibit CDK4 and CDK6 by direct binding of the CDK alone, 
which distorts both the ATP and cyclin-binding sites (Brotherton et al. 1998; 
Russo et al. 1998; McConnell et al. 1999; Jeffrey et al. 2000).  The family 
includes p15(INK4b), p16(INK4a), p18(INK4c) and p19(INK4d).  p16 was the 
first to be identified, as a CDK4 interactor in fibroblasts transformed with the 
viral oncoprotein SV40 LT, and by yeast 2-hybrid, which inhibited the kinase 
activity  of  the  cyclin  D-CDK4  complex  (Serrano  et  al.  1993;  Xiong  et  al. 
1993b).  p15 was then identified as a p16-related protein in cells arrested by the 
extracellular  ‘transforming  growth  factor’  TGFß  (Hannon  and  Beach  1994).  
p18 and p19 were identified by yeast 2-hybrid as CDK6 interactors (Guan et al. 
1994; Guan et al. 1996).  p16 expression was found to be repressed by the 
tumour  suppressor  protein  Rb,  which  in  turn  is  inhibited  by  the  cyclin  D-
CDK4/6 complex, resulting in a negative feedback loop (Li et al. 1994).  Since 
the activity of the cyclin D-CDK4/6 complex is crucial in stimulating cell cycle 
re-entry from quiescence, both Rb and p16 are key in controlling proliferation 
of quiescent cells, reflected by their frequent disruption in cancer (Ruas and 
Peters  1998;  Sherr  2001a).    Additionally,  the  INK4a  locus  encodes  another 
tumour suppressor protein, ARF, which activates the transcription factor and 
most commonly mutated tumour suppressor protein, p53 (Levine et al. 1991).  
Losing expression from this locus, whether by deletion, mutation or silencing, 
will  therefore  remove  two  tumour  suppressors  at  a  stroke  (Sherr  2001b).  
Further  introduction  to  the  role  of  tumour  suppressors  in  cancer  is  given  in 
section 1.3. 
The  Cip/Kip  family  of  CDKIs  consists  of  p21(Cip1),  p27(Kip1)  and 
p57(Kip2).  p21 was discovered in 1993 as a CDK2 interactor by yeast 2-hybrid 
and by immunoprecipitation, as a CDK2 inhibitor, and as a p53 target (el-Deiry 
et al. 1993; Gu et al. 1993; Harper et al. 1993; Xiong et al. 1993a).  p27 was 
identified as a p21-related protein, an inhibitor for both cyclin A-CDK2 and   31 
cyclin E-CDK2  that accumulates in G0- and G1-arrested cells and as a cyclin 
D-CDK4  interactor  in  proliferating  cells  (Hengst  et  al.  1994;  Polyak  et  al. 
1994a; Polyak et al. 1994b; Toyoshima and Hunter 1994).  p57 was identified 
by  homology  to  p21  and  by  yeast  2-hybrid  as  a  cyclin  D1  interactor, 
upregulated in terminally differentiated cells (Lee et al. 1995; Matsuoka et al. 
1995).  Later, the p57 gene was found to be imprinted in humans, with only the 
maternal  allele  expressed;  and  mutated  in  Beckwith-Wiedemann  syndrome, 
which predisposes patients to cancer (Hatada et al. 1996).  p57 is involved in 
regulating the endoreduplication cycles of DNA replication in trophoblast cells, 
by controlling CDK activity (Hattori et al. 2000).  
All three family members preferentially bind cyclin-CDKs in complex.  
The  N-terminal  inhibitory  domain  of  amino  acids  is  conserved,  and  is  both 
necessary and sufficient for CDK2 inhibition (Chen et al. 1995; Luo et al. 1995; 
Nakanishi et al. 1995; Chen et al. 1996a).  When bound to cyclin-CDK, the 
inhibitory  domain  contacts  both  the  cyclin  box  and  the  catalytic  site  of  the 
kinase, effectively inhibiting both kinase activity and substrate recruitment by 
the cyclin (Russo et al. 1996).  In stoichiometric experiments, one molecule of 
p21 was shown to be sufficient for complete inhibition of one cyclin A-CDK2 
complex (Hengst et al. 1998) despite an earlier report suggesting a multiple 
p21:complex ratio might be needed for full CDK inhibition (Harper et al. 1995).  
Expression levels of both p21 and p27 peak in G1 phase, and they are both 
proteolytically  regulated:  p27  is  targeted  for  ubiquitination  by  SCF
Skp2 
following phosphorylation by cyclin E-CDK2 on Thr187, and p21 similarly but 
by both phosphorylation-dependent and independent mechanisms (Sheaff et al. 
1997; Vlach et al. 1997; Sheaff et al. 2000; Bornstein et al. 2003).  p27 levels 
are therefore controlled by a positive feedback loop: in S phase, when cyclin-
CDK2  complexes  are  active,  Thr187  phosphorylation  of  p27  will  tag  it  for 
proteolysis via SCF
Skp2, reducing the amount available to inhibit cyclin-CDK2 
complexes and increasing CDK activity and p27 phosphorylation further (Malek 
et al. 2001).  This feedback loop contributes to the ‘switch-like’ activation of 
CDK  activity  at  the  G1/S  phase  transition.    A  second  phosphorylation 
mechanism regulates p27 binding to cyclin D-CDK4, where it can act as either a 
bound inhibitor, or a bound non-inhibitor (Ray et al. 2009).  As a bound non-  32 
inhibitor, p27 is phosphorylated on Tyr88, and helps the formation of cyclin D-
CDK4 complexes and the translocation of cyclin D1 to the nucleus in G1 phase.  
In this conformation, CAK phosphorylation of CDK4 on Thr172 is possible and 
the  complex  can  be  activated.    When  p27  is  unphosphorylated  on  Tyr88, 
however, such as in contact-arrested cells, it simultaneously occludes the active 
site of CDK4, and prevents the activating CAK phosphorylation, leaving the 
cyclin  D-CDK4  complexes  inactive  (Soos  et  al.  1996;  LaBaer  et  al.  1997; 
Cheng et al. 1999; Alt et al. 2002; Olashaw et al. 2004; Ray et al. 2009).  It is 
thought that p27 binding to cyclin D-CDK4/6 complexes titrates it away from 
cyclin E/A-CDK2 (Cheng et al. 1998; Perez-Roger et al. 1999), but since it 
binds cyclin D-CDK4/6 constitutively, the extent of this titration depends on the 
levels of cyclin D complex available.  For example, stimulating quiescent cells 
with  mitogen  induces  cyclin  D  production,  which  simultaneously  allows 
formation of cyclin D-CDK4 complexes and removal of p27 from cyclin E-
CDK2.   
The total levels of p27 available are regulated in other ways.  These 
include proteolysis (as described above), increased expression in response to 
contact inhibition or mitogen withdrawal, particularly by translation from an 
internal  ribosome  entry  site  (Millard  et  al.  2000;  Miskimins  et  al.  2001; 
Kullmann et al. 2002; Bagui et al. 2009), and altered nuclear versus cytoplasmic 
localisation.    Localisation  has  been  shown  to  depend  on  both  Akt  and  Ras 
signalling.  Phosphorylation by Akt in p27’s nuclear localisation domain at Thr 
157 favours export from the nucleus to the cytoplasm (Liang et al. 2002; Shin et 
al. 2002; Viglietto et al. 2002a).  Phosphorylation of p27 on Ser10 via Ras also 
promotes  its  nuclear  export  and  reduces  its  assembly  into  cyclin-CDK 
complexes (Besson et al. 2006).  Cytoplasmic mislocalisation of p27 has been 
revealed as a mechanism of increasing cyclin-CDK2 activity in cancer cells, 
since the inhibition of CDK2 complexes takes place in the nucleus (Viglietto et 
al. 2002b; Chu et al. 2008).  Low p27 levels in the nucleus have been found to 
correlate with poor prognosis in a range of cancers (Singh et al. 1998; Sgambato 
et al. 1999; Hurteau et al. 2001; Psyrri et al. 2005).  This misregulation has gone 
some  way  to  explaining  why  loss  or  mutation  of  p27  is  rare  in  cancer 
(Kawamata  et  al.  1995).    Germline  disruption  of  p27  in  mice  results  in   33 
hyperplasia, increased body size, and tumour formation, particularly where the 
CDK-inhibitory function is specifically disrupted (Fero et al. 1996; Kiyokawa et 
al. 1996; Nakayama et al. 1996; Besson et al. 2007).  Oncogenic activity has 
been directly linked to p27 inactivation and turnover via SCFSkp2, which also 
removes inhibition from cyclin-CDK2 complexes normally targeted by Cip/Kip 
inhibitors  (Kawada  et  al.  1997;  Grimmler  et  al.  2007).    p27  and  p21  are 
normally upregulated in cells detached from the substratum, just as they are in 
mitogen-starved cells (Fang et al. 1996; Zhu et al. 1996), and hence reduced p27 
levels have been implicated in anchorage independent proliferation of cancer 
cells (Chen et al. 1996b; Kawada et al. 1998).  The role of p27 in maintaining 
anchorage dependence is a major theme of this thesis, and the role of anchorage 
signals in cell cycle control is further described in section 1.2.   
 
1.1.2.5 How cyclin-CDK activity drives the cell cycle 
From  inhibitor  experiments  and  a  large  number  of  mouse  knockout 
models (Figure 1- 4), it is clear that cyclin-dependent kinase activity is essential 
for cell division, although individual cyclins and CDKs can substitute for one 
another,  and  expression  of  just  one  CDK  is  sufficient  for  proliferation 
(Santamaría et al. 2007).  The classical view, of cyclin D-CDK4/6 initiating the 
cell cycle, cyclin E-CDK2 and cyclin A-CDK2 regulating S phase, and cyclin 
A-CDK1  and  cyclin  B-CDK1  triggering  mitosis,  came  in  most  cases  from 
blocking antibody or antisense DNA injection experiments.  Injection of anti-
cyclin D blocked cells in G1 phase and did not affect those later in the cell cycle 
(Baldin et al. 1993; Quelle et al. 1993).  Injection of anti-cyclin E, anti-cyclin A 
or anti-CDK2 antibodies or antisense, but not anti-cyclin B, all prevented S 
phase entry, at later points than the requirement for cyclin D (Girard et al. 1991; 
Pagano et al. 1992; Zindy et al. 1992; Tsai et al. 1993; Ohtsubo et al. 1995).  
The requirement for cyclin D, but not cyclin E, was found to be bypassed by 
inactivation of the Rb protein, placing cyclin D-CDK4/6 activity ahead of cyclin 
E-CDK2 activity in the cell cycle (Lukas et al. 1994; Tam et al. 1994; Ohtsubo 
et al. 1995).  Following cell-cycle entry from quiescence, cyclin E-CDK2 was 
required  to  load  MCM  helicases  onto  preinitiation  complexes  at  DNA 
replication  origins,  while  cyclin  A-CDK2  was  required  to  activate  DNA  34 
 
Phenotypes of mice lacking cyclins/CDKs 
Genes disrupted  Phenotype  References 
Cyclin D1  Viable, no embryonic lethality; minor 
developmental abnormalities; small 
size 
(Fantl et al. 1995; 
Sicinski et al. 1995) 
Cyclin D2  Viable; impaired female fertility, 
postnatal cerebellar development and 
expansion of B lymphocytes  
(Sicinski et al. 
1996) 
Cyclin D3  Viable; impaired lymphocyte 
maturation 
(Sicinska et al. 
2003) 
Cyclins D2 and 
D3 
Death @ E18.5; hypoplastic retinas; 
megaloblastic anaemia 
(Ciemerych et al. 
2002) 
Cyclins D1 and 
D2 
Postnatal death; cerebellar 
abnormalities 
(Ciemerych et al. 
2002) 
Cyclins D1, D2 
and D3 
Death @ midgestation (E16.5); defects 
in heart development; haematopoietic 
stem cell problems; MEFs defective in 
entry to and exit from quiescence 
(Kozar et al. 2004) 
Cyclins E1 and 
E2 
Death @ E11.5 due to defects in 
endoreduplication of placental 
trophoblast cells (viable and healthy 
with either E1 or E2 alone); MEFs 
unable to enter S phase from 
quiescence 
(Geng et al. 2003; 
Parisi et al. 2003) 
Cyclin A2  Early embryonic lethality (@E5.5)  (Murphy et al. 
1997) 
CDK4  Viable; small size; sterile; diabetic due 
to lack of pancreatic islet cells; MEFs 
defective in cell cycle re-entry 
following quiescence and senesce 
rapidly in culture 
(Rane et al. 1999; 
Tsutsui et al. 1999; 
Zou et al. 2002) 
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Phenotypes of mice lacking cyclins/CDKs continued 
Genes disrupted  Phenotype  References 
CDK6  Viable; defects in haematopoietic 
compartment 
(Malumbres  et  al. 
2004) 
CDK4 and 
CDK6 
Die in utero; failure of 
haematopoiesis/megaloblastic 
anaemia; MEFs defective in cell cycle 
entry after quiescence and senesce 
rapidly in culture; form compensatory 
cyclin D2-CDK2 complexes with Rb 
kinase activity 
(Malumbres  et  al. 
2004) 
CDK2   Viable up to 2 years; sterile; MEFs 
defective in exit from quiescence and 
S phase entry 
(Berthet et al. 2003; 
Ortega et al. 2003) 
CDK2 and 
CDK4 
Embryonic lethality @E15; thin-
walled heart; MEFs have decreased 
proliferation rate, Rb 
hypophosphorylation, senesce 
prematurely and show reduced E2F 
target expression (CDK1, cyclin A). 
(Berthet et al. 2006) 
CDK1  Fail to develop even to blastocyst 
stage 
(Santamaría  et  al. 
2007) 
CDK2, CDK3, 
CDK4 and 
CDK6 
Develop to midgestation (E12.5); 
some liver apoptosis; thin-walled 
heart; reduction in haematopoiesis; 
MEFs proliferate with an extended 
cell cycle; CDK1 binds to all cyclins 
(Santamaría  et  al. 
2007) 
Figure 1- 4: Phenotypes of mice lacking various cyclins and CDKs 
Table  adapted  from  Sherr  and  Roberts  2004.    Note  that  CDK1  is  the  only  one 
absolutely required for cell division.  In the case of cyclin isoforms, e.g. cyclins D2 and 
D3, the phenotypes reflect the normal tissue expression patterns: affected organs are 
those that principally express a single cyclin type.   36 
synthesis  at  assembled  replication  complexes  (Coverley  et  al.  2002).  
Microinjection of anti-cyclin A also prevented entry into mitosis, at a time when 
it was observed to bind and activate CDK1 (Pagano et al. 1992).  Accumulation 
of cyclin B was shown to be required for mitotic entry in cell-free extracts of 
Xenopus eggs (Minshull et al. 1989).   
Though  studies  of  cyclin-CDK  complexes  have  revealed  multiple 
mechanisms  regulating  their  activity,  discoveries  of  CDK-phosphorylated 
targets that have a direct effect on cell cycle progression have been relatively 
few.  Most direct CDK targets are of regulatory proteins, such as Rb (Kato et al. 
1993).  CDK4/6 targets Rb through binding to the LxCxE amino acid motif on 
cyclin  D,  while  CDK2  preferentially  phosphorylates  Rb  on  different  sites, 
leading to its hyperphosphorylation and inactivation (Knudsen and Wang 1996; 
Lundberg and Weinberg 1998; Harbour and Dean 2000).  Another CDK2 and 
CDK4  cell  cycle  -regulatory  target  is  the  transcription  factor  Smad3,  whose 
antiproliferative activity is inhibited by CDK phosphorylation (Matsuura et al. 
2004).  CDK2 also has targets more directly involved in cell cycle progression, 
including  those  regulating  centrosome  duplication,  histone  transcription,  and 
DNA  replication  initiation,  where  CDK  activity  causes  firing  of  replication 
origins (Krude et al. 1997; Hua and Newport 1998; Ma et al. 2000; Okuda et al. 
2000; Zhao et al. 2000; Chen et al. 2002; Coverley et al. 2002).  Targets for 
CDK1 phosphorylation in mitosis include lamins, to induce nuclear envelope 
breakdown, stathmin, a regulator of mitotic spindle formation, and condensin, to 
induce chromosome condensation (Ward and Kirschner 1990; Marklund et al. 
1996; Kimura et al. 1998).  The phosphorylation targets of the CDKs are still 
incompletely known, as hundreds of proteins contain CDK consensus sites and 
many  of  these  have  yet  to  be  validated  as  functional  CDK  targets  in  vivo.  
CDK1, for example, has more than 70 substrates (Ubersax et al. 2003; Blethrow 
et al. 2008). 
 
1.1.3 Cell cycle checkpoints 
The  effect  of  the  complex  network  of  regulatory  mechanisms 
surrounding  cyclin-CDK  activity  is  to  produce  several  ‘checkpoints’  at  key 
junctures in the cell cycle, where it is crucial that events are correctly timed in   37 
order to maintain smooth cell cycle progression and the stability of the genome.  
At these points, cell cycle progression is paused while several signals indicating 
the completion of previous processes are integrated.  Once all the necessary 
cues are present, the cell is ready to go on to the next stage and the ‘wait’ signal 
is removed, allowing continuation of the cycle.  If there is a problem and the 
checkpoint cannot be passed, the cell may either remain arrested at the previous 
stage,  or  undergo  apoptosis  (Elledge  1996).    The  mammalian  cell  cycle  is 
controlled predominantly at three main checkpoints. 
   
1.1.3.1 The Rb-E2F checkpoint 
The Rb-E2F checkpoint, in G1 phase, ensures that cells have received 
appropriate pro-proliferative signals before committing to a full cell cycle.  This 
was classically known as the “restriction point”, roughly equivalent to START 
in the yeast S. cerevisiae (Hartwell et al. 1974; Pardee 1974).  Instead of being 
dependent on cell size and nutrient availability to trigger cell cycle initiation, as 
in  yeast,  mammalian  cells  respond  to  cues  from  mitogens  and  from  the 
surrounding environment, notably anchorage signals via integrins (Assoian and 
Schwartz 2001).  Removal of mitogen signals in early G1 results in a G1 arrest, 
which is reversible upon reintroduction of the signal.  This arrest is caused by a 
lack  of  cyclin  D,  which  is  an  unstable  protein  sensitive  to  the  removal  of 
mitogens (Matsushime et al. 1991; Diehl et al. 1997).  If mitogens are removed 
after the cell cycle has passed the restriction point, however, the cell will go on 
to complete one entire cycle and then both daughter cells will arrest once they 
return to G1 (Temin 1971; Zetterberg and Larsson 1985).  The checkpoint is 
controlled  by  the  Rb  family  of  tumour  suppressor  proteins,  which  bind  and 
repress  the  class  of  transcription  factors  known  as  E2F  (Figure  1-  5).    Rb 
repression  is  mediated  both  by  direct  binding  and  inhibition  of  E2F  family 
transcription factors, and by the recruitment of histone deacetylase (HDAC1) to 
some promoters, which modifies the chromatin to an inaccessible state (Brehm 
et al. 1998; Luo et al. 1998).  Integration of pro-proliferative signals results in 
phosphorylation of Rb and its dissociation from E2F, allowing transcription of 
genes required for progression into S phase, including cyclin E, cyclin A and   38 
components of the pre-replication complex (Chellappan et al. 1991; Schulze et 
al. 1995; Geng et al. 1996; Yan et al. 1998; Ohtani et al. 1999).  
The  initial  phosphorylation  of  Rb  is  carried  out  by  cyclin  D-CDK4, 
which  prevents  Rb  acting  as  a  repressor.    Once  cyclin  E  genes  have  been 
derepressed  by  this  partial  inhibition  of  Rb,  cyclin  E-CDK2  complexes  will 
further  phosphorylate  the  Rb  protein,  leading  to  the  ‘hyperphosphorylated’ 
form, which dissociates from E2F (Knudsen and Wang 1997; Lundberg and 
Weinberg 1998; Harbour et al. 1999; Rubin et al. 2005).  The activation of 
cyclin  E-CDK2  complexes  results  in  further  E2F-mediated  cyclin  E 
transcription, in a positive feedback loop (Figure 1- 5).  E2F also activates its 
own transcription (Neuman et al. 1994).  Once cyclin A-CDK2 complexes have 
been  assembled,  they  may  maintain  Rb  in  the  hyperphosphorylated  state  to 
drive cells through S phase, but also act to release E2F from DNA and switch 
off the S phase initiation signal (Dynlacht et al. 1994; Krek et al. 1994; Sherr 
1996).    Expression  of  cyclin  D  is  crucial  for  beginning  this  process  of  Rb 
inactivation,  and  this  in  turn  requires  a  strong,  sustained  activation  of  the 
mitogen-activated  protein  kinase  (MAPK)  pathway  by  a  combination  of 
mitogen  binding  to  receptors  at  the  cell  surface  and  integrin  adhesion  to 
extracellular  matrix  (ECM)  proteins (Chen  et  al.  1994;  Weber  et  al.  1997b; 
Roovers  et  al.  1999;  Assoian  and  Schwartz  2001).    Once  Rb  is 
hyperphosphorylated  and  no  longer  requires  cyclin  D-CDK4/6  activity,  Rb 
inactivation  becomes  independent  of  mitogen  stimulation,  and the  cell  cycle 
progresses through the checkpoint (Sherr 1996). 
 
1.1.3.2 The DNA replication checkpoint and response to DNA damage 
The  second  major  checkpoint  mechanism  in  the  cell  cycle  monitors 
DNA  replication,  ensuring  the  genome  has  been  completely  and  accurately 
copied  before  the  cell  enters  mitosis  (Hartwell  and  Weinert  1989).    Since 
uninterrupted DNA replication requires intact DNA, this monitoring system also 
responds  to  DNA  damage,  even  before  it  can  impede  replication  fork 
progression  (Kastan  et  al.  1991;  Di  Leonardo  et  al.  1994).    In  mammals, 
evidence of a system to detect DNA breaks was first observed in cells from    39 
 
 
 
 
 
 
 
Figure 1- 5: The Rb-E2F checkpoint. 
Diagram showing the Rb-E2F checkpoint mechanism linking mitogen and anchorage 
signalling  input  through  G1  phase  to  S  phase  entry.    Note  the  feedback  loops:  (a) 
negative feedback involving cyclin D-CDK4/6 activity, Rb and p16; (b) E2F release 
activating  its  own  transcription;  and  (c)  cyclin  E-CDK2  activity  releasing  E2F  to 
activate further cyclin E transcription and Rb hyperphosphorylation.  Adapted from 
Zetterberg et al. 1995.   40 
patients  with  ataxia  telangiectasia,  which  fail  to  arrest  in  response  to  DNA 
damage from x-ray irradiation (Taylor 1978; Painter and Young 1980).  Work in 
yeast and in mammalian cells has since expanded the role of the ‘checkpoint’ to 
encompass not only the sensing of DNA damage and the implementing of cell 
cycle arrest, but also the activation of DNA repair and recovery mechanisms 
(Zhou and Elledge 2000).  In fact, this mechanism does not ‘check’ the cell at a 
single point in the cell cycle, but instead is activated as needed throughout G1, S 
and G2 phases, an indication of the importance of detecting breaks in DNA 
before cell division makes them irreparable and parts of the genome are lost.  
Thus, in addition to monitoring DNA replication, the DNA damage response 
plays  an  important  role  in  maintaining  genome stability (Hartwell  1992),  as 
discussed in section 1.4.   
In  G1  and  G2  phases,  cell  cycle  arrest  in  response  to  DNA  damage 
involves  the  key  transcription  factor  p53.   This  protein  was  first  discovered 
bound  to  the  viral  oncoprotein  LT  in  SV40-transformed  cells  (Lane  and 
Crawford 1979; McCormick et al. 1981) and later came to be known as the 
‘guardian of the genome’ for its central tumour-suppressive role in the DNA 
damage  checkpoint  (Kastan  et  al.  1992;  Lane  1992).    p53  is  stabilised  in 
response  to  both  ultraviolet  and  ionising  radiation  insults,  and  mediates  cell 
cycle arrest via induction of the  CDK inhibitor p21 (Maltzman  and Czyzyk 
1984;  Lu  and  Lane  1993;  Bunz  et  al.  1998).    It  is  also  required  to  induce 
apoptosis in response to irreparable damage (Lowe et al. 1993).  The upstream 
‘sensors’  of  DNA  damage,  whether  inflicted  by  exposure  to  environmental 
mutagens  or  by  errors  in  DNA  replication,  are the  kinases  ATM  and  ATR, 
which in turn phosphorylate and activate the ‘effector kinases’ Chk1 and Chk2 
(Chaturvedi  et  al.  1999;  Liu  et  al.  2000;  Matsuoka  et  al.  2000;  Zhao  and 
Piwnica-Worms 2001)(Figure 1- 6).  Both Chk1 and ATR kinases are essential 
for  development,  as  shown  by  early embryonic lethality in Chk1 and ATR-
deficient mice (Brown and Baltimore 2000; de Klein et al. 2000; Liu et al. 2000; 
Takai et al. 2000).  ATM tends to respond to double-strand breaks in DNA, and 
is recruited by the Mre11/Rad50/Nbs1 complex (Petrini 2000), while ATR is 
recruited to stalled replication forks, and other damage which exposes single-
stranded  DNA,  by  its  partner  ATRIP  (Cortez  et  al.  2001;  Zou  and  Elledge   41 
2003).  Chk1 and Chk2 are recruited via interaction with adaptor proteins such 
as  Claspin  (Kumagai  and  Dunphy  2000).    In  G1  phase,  phosphorylation  by 
Chk1 and Chk2 stabilises p53 to induce cell cycle arrest (Chehab et al. 1999; 
Chehab et al. 2000; Hirao et al. 2000; Shieh et al. 2000).  ATM and ATR may 
also phosphorylate p53 directly (Khanna et al. 1998; Hall-Jackson et al. 1999).  
In G2 phase, Chk1 is activated by BRCA1 in response to DNA damage, and 
stabilises securin, thus preventing separation of chromosomes until DNA has 
been repaired (Yarden et al. 2002; Agarwal et al. 2003).  Chk1 and Chk2 also 
directly inhibit CDC25, and Chk1 activates Wee1, preventing the activation of 
cyclin-CDK complexes (Sanchez  et al. 1997; Blasina et al. 1999; Lee et al. 
2001).  For example, Chk1 keeps cyclin B-CDK1 inactive when activated by 
ATR  in  response  to  unreplicated  DNA,  to  prevent  mitotic  entry  with  an 
improperly replicated genome (Guo et al. 2000; Hekmat-Nejad et al. 2000; Lee 
et al. 2005).   
Although S phase is not initiated while DNA damage is present, a DNA 
damage response may be activated during S phase, in response to inhibition of 
replication  (leading  to  replication  fork  stalling),  or  errors  in  DNA  synthesis 
(Zhou and Elledge 2000; Lopes et al. 2001; Tercero and Diffley 2001).  When 
induced  by  environmental  factors  or  oncogenes,  this  S  phase  inhibition  is 
known  as  replication  stress  (Desany  et  al.  1998;  Osborn  et  al.  2002).    The 
induction  of  replication  fork  stalling  and  the  DNA  damage  response  by 
oncogenes will be discussed in  section 1.3.  Intra-S phase damage does not 
result in immediate global arrest, but S phase progression is slowed, as the DNA 
damage  response  prevents  firing  of  late  replication  origins  (Santocanale  and 
Diffley 1998; Heffernan et al. 2002).  The response also prevents entry into 
mitosis, via activation of Chk1, as described above.  In order to maintain the 
activation of the checkpoint in regions of damaged DNA, the histone variant 
H2A is phosphorylated by ATM or ATR to produce the marker known as γ-
H2AX  (Rogakou  et  al.  1999;  Burma  et  al.  2001;  Fernandez-Capetillo  et  al. 
2002;  Furuta  et  al.  2003;  Shroff  et  al.  2004).    Although  not  required  for 
initiation of the checkpoint (Celeste et al. 2003), γ-H2AX interacts with adaptor 
proteins such as MDC1 to increase recruitment of other DNA damage proteins 
and amplify the response (Stucki et al. 2005).  The ‘spreading’ of the signal   42 
 
 
 
 
 
 
Figure 1- 6: The DNA damage response. 
Overview of the DNA damage response, involving recruitment of the ‘sensor kinases’ 
ATM or ATR to the damage site, and activation of the ‘effector kinases’ Chk1 and 
Chk2 to produce either DNA repair, cell-cycle arrest, or p53-induced cell death.  See 
text for more details, and references.  Diagram adapted from Morgan 2007.   43 
along DNA allows recruitment of cohesins to assist repair by sister-chromatid 
exchange in G2 phase (Ström et al. 2004; Unal et al. 2004).  Once repaired, the 
checkpoint is alleviated by dephosphorylation of key proteins such as p53 and 
Chk1, mediated by phosphatases such as PPM1D (Lu et al. 2005).  Coordination 
of  this  checkpoint  by  proteins  located  at  the  replication  fork  also  ensures 
complete and proper DNA replication, as the presence of a fork in itself means 
that replication has not finished (Tercero et al. 2003). 
 
1.1.3.3 The spindle assembly checkpoint 
The final cell cycle checkpoint acts during mitosis, to ensure that the  sister 
chromatids are equally segregated to the daughter cells so that each cell inherits 
a  complete  set  of  chromosomes.    The  spindle  assembly  checkpoint  (SAC) 
verifies that all chromatids are attached to the spindle at the kinetochore by 
microtubules, and are under tension, before anaphase is triggered and cohesin is 
cleaved.    The  SAC  mechanism  (Figure  1-  7)  senses  unattachment  of 
kinetochores to the microtubules and responds to the tension produced when 
both chromatids are securely tethered to opposite spindle poles and ready to be 
separated (Waters et al. 1998; Shannon et al. 2002).  While the SAC is active, 
the APC does not recognise cyclin B or securin, and so anaphase is inhibited, 
thus  preventing  unequal  segregation  of  chromosomes  and  aneuploidy 
(Musacchio  and  Salmon  2007).      The  components  of  the  SAC  were  first 
discovered in yeast, from mutants defective in mitotic arrest (Hoyt et al. 1991; 
Li and Murray 1991), and these are conserved throughout the eukaryotes.  A 
mitotic checkpoint complex (MCC) composed of Mad2, BubR1, Bub3 and the 
APC  activator  Cdc20  was  proposed  to  mediate  the  SAC  effector  signal  at 
kinetochores  (Sudakin  et  al.  2001).   By  laser  ablation  experiments,  a single 
unattached kinetochore was shown to be sufficient to activate the checkpoint 
(Rieder et al. 1995).  The kinase Aurora B was shown to target BubR1 and 
Mad2  to  kinetochores,  and  to  correct  improper microtubule  attachments,  for 
example having both sides of the kinetochore connected to the same spindle 
pole (Ditchfield et al. 2003; Morrow et al. 2005; Tanaka et al. 2005). 
The key target of the SAC mechanism is the APC activator Cdc20, and 
overexpression of Cdc20 was shown to be sufficient to overcome the checkpoint  44 
  
 
 
 
 
 
Figure 1- 7: The spindle assembly checkpoint. 
Cartoon shows  a mitotic chromatid pair (blue) in the process of being captured by 
spindle  microtubules  (yellow).    In  prometaphase  (left),  Mad2  levels  at  unattached 
kinetochores are high, and Cdc20 is targeted for degradation, generating a ‘wait’ signal.  
The bioriented attachment of chromosomes at metaphase (centre) results in application 
of  tension  to  the  kinetochores  and  inactivates  the  spindle  checkpoint  ‘wait’  signal.  
Checkpoint inactivation triggers anaphase (right): activation of APC
Cdc20 and separation 
of the sister chromatids by cohesin cleavage.  See text.  Figure adapted from Musacchio 
and Salmon 2007.   45 
(Hwang et al. 1998; Kim et al. 1998; Pan and Chen 2004).  However, it was 
unclear whether the MCC acted to sequester Cdc20, or inhibit it.  It was also 
suggested that the SAC is turned off by disruption of the MCC following APC-
mediated ubiquitination of Cdc20 (Reddy et al. 2007).  Recently, a new study 
(Nilsson et al. 2008) has challenged this idea, with data suggesting that Mad2 
only transiently associates with the MCC, and instead it may collaborate with 
BubR1  and  Bub3  to  ‘present’  Cdc20  to  the  APC  for  ubiquitination.    Their 
results  also  suggest  that,  far  from  turning  the  SAC  signal  off,  Cdc20 
ubiquitination by the APC acts to maintain the checkpoint by destroying the 
subunit responsible for recognition of cyclin B and securin.  This would prevent 
APC activation and separation of the chromosomes until the checkpoint has 
been deactivated and Cdc20 is able to associate with the APC normally (Nilsson 
et al. 2008). 
 
1.1.3.4 Other regulatory mechanisms: DNA licensing 
Early  cell  fusion  experiments  demonstrated  that  G1  nuclei  are 
competent, or ‘licensed’ for DNA replication, and S phase nuclei can promote 
early DNA synthesis in G1; but that G2 nuclei are not competent to replicate 
and are refractive to S phase activation (Rao and Johnson 1970; Stillman 1996).  
This DNA ‘licensing’ mechanism ensures that each strand is replicated exactly 
once per cell cycle (Blow and Dutta 2005).  Either incomplete replication or 
rereplication  of  any  portion  of  DNA  leads  to  improper  separation  of  the 
daughter strands, so that chromosomes are likely to break at mitosis, resulting in 
genome  instability  and  possible  initiation  of  a  fatal  cycle  of  chromosome 
breakage  and  fusion  (see  section  1.4).    To  prevent  this,  DNA  replication 
initiation has a complex ‘firing’ mechanism, which requires the recruitment and 
co-operation of several proteins at replication origins (Figure 1- 8).  The pre-
replication complex (pre-RC) consists of the origin recognition complex (ORC), 
the minichromosome maintenance (MCM) helicase complex, and the Cdc6 and 
Cdt1 regulatory proteins.  Both MCM subunit and Cdc6 genes are targets of 
E2F regulation, and their expression is therefore cell-cycle regulated (Yan et al. 
1998; Ohtani et al. 1999).  The pre-RC is assembled on DNA only during late M    46 
 
 
 
 
Figure 1- 8: DNA replication licensing. 
(1)  In  late  M  and  early  G1  phase,  CDK  activity  is  low  and  pre-replicative 
complexes (pre-RC) assemble at replication origins. 
(2)  As  CDK  activity  rises  in  G1  phase,  pre-RC  components  are  targeted  for 
removal, either by proteolysis or by nuclear export, so that no further licensing 
can occur. 
(3)   High CDK activity triggers origin firing, marking the start of S phase.  MCM 
helicases move away from replication origins with the replication fork in both 
directions, leaving the origin unlicensed.  As DNA replication ends, replication 
forks meet and MCMs are displaced from DNA. 
(4)  During  G2 and early M phases, CDK activity remains high, thus inhibiting 
further replication licensing until the genome has segregated and the next cycle 
begins.  See text for references.   47 
and early G1 phase, when cyclin-CDK activity is low (Blow and Hodgson 2002; 
Nishitani and Lygerou 2002).  CDKs and cdc7, which forms a cyclin-CDK-like 
complex  with  Dbf4p  (ASK),  then  recruit  DNA  replication  enzymes  to  the 
complex and trigger initiation of DNA replication - the ‘firing’ of replication 
origins  (Sclafani  2000;  Walter  and  Newport  2000;  Zou  and  Stillman  2000; 
Masai and Arai 2002; Devault et al. 2008).  Elongation requires MCM helicase 
activity, so the MCM complex moves along with the replication fork, leaving 
the  origin  once  more  unlicensed  (Aparicio  et  al.  1997;  Labib  et  al.  2000; 
Shechter et al. 2004).  Cdt1 protein is necessary for licensing, but it is bound 
and inactivated by the replication inhibitor Geminin during S and G2, so that 
origin licensing is inhibited during this time (Hodgson et al. 2002; Lee et al. 
2004).  Cdt1 is also degraded in S and G2 phases by the proteasome, to prevent 
re-licensing of replication origins before mitosis (Li and Blow 2005; Nishitani 
et al. 2006).  Geminin is destroyed by the APC in late mitosis, releasing Cdt1 to 
allow  the  next  round  of  origin  licensing  (McGarry  and  Kirschner  1998; 
Ballabeni et al. 2004).   
The  reliance  of  origin  ‘firing’  and  licensing  on  high  and  low  CDK 
activity respectively ensures that origins cannot be licensed and ‘fired’ at the 
same time, and restricts licensing to one short period per cell cycle so that DNA 
is replicated only once (Blow and Dutta 2005).  In yeast, CDK activity normally 
inhibits  rereplication  by  phosphorylating  the  origin  recognition  complex,  by 
downregulating cdc6 activity and by excluding MCM proteins from the nucleus 
(Nguyen et al. 2001; Liku et al. 2005).  In metazoans, CDK activity regulates 
chromatin binding of the pre-RC components to control licensing (Findeisen et 
al.  1999).    CDK  phosphorylation  of  cdt1  also  leads  to  its  proteasomal 
degradation (Sugimoto et al. 2004). 
Inhibition  of  CDK  activity  can  lead  to  rereplication  and  genome 
instability  (Itzhaki  et  al.  1997;  Bates  et  al.  1998;  Machida  and  Dutta  2007; 
Porter  2008).    Removal  of  geminin-mediated  Cdt1  inhibition  also  leads  to 
rereplication, and this also triggers the DNA damage checkpoint (Mihaylov et 
al. 2002; Melixetian et al. 2004; Zhu et al. 2004; Davidson et al. 2006; Gonzalez 
et al. 2006a; Zhu and Dutta 2006; Kerns et al. 2007).  Endoreduplication cycles, 
where  the  genome  is  repeatedly  replicated  without  intervening  mitoses,  are   48 
required in specialised cell types such as placental trophoblast cells and must be 
carefully  controlled.    Initiation  of  endoreduplication  requires  a  decrease  in 
cyclin  A/B-CDK1  activity,  either  by  inhibiting  the  CDK  or  decreasing 
expression of the cyclin (Coverley et al. 1998).  The endocycles themselves are 
characterised by an oscillation of cyclin E-CDK2 activity (Lilly and Spradling 
1996;  MacAuley  et  al.  1998;  Hattori  et  al.  2000).    Consistent  with  the 
expression of replication licensing factors being characteristic of proliferating 
cells, inappropriate overexpression of proteins such as cdc6 and Cdt1 can be 
seen in cancer cells, and may contribute to driving their proliferation (Arentson 
et al. 2002; Karakaidos et al. 2004; Gonzalez et al. 2006b; Lau et al. 2007).  Rb 
loss, frequently seen in cancer cells, is also associated with overreplication, and 
is thought to promote association of replication factors with chromatin under 
nonpermissive conditions (Niculescu et al. 1998; Srinivasan et al. 2007).   49 
1.2 Signals from anchorage 
1.2.1 Integrins and the extracellular matrix 
Physical  attachment  of  cells  to  the  extracellular  matrix  (ECM)  is 
mediated by integrins, as well as other glycoprotein receptors for ECM, such as 
syndecans and CD44 (Buck and Horwitz 1987; Saunders et al. 1989; Aruffo et 
al.  1990;  Morgan  et  al.  2007).    Cell-matrix  adhesion  is  fundamental  to 
determining  cell  behaviour,  and  anchorage  signals  provide  the  cell  with 
information about the tissue microenvironment as well as input into controls for 
proliferation, differentiation, and survival (Adams and Watt 1989; Meredith et 
al. 1993; Assoian 1997; Lukashev and Werb 1998).  Integrins, for example, can 
sense the composition of the surrounding matrix and actively signal to the cell 
via  proteins  associated  with  the  integrin  cytoplasmic  domain  (Geiger  et  al. 
2001).  Integrins are structured as protein heterodimers of one alpha and one 
beta chain (Buck and Horwitz 1987).  24 heterodimer combinations of the 18 
alpha and 8 beta subunits are known in human cells, and these have different 
ligand-binding specificities (Takada et al. 2007).  The beta chain has a longer 
cytoplasmic tail than the alpha, containing the protein-protein interaction motifs 
NXXY and NPXY, which bind the cytoskeleton-associated proteins talin and 
paxillin (Mitra and Schlaepfer 2006).   
A  key  property  of  integrins  is  mechanotransduction  of  physical 
information, such as stiffness and tension, into biochemical signals within the 
cell, by modifying their structural conformation in response to applied forces 
(Zhu et al. 2008).  They are ideally placed for this role, acting as anchor points 
at the cell membrane for the cytoskeleton, in clusters of protein known as focal 
adhesions (Burridge et al. 1988; Geiger et al. 2009).  Focal adhesion complexes 
also interact with mitogen receptor tyrosine kinases (Figure 1- 9).  Within the 
protein clusters is a vast concentration of signalling molecules, among them the 
kinases  FAK  (focal  adhesion  kinase)  and  ILK  (integrin-linked  kinase) 
(Miyamoto et al. 1995; Plopper et al. 1995; Li et al. 1999).  Both these and the 
integrins themselves interact with adaptor proteins to affect signalling by the 
Rho, Rac, PI3K and MAPK pathways, influencing cell migration, proliferation 
and apoptosis (Schaller et al. 1994; Schlaepfer et al. 1994; Frisch et al. 1996; 
Wary et al. 1996; Lin et al. 1997; Clark et al. 1998; D'Amico et al. 2000).  50 
 
 
 
 
Figure 1- 9: Signalling downstream of integrins at focal adhesions. 
Cartoon shows the interaction of signalling proteins with integrins, including integrin-
linked  kinase  (ILK)  and  focal  adhesion  kinase  (FAK),  with  some  of  the  adaptor 
proteins linking them to receptor tyrosine kinases and the cytoskeleton.  An indication 
of the signalling pathways downstream of the kinases (Ras/MAPK, Akt, Rac, etc.) is 
shown in simplified form.  Adapted from Hehlgans et al. 2007.   51 
The stiffness and composition of the extracellular matrix is known to affect the 
morphology and differentiation of attached cells (Garcia et al. 1999; Discher et 
al. 2005; Yeung et al. 2005; Engler et al. 2006), by altering the tension applied 
to  the  elastic  cytoskeletal  network  and  the  signalling  from  focal  adhesions 
(Chen et al. 1997; Chen et al. 2003a; Ingber 2003).  Tumour microenvironments 
are often less pliable than normal tissue, which has been suggested to contribute 
to  altering  the  integrin  expression  profile  and  the  consequent  change  in 
signalling observed in cancer cells (Paszek et al. 2005).  The presence of certain 
extracellular  matrix  components,  such  as  fibronectin,  or  expression  of  the 
fibronectin receptor α5β1 can inhibit invasion and metastasis, while expression 
of promiscuous integrins such as αvβ3 can promote migration of cells on many 
different extracellular matrix proteins and encourage angiogenesis (Varner and 
Cheresh 1996).  Cells may also modify their microenvironment by secreting 
their own ECM components and matrix-degrading enzymes, thus influencing 
the  behaviour  of  surrounding  cells  as  well  as  their  own:  a  situation  that  is 
particularly  relevant  in  tumours  (Kubo  et  al.  1984;  Chernousov  et  al.  1996; 
Liotta and Kohn 2001; Phillips et al. 2003; Larsen et al. 2006). 
 
1.2.2 Detachment: Arrest or anoikis? 
When detached from the extracellular matrix, normal mammalian cells 
may respond in several ways: either programmed cell death, known as anoikis, 
in epithelial or endothelial cells; differentiation, in keratinocytes; reversible cell 
cycle arrest, in mesenchymal and fibroblastic cell types; and in transformed or 
cancerous cell types, cells continue to proliferate (Stoker et al. 1968; Otsuka and 
Moskowitz 1975; Green 1977; Frisch and Francis 1994).  Most proliferating 
cells cell-cycle arrest following detachment from the ECM in the G1 phase of 
the cell cycle, at the classical Rb/E2F checkpoint, due to insufficient cyclin D 
induction  (Assoian  and  Klein  2008).    Cell-cycle  arrest  at  G1/S  phase  by 
overexpression  of  CDK  inhibitors  allows  evasion  of  anoikis  in  mammary 
epithelial cells (Collins et al. 2005).  Anoikis occurs where the lack of integrin 
signalling results in insufficient activation of pro-survival pathways by PI3K, 
and apoptotic cell death (Khwaja et al. 1997).  Signalling via PI3K and Akt 
mediates survival in several ways, including the phosphorylation and inhibition   52 
of pro-apoptotic proteins such as Bad and caspase 9 (Datta et al. 1999; Khwaja 
1999).  Both ILK and FAK signalling downstream of integrins have been shown 
to suppress anoikis (Attwell et al. 2000; Sonoda et al. 2000).  Loss of integrin 
signalling  can  also  result  in  the  downregulation  of  growth  factor  signalling, 
which  contributes  to  anoikis,  since  both  IGF  and  EGF  receptor  signalling 
promote  survival  (Moro  et  al.  1998;  Valentinis  et  al.  1998;  Reginato  et  al. 
2003).  In mesenchymal cells such as fibroblasts, growth factor signalling alone 
is sufficient for survival, whereas in epithelial cells, both integrin and growth 
factor  signalling  is  needed  (Frisch  and  Screaton  2001).    Disruption  of  the 
cytoskeleton following loss of anchorage in epithelial cells causes release of 
pro-apoptotic  factors  from  their  sequestration  on  cytoskeletal  filaments, 
contributing  to  anoikis  (Puthalakath  et  al.  1999;  Puthalakath  et  al.  2001).  
Epithelial  cells  also  receive  adhesion  signals  from  surrounding  cells  via 
adherens junctions, mediated primarily by E-cadherin (Nagafuchi et al. 1987).  
Removal  of  E-cadherin  signalling  is  thought  to  contribute  to  detachment-
induced anoikis (Fouquet et al. 2004).   
Oncogenes  such  as  Ras  allow  anoikis  evasion  via  activation  of  pro-
survival pathways, including PI3K/Akt and Raf/MAPK, and inhibition of pro-
apoptotic  proteins  including  Bad,  Bim,  Bak,  and  Fas  (Khwaja  et  al.  1997; 
Fenton et al. 1998; Rosen et al. 1998; Bonni et al. 1999; Rosen et al. 2000; 
McFall et al. 2001; Rong et al. 2005; Liu et al. 2006; Jin et al. 2007; Vasudevan 
et al. 2007; Goldstein et al. 2009).  It has recently been reported that autophagy 
is induced following cell detachment of all kinds, and that this may promote the 
survival of cells rather than apoptosis (Fung et al. 2008).  This discovery led 
review authors to speculate that autophagy may allow detached cancer cells to 
survive for long periods ‘dormant’, as did cells in a breast cancer model lacking 
β1  integrin  expression  (White  et  al.  2004;  Aguirre-Ghiso  2007;  Lock  and 
Debnath 2008). 
  
1.2.3 How anchorage signals feed into cell cycle controls 
Mitogen signals alone are not sufficient to drive cell cycle progression, 
and a combination of anchorage and mitogenic signals is required to bypass the 
G1/S phase restriction point in normal adherent cells (Assoian and Schwartz   53 
2001).  This is due to the level of sustained ERK signalling needed to induce 
cyclin D1 transcription – if either mitogens or anchorage are missing, then the 
period of ERK phosphorylation is limiting (Zhu and Assoian 1995; Lavoie et al. 
1996;  Miyamoto  et  al.  1996;  Renshaw  et  al.  1997;  Weber  et  al.  1997a).  
Consistent with this, cyclin D1 transcription can be restored by constitutively 
activating  ERKs,  and  ERK  activation  is  dispensable  if  cyclin  D1  is 
overexpressed (Roovers et al. 1999; Villanueva et al. 2007).  As well as integrin 
ligation, cytoskeletal integrity and a ‘spread’ cell shape have been identified as 
essential for cell cycle progression in anchorage-dependent cells (Böhmer et al. 
1996; Huang et al. 1998; Aplin and Juliano 1999).  
When translated, cyclin D1 binds to CDK4/6 and this enzyme complex 
phosphorylates the retinoblastoma protein Rb, thus releasing E2F transcription 
factors from their repressed state and allowing transcription of S phase genes 
such as cyclin A (Weinberg 1995) (Figure 1- 10).  Cyclin D1 overexpression is 
sufficient to promote S phase entry in suspended Rat1 cells (Resnitzky 1997).  
However,  in  the  absence  of  anchorage,  cyclin  D-CDK4/6  is  not  induced  in 
sufficient quantities to titrate p27 away from cyclin E-CDK2, and Rb cannot be 
phosphorylated by either CDK (Assoian 1997).  Not all ECM components have 
a  positive  effect  on  cyclin  D1  transcription:  for  example,  fibronectin  will 
promote transcription and cell-cycle progression, while high molecular weight 
hyaluronan antagonises mitogenic signalling and inhibits cyclin D1 induction 
(Kothapalli et al. 2007).   This demonstrates that the cell cycle is sensitive to 
changes in the composition of the microenvironment, and does not respond only 
to its state of physical attachment.  Cyclin D1 is therefore a key barometer of 
the total anchorage input to the cell cycle, and because the protein is so labile, 
levels are quick to respond to downregulation when the cell is unattached (Diehl 
et al. 1998). 
In addition to activation of the ERK-MAPK pathway, by integrins via 
Rho, the focal adhesion kinase (FAK) also contributes to cell cycle signalling 
from  integrin  clusters,  both  by  activating  cyclin  D1  transcription  via  the 
transcription factor KLF8 (Zhao et al. 2003) and by promoting the proteolytic 
destruction of p27 via the E3 ubiquitin ligase component Skp2 (Carrano et al. 
1999;  Bond  et  al.  2004).    Both  p21  and  p27  CDK  inhibitors  are  induced  54 
 
 
 
 
 
 
Figure 1- 10: How anchorage signals contribute to G1/S phase progression. 
Signals from the  extracellular matrix cooperate  with mitogens to drive cells into S 
phase.  In particular, anchorage signals are required for cyclin D1 induction at both the 
mRNA and protein level; downregulation of the  CDK inhibitors p21 and p27; and 
induction of cyclin A transcription.  See text for references. Diagram adapted from 
Assoian 1997.   55 
following detachment and loss of integrin signalling (Zhu et al. 1996).  In the 
case  of  p27,  this  is  achieved  through  increased  stabilisation  and  decreased 
proteolysis of the protein via control of Skp2 mRNA and protein by FAK. In the 
case of p21, control is again through proteasomal degradation, via Cdc42 and 
Rac1  signalling  from  integrins  (Bao  et  al.  2002).   These  results  explain  the 
anchorage dependence of cyclin E-CDK2 activity, which is inhibited by p21 
and p27 (Fang et al. 1996). 
Cyclin A induction is another factor limiting cell cycle progression in 
detached cells, as this was found to be lacking, independent of cyclin D and 
cyclin E expression, in NRK cells, and re-expression of cyclin A was sufficient 
to rescue S phase entry and cell division (Guadagno et al. 1993).  Cyclin A 
promoter  activity  depends  on  both  Rb-family  phosphorylation,  which 
determines the timing of activation, and on CREB phosphorylation and binding 
to the cAMP response element (CRE) located in the cyclin A promoter, which 
regulates the extent of induction (Bottazzi et al. 2001).  However, Bottazzi et al 
found  that  CREB  phosphorylation  depends  only  on  mitogenic  and  not  on 
anchorage signalling, so the reason why cyclin  A expression was anchorage 
dependent in NRK cells, which already have a defective Rb checkpoint, was 
unclear.  Kramer et al found that the binding of CCAAT-binding protein (CBP) 
to the cyclin A promoter correlated with cyclin A expression and was anchorage 
dependent  in  NRK  cells,  so  this  may  explain  the  anchorage  dependence  of 
cyclin A expression seen in the later paper (Krämer et al. 1997). 
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1.3 Cell transformation and cancer 
1.3.1 Transformation and tumourigenesis as multistep processes 
Cancer  has  long  been  recognised  as  a  heterogeneous  disease,  with 
manifold causes, including exposure to environmental carcinogens, congenital 
and spontaneous mutations, and viral infection.  Any tissue can be affected, 
from  skin  epithelia  to  blood  leukocytes,  with  the  common  factor  being  the 
inappropriate proliferation of cells at the expense of healthy tissue function.  
Malignancies are clinically subdivided into three types, according to the cell of 
origin:  epithelial  carcinomas,  e.g.  breast  cancer;  cancers  in  tissues  of 
mesenchymal  origin,  such  as  connective  tissue,  muscle,  and  bone,  e.g. 
osteosarcomas;  and  leukaemias  and  lymphomas,  originating  in  the 
haematopoietic cells of the blood and lymph.  Although the causative lesions 
vary  between  subtypes,  there  are  broad  parallels  in  the  process  whereby  a 
normal healthy cell becomes cancerous and forms a tumour, known as cellular 
transformation and tumourigenesis.  The discovery over many years of cancer-
causing  genetic  changes  has  revealed  that  more  than  one  modification  is 
required  to  transform  a  cell,  although  often  one  change  will  increase  the 
probability of further spontaneous mutation (Loeb et al. 1974; Clark et al. 1988; 
Christofori and Hanahan 1994; Kinzler and Vogelstein 1996; Loeb et al. 2008).  
Generally,  these  changes  can  be  classified  into  oncogenes,  which  promote 
tumourigenesis  upon  activation  or  overexpression,  and  tumour  suppressors, 
whose inactivation precipitates tumourigenesis.  Occasionally a single protein 
turns out to have both oncogenic and tumour-suppressive properties depending 
on the cellular context, but these distinctions are still useful in thinking about 
the aetiology of cancer and the tumourigenic process.  
Oncogenes were first isolated as transforming components from tumour-
promoting viruses (Vogt and Dulbecco 1960; Harvey 1964; Todaro et al. 1964; 
Huebner  and  Todaro  1969;  Martin  1970).    The  DNA  from  tumours  was 
sufficient to transform normal cells, and normal cells were found to contain 
endogenous ‘proto-oncogenes’ related to the genes in tumour viruses (Stehelin 
et al. 1976; Shih et al. 1979).  The Ras family of oncogenes were identified in 
rat  sarcoma  viruses  and  found  to  encode  GTP-binding  proteins,  unlike  the 
original viral oncogene, src, which is a tyrosine kinase (Scolnick et al. 1979).    57 
The oncogenic mutation in bladder cancer cells was discovered to be a single 
amino acid change at position 12, replacing glycine with valine (Reddy et al. 
1982; Tabin et al. 1982).  This bladder cancer mutation was found to be in the 
Ras gene (Der et al. 1982; Parada et al. 1982).  Cancers induced by chemical 
mutagens were also found to have mutant Ras, indicating oncogenic mutation as 
the mechanism underlying tumourigenesis in all cancers, whether from viruses, 
carcinogens or spontaneous lesions (Sukumar et al. 1983).  The G12V activating 
mutation in Ras was found to decrease its intrinsic GTPase activity (Gibbs et al. 
1984; McGrath et al. 1984; Sweet et al. 1984) and more importantly, prevent the 
stimulation  of  GTP  hydrolysis  by  GTPase-activating  proteins,  or  RasGAPs 
(Trahey and McCormick 1987; Adari et al. 1988).  Since Ras is active in its 
GTP-bound  form,  the  G12V  mutation  confers  constitutive  activation  of  Ras 
downstream effectors, including the Ras/ Raf/ MEK/ ERK MAPK pathway, and 
PI3K/ Akt signalling (Marshall 1996). 
The  first  tumour  suppressor  gene  to  be  defined  was  Rb,  which  was 
cloned following initial mapping of the locus in patients with retinoblastoma 
(Cavenee  et  al.  1983;  Friend  et  al.  1986)  and  subsequently  found  to  play  a 
central  role  in  the  G1/S  checkpoint  due  to  its  inhibition  of  E2F-mediated 
transcription  (Chellappan  et  al.  1991;  Bartek  et  al.  1996).    The  celebrated 
‘guardian of the genome’, p53, mediator of the DNA damage checkpoint, was in 
fact originally thought to be an oncogene when the protein was first isolated 
bound to the viral oncoprotein LT (Lane and Crawford 1979; Linzer and Levine 
1979).  Subsequent work showed that both LT binding, and the frequent p53 
mutations found in cancer cells, actually inactivated the protein, establishing it 
as a tumour suppressor (Baker  et al. 1990; Levine et al. 1991; Lane 1992).   
Most  tumour  suppressors  either  directly  inhibit  proliferation,  such  as  Rb 
(“gatekeepers”), or maintain genome stability, such as BRCA2 (“caretakers”).  
p53’s key role in the DNA damage checkpoint means it may be regarded as 
both a gatekeeper, controlling cell cycle arrest and apoptosis, and a caretaker, 
whose function ensures the stability of the genome (Kastan et al. 1991; Lane 
1992; Kinzler and Vogelstein 1997; Bunz et al. 1998).  
The classical view assumes that oncogenic mutations, such as activation 
of  Ras,  are  dominant,  while  tumour  suppressive  mutations,  such  as  Rb   58 
inactivation,  are  recessive,  and  both  gene  copies  must  be  inactivated  before 
cancer  can  occur.    This  is  known  as  the  two-hit  hypothesis,  and  was  first 
described following statistical analysis of retinoblastoma incidence in patients 
with  both  inherited  and  spontaneous  Rb  mutations  (Knudson  1971).  
Subsequently, some tumour suppressor genes were found to be exceptions to 
this rule, since inactivation of just one allele produces a phenotype.  Such genes, 
for example the CDK inhibitor p27, are known as haploinsufficient (Fero et al. 
1998).  
In  cancers  that  characteristically  show  particular  mutations  at  certain 
histological  stages,  a  ‘typical’  process  of  cellular  transformation  and 
tumourigenesis can be described (Figure 1- 11).  This was first carried out for 
colon cancer, where the inactivation of the APC (adenomatous polyposis coli), 
DCC (deleted in colon cancer), and p53 tumour suppressor genes together with 
the  oncogenic  activation  of  Ras  were  described  as  contributory  to  the 
tumourigenic  process:  in  this  case,  progression from  normal  epithelium  to  a 
non-cancerous benign polyp through intermediate and late adenoma stages to a 
fully invasive and possibly metastatic carcinoma (Fearon and Vogelstein 1990). 
While it may be argued that there is no ‘typical’ tumourigenic process, 
this model remains the basis for considering the mechanisms of tumourigenesis 
as a stepwise process.  Notably, the original Vogelstein model did not specify 
with  any  rigidity  the  precise  order  of  mutations;  now  the  timing  of  genetic 
alterations  in  all  cancer  types  has  assumed  greater  importance  (alongside 
frequency of presentation in tumours), indicating which are truly independent 
causative or initiating events, which are necessary to support other mutations, 
and which are simply incidental to the state of hyperproliferation (Kinzler and 
Vogelstein 1996; Buerger et al. 1999; Futreal et al. 2004; Welsch et al. 2007; 
Loeb  et  al.  2008).    In  the  case  of  Ras  and  p53,  the  mutations  often  occur 
together,  as  oncogenic  Ras  is  antiproliferative  in  the  presence  of  a  p53 
checkpoint (Hirakawa and Ruley 1988; Ridley et al. 1988; Hicks et al. 1991).  
Together,  oncogenic  Ras  and  mutant  p53  cooperate  to  cause  a  catalogue  of 
genetic changes characteristic of transformation (Lloyd et al. 1997; McMurray 
et al. 2008).   59 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- 11: Vogelstein’s colon cancer model. 
Examples of common genetic changes associated with the progression from normal 
colon epithelium to cancer.  Colorectal cancer is especially amenable to this type of 
analysis, since the histological stages of tumourigenesis are  well defined and many 
tissue samples are available for study.  APC = adenomatous polyposis coli, an inhibitor 
in the  Wnt  mitogenic pathway  frequently lost in both inherited and sporadic colon 
cancers.  DCC = deleted in colon cancer, a protein involved in cell adhesion.  The gene 
is at the 18q chromosome locus, which also contains the Smad4 gene, and is frequently 
lost in colon cancer.  Diagram adapted from Kinzler and Vogelstein 1996.   60 
In  parallel  with  investigations  into  the  causative  mutations  in  human 
cancers,  work  in  several  cell  lines  has  sought  to  determine  the  biochemical 
effects  of  and  interplay  between  these  genetic  changes,  studying  in  vitro 
‘transformation’  as  a  model  for  in  vivo  tumourigenesis.    From  the  earliest 
studies  on  the  effect  of  tumourigenic  viruses  on  established  cell  lines,  with 
unknown mutations (Vogt and Dulbecco 1960; Todaro et al. 1964), work has 
moved  on  to  using  cultured  cells  with  defined  genetic  changes  introduced.  
Genetic  changes  can  be  introduced  one  by  one,  to  study  their  effects  both 
individually  and  in  combination  (Hahn  et  al.  1999;  Rangarajan  et  al.  2004; 
Funes  et  al.  2007).    These  cellular  models  of  tumourigenesis  have  had 
significant success in reproducing features of human cancers, including ovarian 
cancer (Liu et al. 2004b), breast cancer (Elenbaas et al. 2001), and glioma (Rich 
et al. 2001).  The classical characteristics common to transformed cells include 
focus formation (proliferation of a small clone over and above a monolayer, 
indicating loss of contact inhibition); mitogen independence; increased motility 
and other morphological changes; and colony formation in soft agar (indicating 
loss  of  anchorage  dependence).    These  and  other  properties  are  also 
characteristic of cancer cells, as detailed below.  
 
1.3.2 Hallmarks of cancer: independence from extracellular cues 
The reason for several changes being required to transform normal cells 
into  a  cancer  is  twofold:  firstly,  because  of  the  multiple  internal  control 
mechanisms that regulate the behaviour of normal cells to achieve coordinated 
function of the tissue; and secondly, because of the reliance of normal cells on 
extracellular cues to drive their growth and proliferation.  In order to become 
tumourigenic, cells must be able to divide regardless of external signals, and 
also escape any antiproliferative or pro-apoptotic cues.  These key elements led 
Hanahan and Weinberg to propose the six “hallmarks of cancer” (Hanahan and 
Weinberg 2000): 
1)  Self-sufficiency in growth signals 
2)  Insensitivity to anti-growth signals 
3)  Limitless replicative potential 
4)  Evading apoptosis   61 
5)  Sustained angiogenesis 
6)  Tissue invasion and metastasis 
The first four points refer to cancer at the cellular level, while the latter two 
refer to the maintenance and development of the tumour as a whole, and are 
relevant to solid-tissue cancers of epithelial and mesenchymal origin rather than 
haematological disorders. 
   
1.3.2.1  Self-sufficiency  in  growth  signals/  Insensitivity  to  anti-growth 
signals 
A cell can become self-sufficient for mitogens in several ways: (a) by 
overproduction  of  the  mitogens  themselves,  such  as  PDGF  (Potapova  et  al. 
1996); (b) by hyperactivation of mitogen receptors such as the EGFR (Haley et 
al.  1989);  (c)  by  activation  of  downstream  signalling  proteins,  such  as  Ras 
(Malumbres and Pellicer 1998);  and (d) by activation of transcription factor 
targets  of  mitogen  signalling,  such  as  Myc  (Pelengaris  et  al.  2002).  
Overactivation of signals earlier in the hierarchy can affect several downstream 
pathways, including cell growth and survival as well as proliferation.  In this 
way, a single mutation can fulfil more than one cancer requirement at once.  For 
example,  Ras  downstream  targets  include  PI3K,  which  signals  to  promote 
growth via mTOR and to inhibit apoptosis, as well as the well-characterised 
Raf/MEK/ERK  MAPK  pathway  promoting  cell-cycle  progression  (Marshall 
1996).  Constitutive activation of oncogenes may in itself confer insensitivity to 
anti-growth signals, but in many cases inactivation of tumour suppressors is also 
required  to  overcome  mechanisms  that  act  to  prevent  inappropriate 
proliferation, such as cell cycle arrest, apoptosis and senescence.  Enforced cell 
cycle progression by oncogenes can initiate a DNA damage response by causing 
replication  stress,  leading  to  double-strand  breaks  and  activation  of  p53-
dependent checkpoint mechanisms.  This will result in senescence, unless p53 
or  Chk2  is  also  inactivated  (Bartkova  et  al.  2006;  Di  Micco  et  al.  2006).  
Activation of a DNA damage response by oncogenes therefore presents a strong 
selection pressure for p53 mutation, potentially explaining the high incidence of 
p53 mutations in tumours (Gorgoulis et al. 2005; Halazonetis et al. 2008). 
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1.3.2.2 Limitless replicative potential 
Limitless replicative potential can be regarded partly as an evasion of 
cellular  senescence  and  partly  as  maintenance  of  a  more  ‘primitive’, 
undifferentiated cell phenotype.  Since these are also properties of stem cells, 
much has been made recently of the possibility that tumours contain initiating 
‘cancer  stem  cells’  as  well  as  mutated  ‘progenitor’  cells  and  peripherally 
recruited stromal cells, which are not in themselves tumourigenic (Reya et al. 
2001; Visvader and Lindeman 2008).  These cancer stem cells are thought to be 
refractive  to  both  chemotherapy  and  radiotherapy,  thus  allowing  relapse  of 
tumour formation after treatment (Hirschmann-Jax et al. 2004; Setoguchi et al. 
2004; Locke et al. 2005; Patrawala et al. 2005; Diehn et al. 2009).  Although 
this appears to contradict the ‘clonal expansion’ theory of cancer progression, 
where the single most successful genotype dominates, it is likely that tumour 
evolution involves a relatively high mutation rate and not all cells would be 
under selective pressure to maintain stem-like properties (Nowell 1976; Stingl 
and  Caldas  2007).      However,  recent  evidence  has  suggested  that  more 
individual tumour cells may possess ‘stem-like’ tumourigenic properties than 
previously thought, as defined by the conditions in which single cells are able to 
initiate  tumours  in  nude  mice  (Quintana  et  al.  2008).    In  cells  which  are 
naturally  able  to  dedifferentiate,  such  as  Schwann  cells,  the  reacquisition  of 
stem-like  proliferative  ability  is  relatively  simple  to  achieve,  but  it  is  still 
unclear how ‘terminally’ differentiated tissues revert to unlimited proliferation, 
unless the tumour initiates in the stem cell compartment, as increasingly looks 
to be the case (Stevens and Fields 2002; Perez-Caro et al. 2009).  
There  are  two  senescence  mechanisms  that  limit  the  proliferation  of 
potential  cancer  cells:  replicative  senescence  due  to  telomere  erosion,  and 
senescence  in  response  to  intracellular  or  extracellular  stresses (Mathon  and 
Lloyd 2001).  Evading replicative senescence in human cells requires either the 
activation of telomerase, or an alternative mechanism for lengthening telomeres 
(ALT) (Meyerson et al. 1997; Neumann and Reddel 2002).  Importantly, p53 
mutation also allows cells to tolerate telomere shortening, but this additionally 
results in chromosome fusions and genome instability (Chin et al. 1999).  Since 
activation of oncogenes in itself constitutes an intracellular stress, as described   63 
above, there is already a high selective pressure for p53 mutation in neoplastic 
cells.   
Paradoxically,  although  senescence  is  often  regarded  as  a  barrier  to 
tumourigenesis,  senescence  mechanisms  may  also  play  a  role  in  promoting 
cancer (Campisi and Judith 2008).  Genotoxic stress, such as that encountered in 
cells with oncogenic Ras mutations, can lead to a senescent phenotype which 
involves the secretion of inflammatory cytokines, creating a microenvironment 
favourable for tumour development (Coppé et al. 2008).  
 
1.3.2.3 Evading apoptosis 
As  described  in  section  1.2.2,  many  oncogenes  upregulate  signalling 
through survival pathways, which inhibit pro-apoptotic proteins such as Bad and 
Bim in cancer cells (Bonni et al. 1999; Goldstein et al. 2009).  p53 inactivation 
prevents the apoptotic response to DNA damage checkpoint activation (Gottlieb 
and Oren 1998).  Both Ras and Myc can promote apoptosis in the absence of 
cooperating mutations (Fikaris et al. 2006; Murphy et al. 2008).  Myc, when 
activated  alone,  induces  programmed  cell  death,  but  when  an  anti-apoptotic 
gene  such  as  Bcl-2  is  also  activated,  the  combination  effectively  drives 
overproliferation (Strasser et al. 1990). 
 
1.3.2.4 Sustained angiogenesis 
Angiogenesis allows a tumour mass to grow beyond the maximum size 
for  oxygen  diffusion  alone  to  support  normal  aerobic  cellular  respiration 
(Folkman  1992).    New  blood  vessel  formation  is  triggered  under  hypoxic 
conditions,  but  counteracted  by  p53;  hence  p53  loss  promotes  sustained 
angiogenesis  (Teodoro  et  al.  2006).    In  addition,  cancer  cells  frequently 
upregulate glycolytic respiratory pathways in order to better survive in hypoxic 
conditions (Funes et al. 2007). 
  
1.3.2.5 Loss of anchorage dependence, tissue invasion and metastasis 
The invasive and/or metastatic properties of late-stage cancers define 
them  as  malignant  and  are  often  the  cause  of  fatality,  as  they  grow  to  the 
detriment  of  surrounding  healthy  tissue  (Sahai  2007).    Acquisition  of  an   64 
invasive and metastatic phenotype is associated  with altered adhesion to the 
extracellular matrix, often in response to an inflammatory microenvironment, 
and changes in signalling to the cytoskeleton to produce a motile cell (Brown 
and  Ruoslahti  2004;  Mantovani  2008;  Sanz-Moreno  et  al.  2008;  Kim  et  al. 
2009b).    For  epithelial  cancers,  the  process  may  involve  an  epithelial-
mesenchymal  transition  (EMT),  characterised  by  downregulation  of  the 
adherens junction protein E-cadherin, a morphological change from a cuboid to 
a  more  elongated,  ‘fibroblast-like’  shape  due  to  dismantling  of  cell-cell 
junctions and loss of cell polarity, and an increase in migratory characteristics 
(Thompson et al. 2005).  The expression of matrix metalloproteases such as 
MMP3 can induce EMT, via induction of Rac1b (Radisky et al. 2005).  Along 
with the downregulation of E-cadherin, cells acquire the mesenchymal ability to 
survive  detachment  from  their  neighbours,  and  no  longer  undergo  anoikis 
(Derksen et al. 2006).  
Anchorage independence forms part of the general self-sufficiency in 
growth signals that is the first cellular hallmark of cancer.  Both the anchorage-
controlled  kinases,  FAK  and  ILK,  have  been  found  to  be  overexpressed  in 
cancers,  allowing  signalling  independent  of  integrin  ligation  (Radeva  et  al. 
1997; Kahana et al. 2002; Hecker et al. 2004; McDonald et al. 2008).  Loss of 
anchorage dependence for survival is an essential requirement for metastasis to 
distant sites, since it involves movement through blood and/or lymphatic fluid 
(Mahoney et al. 2002; Geiger and Peeper 2007).  Loss of anchorage dependence 
for proliferation is equally important in metastatic cells, as they must be able to 
divide  in  a  new  tissue  microenvironment (Moore  et  al.  1998;  Weber  2008).  
Anchorage  independence  in  vitro  correlates  strongly  with  tumourigenic 
potential and metastasis in nude mice (Shin et al. 1975; Cifone and Fidler 1980; 
Nakanishi et al. 2002).  
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1.4 Genome instability 
Genome  instability  was  described  by  Hanahan  and  Weinberg  as  a 
facilitating mechanism which would help cells  acquire the six ‘hallmarks of 
cancer’, considering the low probability of accumulating enough genetic lesions 
to achieve this in a single cell given a normal, stable genome (Hanahan and 
Weinberg  2000).    The  concept  of  genome  instability  may  be  defined  as  an 
increase  in  the  rate  at  which  DNA  and  chromosomes  are  damaged,  lost  or 
rearranged, sometimes known as a mutator phenotype (Morgan 2007; Loeb et 
al. 2008).  Although it has been argued that the spontaneous mutation rate is 
sufficient  to  explain  the  number  of  genetic  changes  necessary  for 
tumourigenesis (Tomlinson et al. 2002; Bodmer et al. 2008), it is nevertheless 
clear that the majority of cancers exhibit some form of genome instability, and 
this often accelerates tumour progression (Lengauer et al. 1998; Cahill et al. 
1999; Stoler et al. 1999; Shih et al. 2001; Nowak et al. 2002; Sieber et al. 2003; 
Kops et al. 2005).  Large-scale genomic changes such as translocations and gain 
or loss of whole chromosomes have long been recognised as a feature of tumour 
cells – the work of Theodor Boveri led him to propose that aneuploidy is a 
cause  of  cancer  in  1914  (Boveri  1914),  and  the  Philadelphia  chromosome 
translocation in chronic myelogenous leukaemia was described in 1973 (Rowley 
1973).  The discovery of oncogenes and tumour suppressors and their roles in 
cellular transformation dominated cancer research in the latter part of the 20
th 
century  (McCormick  1999).    Although  work  initially  focused  on  mitogen 
signalling  pathways,  the  discovery  that  inherited  cancer  predisposition 
syndromes  were  caused  by  mutations  in  genes  involved  in  DNA  damage 
sensing and repair reignited interest in genome stability as a tumour suppressive 
mechanism  (Kinzler  and  Vogelstein  1997;  Hoeijmakers  2001;  Cheok  et  al. 
2005; Deng 2006).  
Instability  can  arise  at  both  the  chromosomal  and  single-nucleotide 
level,  through  a  multitude  of  mechanisms  (Aguilera  and  Gómez-González 
2008).  An increase in point mutation may be due to defects in mismatch repair, 
such as the MSH2 gene mutated in hereditary non-polyposis colorectal cancer 
(HNPCC) (Fishel et al. 1993; Papadopoulos and Lindblom 1997).  Since short 
repeating  sequences  or  ‘microsatellites’  are  particularly  prone  to  replication   66 
errors, defects in mismatch repair also lead to microsatellite instability, where 
the  repeating  sequences  vary  in  length  (Ionov  et  al.  1993;  Thibodeau  et  al. 
1993).  Where repeated stretches occur within genes, the variation in number of 
nucleotides can lead to frame shifts, leading to protein truncations.  Truncations 
of proteins such as the TGFβ receptor, which mediates antiproliferative signals, 
are  extremely  common  in  both  HNPCC  and  sporadic  colorectal  cancers 
exhibiting microsatellite instability (Jacob and Praz 2002). 
Defects in nucleotide excision repair can also lead to increased point 
mutation  (Hoeijmakers  2001).    For  example,  xeroderma  pigmentosum  (XP) 
patients are hypersensitive to UV radiation and have an increased risk of cancer 
due  to  mutations  in  one  of  the  8  XP  genes,  encoding  damage  recognition, 
helicase  and  nuclease  components  of  the  repair  pathway  (Cleaver  2005).  
Defects  in  DNA  repair  may  initially  cause  a  damage  checkpoint  response, 
resulting in a selective pressure for p53 mutation to allow cancer to develop 
(Spatz et al. 2001). 
Chromosomal  instability  exists  in  two  forms:  structural,  involving 
inappropriate  chromosome  fusions,  breakages  and  translocations,  and 
numerical, where gains or losses of whole chromosomes results in aneuploidy 
(Gollin 2005).  Structural abnormalities may result from: 
•  DNA double-strand breaks (DSBs).  These arise because of defects in 
DSB  repair  (Mills  et  al.  2003),  collapsed  replication  forks  due  to 
impaired DNA damage response and replication stress (Halazonetis et 
al. 2008), or failure to separate or disentangle sister chromatids due to 
topoisomerase or separase mutations (Shepard et al. 2007; Luo et al. 
2009). 
•  Telomere  erosion  (‘crisis’)  followed  by  end-to-end  fusion  of 
chromosomes (Hastie et al. 1990; DePinho 2000; Hackett et al. 2001). 
•  Incomplete replication, or rereplication of DNA, leading to breakage, or 
recombination  as  intrachromosomal  duplications  (Blow  and  Gillespie 
2008). 
When  subjected  to  replication  stress,  chromosome  breakages,  amplifications 
and  deletions  occur  at  common  fragile  sites  due  to  incomplete  replication 
(Glover et al. 1984; Coquelle et al. 1997).  Microsatellite expansion resulting   67 
from mismatch repair defects may also increase breakage at rare fragile sites 
(Hewett et al. 1998).  Fusion of two broken ends may result in the formation of 
a dicentric chromosome and initiation of a breakage-fusion-bridge cycle, where 
the chromosomes are attached at two centromeres instead of one, leading to 
random breakage of the DNA when the chromosome is pulled to opposite poles 
at anaphase (McClintock 1939).  This extreme instability is frequently fatal if it 
occurs  in  many  chromosomes,  even  in  cells  with  a  defective  DNA  damage 
checkpoint (mitotic catastrophe) (Castedo et al. 2004).  All these mechanisms 
involve DNA damage, and so normally activate a pro-apoptotic or pro-senescent 
response,  which  acts  as  a  barrier  to  genome  instability  (Vaziri  et  al.  2003; 
Zhivotovsky and Kroemer 2004; Gorgoulis et al. 2005). 
Numerical abnormalities, or aneuploidy, may result from: 
•  Defects in the spindle checkpoint, such as Bub1 mutation, leading to 
nondisjunction of chromatid pairs (Cahill et al. 1998; Musio et al. 2003; 
Weaver et al. 2006) 
•  Cytokinesis failure, leading to tetraploidy, centrosome reduplication in 
the following cycle, and increased risk of non-disjunction (Ganem et al. 
2007). 
•  Multipolar  spindle  formation,  due  to  extra  centrosome  duplication 
cycles, the presence of extra centrosomes following cytokinesis failure, 
or  abnormal  cell  shape,  leading  to  unequal  chromatid  segregation 
between more than two spindle poles (Zhou et al. 1998; Meraldi et al. 
2002; Sluder and Nordberg 2004; Théry et al. 2007) 
Non-disjunction,  caused  by  premature  spindle  checkpoint  inactivation  and 
resulting  in  trapping  of  lagging  chromosomes  at  the  midbody,  will  block 
cytokinesis (Shi and King 2005; Steigemann et al. 2009).  Tetraploidy may also 
occur  due  to  mitotic  slippage,  where  prolonged  activation  of  the  spindle 
checkpoint  leads  to  a  return  to  G1  phase  without  undergoing  mitosis  or 
cytokinesis (Rieder and Maiato 2004; Brito and Rieder 2006).  A p53-dependent 
‘tetraploidy checkpoint’ has been reported to act in G1 to eliminate tetraploid 
cells before progression to S phase (Andreassen et al. 2001; Meraldi et al. 2002; 
Stukenberg  2004;  Fujiwara  et  al.  2005),  but  its  existence  is  controversial 
(Uetake and Sluder 2004; Wong and Stearns 2005; Ganem and Pellman 2007).    68 
It  has  been  argued  that  aneuploidy  most  often  arises  via  a  tetraploid 
intermediate,  which  in  turn  occurs  either  due  to  reduplication  of  the  entire 
genome, mitotic slippage, or cytokinesis failure (Fujiwara et al. 2005; Storchova 
and Kuffer 2008).  The hypothesis predicts that cells with double the usual 
number of chromosomes are far more likely to undergo a spindle checkpoint 
slippage and unequal genome segregation than ordinary diploid cells (Shi and 
King  2005).    The  interplay  between  the  various  mitotic  defects  means  that 
aneuploid cell populations often have a highly unstable chromosome number, or 
will go through a period of rapid variation before settling on a ‘favourable’ 
chromosome  complement  which  is  then  stably  passed  on  to  daughter  cells 
(Albertson et al. 2003). 
In recent years, the role of aneuploidy in tumourigenesis has resurfaced 
as  a  point  of  intense  discussion,  with  the  relative  importance  of  genomic 
instability as a source of mutation, and the selective pressures acting on tumour 
evolution, debated (Cahill et al. 1999; Marx 2002; Sieber et al. 2003).  The 
majority view emerging is that aneuploidy can play both permissive and active 
roles in sporadic cancer development (Pihan 2003; Rajagopalan and Lengauer 
2004; Weaver et al. 2007; Chandhok and Pellman 2009).  Colon cancers, other 
than those initiated due to defects in mismatch repair, tend to show high levels 
of chromosomal instability, but not microsatellite instability (Lengauer et al. 
1997).  This dichotomy lends support to the view that aneuploidy is not simply a 
side effect of tumour development: chromosomal abnormalities do not occur 
where another form of genomic instability exists (Vogelstein, in (Marx 2002)).  
The discovery of a subset of tumours that are both stably diploid and free of 
hypermutation  was  a  puzzle  until  it  was  found  that  cancers  may  also  have 
altered  epigenetic  regulation  (Hawkins  et  al.  2001;  Jones  and  Baylin  2007).  
Genes can therefore be activated or silenced without showing up as mutations 
on  comparative  genomic  arrays,  with  cancers  in  some  cases  giving  single 
nucleotide polymorphism (SNP) patterns almost indistinguishable from normal 
cells.    Despite  being  genetically  stable,  these  tumours  can  be  aggressive, 
indicating  that  although  genome  instability  is  a  contributing  factor  in  many 
cancers, it is not necessary for malignancy (McKenna et al. 2008).   69 
1.5 Introduction to this thesis 
As  described  in  the  previous  sections,  many  aspects  of  cell  cycle 
regulation and its relevance in cancer have already been elucidated.  Anchorage 
independence  has  been  identified  as  a  key  property  of  cancer  cells,  and  is 
thought to promote metastasis (Cifone  and Fidler 1980; Wang 2004;  Weber 
2008).    However,  the  genetic  changes  known  to  correlate  with  anchorage 
independence in cancer cells do not explain some of the observations made in 
anchorage dependent models of cell transformation, as described below.  The 
aim of this work was therefore to investigate the mechanisms underlying the 
establishment of anchorage dependence in tumourigenesis, using a genetically 
defined stepwise transformation model. 
The model I employed made use of the well-characterised cooperation 
between the viral SV40 Large T antigen (LT) and the oncogenic Ras G12V 
mutant (Michalovitz et al. 1987; Clark et al. 1988; Hirakawa and Ruley 1988; 
Ridley et al. 1988).  LT is an oncoprotein from the tumour virus SV40, which 
transformed cells in culture (Todaro et al. 1964).  LT was subsequently found to 
bind and inhibit p53, Rb, and the related pocket proteins p107 and p130, some 
of which were discovered as LT-binding proteins (Lane and Crawford 1979; 
DeCaprio et al. 1988; Dyson et al. 1989; Hannon et al. 1993).  Both the p53- 
and Rb-binding activities of LT were found to cooperate with oncogenic Ras in 
inducing full transformation of primary cells (Beachy et al. 2002).  Lesions in 
p53, Rb and Ras are extremely common in many types of cancer, and these 
changes have been successfully modelled in primary human cells expressing 
telomerase (Hahn et al. 1999; Elenbaas et al. 2001).  Here I have used primary 
rat  Schwann  cells,  which  do  not  require  exogenous  telomerase  for 
immortalisation (Mathon et al. 2001), and expressed LT and oncogenic Ras in a 
stepwise  manner,  to  investigate  their  effects  on  anchorage  dependent 
proliferation.  
Previous work in the lab (Mitchell et al. 2003) has established that both 
normal primary Schwann cells, and cells expressing LT, do not form colonies in 
soft  agar  and  are  therefore  anchorage  dependent.    Additional  expression  of 
oncogenic Ras
G12V in LT-expressing cells confers anchorage independence, and 
both p53 and Rb inactivation by LT, and Ras activation, are required to achieve   70 
this – any combination of two is not sufficient.  Loss of p16(INK4A) was shown 
to substitute for Rb inactivation in allowing proliferation in suspension, as it 
effectively removes the same Rb-dependent checkpoint, but again this was not 
sufficient  to  induce  anchorage  independence  in  combination  with  p53 
inactivation alone (Mitchell et al. 2003).  At the time of beginning work on this 
project, only oncogenic Ras was known to complement the effects of LT and 
allow anchorage-independent proliferation as measured by colony formation in 
soft  agar  suspension.    The  anchorage  dependence  of  LT-expressing  cells  is 
puzzling,  since  previous  reports  would  suggest  that  Rb  inactivation  would 
remove the anchorage requirement for cell-cycle progression (see section 1.2.3). 
Presumably because of the fundamental importance of correct cell cycle 
regulation,  mammalian  cells  have  developed  secondary,  ‘cryptic’  checkpoint 
mechanisms  that  may  not  be  apparent  during  normal  cell  division,  but  are 
revealed when other tumour suppressive mechanisms are lost.  This ‘belt and 
braces’ approach can be exploited when treating cancer: by either strengthening 
the secondary checkpoint, targeting pathways that are redundant in normal cells, 
or thwarting the cancer cell’s checkpoint evasion mechanism, we can hope to 
frustrate  cancerous  proliferation  with  minimal  disruption  to  normal  cell 
division.    For  example,  cancer  cells  with  multiple  centrosomes  may  evade 
potentially catastrophic multipolar divisions by grouping the extra centrosomes 
together to create a normal bipolar spindle.  If this mechanism is disrupted, by 
removing  the  non-essential  kinesin  motor  protein  HSET,  cells  with  multiple 
centrosomes are selectively killed (Kwon et al. 2008).  A similar concept has 
already been used in Phase I trials in the  clinic, to inhibit the non-essential 
poly(ADP-ribose)  polymerase  PARP  in  BRCA2-deficient  cancers,  which  are 
especially sensitive to DNA single-strand breaks (Ashworth 2008; Plummer et 
al. 2008).  The cancers are thought to be unusually dependent on the base-
excision  repair  pathway  mediated  by  PARP  in  the  absence  of  the  BRCA2 
homologous recombination pathway (Bryant et al. 2005; Farmer et al. 2005).  
Here,  we  hypothesised  that  LT-expressing  cells  use  a  secondary  ‘anchorage 
checkpoint’ mechanism, in the absence of the usual Rb-dependent checkpoint 
that senses loss of cell attachment.  This work aimed to clarify the mechanism 
of  this  novel  anchorage  checkpoint  in  cells  lacking  p53  and  Rb  function,   71 
focusing on the molecular basis of cell cycle arrest in suspension, as this could 
represent a critical barrier to transformation and potential means of suppressing 
tumourigenesis in checkpoint-deficient cells.  
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Chapter Two –Materials and Methods 
2.1 Cell Culture 
2.1.1 Schwann cell culture 
Primary Schwann cells purified from the sciatic nerves of 7-day-old rats 
(see Cheng et al. 1995) were maintained in culture on plastic dishes [Nunc] 
coated with poly-L-lysine [Sigma P-6282].  Cells were routinely cultured in 
DMEM  [Gibco  11880,  1mg/ml  D-glucose]  supplemented  with  3%  stripped 
foetal calf serum (FCS) [Biosera], 4mM L-Glutamine [Gibco 25030], 0.1mg/ml 
kanamycin  [Sigma  K1377],  2µg/ml  gentamicin  [Gibco  15710],  1µg/ml 
forskolin [Calbiochem 344270], and glial growth factor (GGF), produced in the 
lab.   Cells were maintained in the above medium, incubated at 37°C in 10% 
CO2 and 95% humidity.  Medium was changed every two days, and cells were 
passaged  every  three  days  (seeding  7x10
5  LT-expressing  cells  or  1.3x10
6 
normal Schwann cells per 15cm diameter dish), on reaching approximately 80% 
confluency.   
 
2.1.2 Phoenix cell culture 
The  retroviral  packaging  cell  line,  Phoenix  [Nolan  lab,  Stanford 
University],  was  used  to  introduce  genetic  material  into  Schwann  cells,  as 
detailed  below.    Phoenix  cells  were  routinely  cultured  on  uncoated  plastic 
dishes,  in  DMEM+Glutamax™  [Gibco  31966,  4.5mg/ml  D-glucose] 
supplemented  with  10%  foetal  bovine  serum  (FBS)  [Sigma],  0.1mg/ml 
kanamycin  [Sigma  K1377],  and  2µg/ml  gentamicin  [Gibco  15710].    Before 
seeding, cells were passed through an 18G needle, to ensure an even distribution 
on the plate.  Cells were incubated at 37°C in 10% CO2 and 95% humidity. 
 
2.1.3 MEF cell culture 
Mouse embryo fibroblasts (MEFs) from wild-type and p27Δ51 knock-in 
mice (Kiyokawa et al. 1996) were a kind gift from Dr Andrew Koff (Memorial 
Sloan  Kettering  Cancer  Center,  New  York,  NY)  and  were  cultured  in 
DMEM+Glutamax™  [Gibco  31966]  supplemented  with  10%  FBS  [Sigma],   73 
plus  antibiotics  as  above.    Cells  were  incubated  at  37°C  in  7%  CO2,  95% 
humidity and 3% O2 conditions.  
 
2.1.4 Generation of cells by Phoenix infection 
Protocol for Phoenix transfection and retroviral infection of cells 
1)  5  million  Phoenix  cells  were  seeded  on  a  10cm  plate  for  each 
transfection and left to settle overnight. 
2)  5µg  of  plasmid  DNA  was  mixed  with  500µl  of  serum  free  medium 
(DMEM  31966  +  antibiotic  only),  followed  by  17.5µl  of  PLUS™ 
reagent  [Invitrogen  18324-012],  and  left  at  room  temperature  for  15 
minutes.  A separate tube was prepared for each of the constructs and for 
the control construct pBIRD-GFP. 
3)  In fresh tubes, 25µl of Lipofectamine™ reagent [Invitrogen 11514-015] 
was mixed with 500µl of serum free medium for each transfection, and 
the DNA/PLUS™ mix from step 2 added.  The transfection mixture was 
left for a further 15 minutes at room temperature to allow DNA/lipid 
complexes to form. 
4)  Medium on Phoenix cells was replaced by 4ml serum-free medium per 
plate, washing once with serum-free medium.   
5)  The DNA/lipid complexes from step 3 were carefully added dropwise to 
the  Phoenix  plates,  rocked  gently  to  mix,  and  incubated  under  usual 
culture conditions for 3-4 hours to deliver the DNA to cells. 
6)  Transfection  medium  was  removed  and  replaced  by  normal  Phoenix 
medium containing 10% serum.  Medium was replaced after 24 hours 
with  6ml  fresh  medium  and  the  cells  were  left  overnight  to  produce 
virus. 
7)  4ml  viral  supernatant  was  collected  from  each  plate,  Polybrene® 
[hexadimethrine  bromide,  Sigma  H9268]  was  added  at  a  final 
concentration of 8µg/ml, and the solution was filtered to remove cell 
debris  before  adding  to  subconfluent  Schwann  cells/MEFs  neat.  
Phoenix plates were topped up with an extra 4ml medium to continue 
virus production.   74 
8)  Schwann  cells/MEFs  were  incubated  for  3  hours  with  the  viral 
supernatant,  then  left  to  recover  for  2  hours  in  normal  medium.    A 
second, 4 hour, infection was then carried out as in step 7, followed by 
recovery overnight.  The following day, cells were subjected to a third 
round of infection for 3 hours, before final recovery in normal medium. 
9)  Infected cells were left to recover for two days in normal medium, then 
cultured  for  at  least  2  weeks  in  medium  containing  G418  selection 
antibiotic  [Calbiochem  345812]  at  1.25mg/ml,  to  remove  non-vector 
expressing cells and ensure stable vector expression. 
 
Schwann cells “NSLT” and “NSLTRas” 
Phoenix producer cells were transfected with either LXSN empty vector, 
or H-Ras
G12V LXSN, according to the protocol above.  Normal Schwann cells 
(NS)  stably  expressing  SV40  LT,  from  the  pBabe-Puro  vector,  had  been 
previously produced in the lab.  These cells were infected at passage 6 with 
LXSN or H-Ras
G12V LXSN retroviral supernatant from the Phoenix cells, to 
create the non-clonal  “NSLT” and “NSLTRas”  cell populations used in this 
thesis.  Control infections using pBIRD-GFP-carrying retrovirus were carried 
out  in  parallel  to  estimate  the  rate  of  infection.    Rates  of  infection  were 
consistently above 50% using this protocol. 
 
shRNA-expressing NSLT cells “2”, “3”, “7”, “itoh”, and “control”  
Phoenix producer cells were transfected with the RNAi-Ready pSIREN-
RetroQ-ZsGreen vector [Clontech 632455] carrying each of the above 5 inserts 
(see  section  2.4.2).    NSLT  cells  were  infected  with  retroviral  supernatant 
produced following Phoenix cell transfection according to the protocol above.  
 
WT and p27∆51 MEFs expressing LT 
Phoenix  producer  cells  were  transfected  with  either  the  Babe-Puro 
empty  vector,  or  LT-Babe-Puro,  using  the  protocol  above.  WT  and  p27∆51 
MEFs were infected with retroviral supernatant as below, except that the second 
and third rounds of infection were omitted and cells were used in experiments 
immediately  following  overnight  recovery,  with  no  selection.    Control   75 
infections using pBIRD-GFP-carrying retrovirus were carried out in parallel to 
estimate the rate of infection.   76 
 
 
 
 
 
 
 
Figure 2- 1: pLXSN. 
The pLXSN retroviral vector (Miller and Rosman 1989) was used as an empty-vector 
control to generate “NSLT” cells, used in most experiments in this thesis.  The H-
Ras
G12VLXSN vector has the H-Ras
G12V oncogene sequence cloned into the EcoRI site 
and  was  used  to  generate  “NSLTRas”  cells  in  parallel  experiments.  The  “SV40” 
sequence  contains  an  early  promoter.  The  retroviral  long  terminal  repeat  (LTR) 
sequence drives strong expression of the cDNA.  The “Neo” gene confers resistance to 
the selection antibiotic G418.   77 
 
 
 
 
 
 
 
Figure 2- 2: pBabe-Puro. 
pBabe-Puro retroviral vector was used both as an empty-vector control, and with SV40 
LT cDNA inserted at the multiple cloning site (MCS) shown above, for MEF infections 
and  expression  of  LT  in  Schwann  cells.    The  “SV40”  sequence  contains  an  early 
promoter. The retroviral long terminal repeat (LTR) sequence drives strong expression 
of  the  cDNA.    The  “Puro”  gene  confers  resistance  to  the  selection  antibiotic 
Puromycin.  78 
 
 
 
 
 
 
 
Figure 2- 3: pSIREN-RetroQ-ZsGreen. 
The  RNAi-Ready  pSIREN-RetroQ-ZsGreen  vector  [Clontech  632455]  was used  for 
stable  expression  of  short  hairpin  RNA  (shRNA)  constructs  in  Schwann  cells  (see 
section 2.4.2).  shRNA duplexes were cloned into the vector between the BamHI and 
EcoRI sites, where insert expression is driven by the U6 promoter.  The CMV promoter 
drives constitutive expression of the Zoanthus sp. green fluorescent protein ZsGreen, 
allowing  enrichment  of  the  vector-expressing  population  by  FACS.    Vector  map 
reproduced  from  Clontech  vector  information  PT3777-5,  freely  available  online.  79 
2.1.5 Suspension culture and cell retrieval 
Schwann  cells  (NS,  NSLT  and  NSLTRas)  were  seeded  in  centrifuge 
tubes,  in  medium  as  described  in  section  2.1.1  but  also  containing  1.8% 
dissolved  methylcellulose  [Sigma  M0512],  to  form  a  semisolid  hydrogel 
suspension.  
 
To make 1.8% methylcellulose medium: 
1)  A  500ml  Duran  bottle  containing  a  magnetic  stir  bar  and  9g 
methylcellulose powder [Sigma M0512] was autoclaved. 
2)  A 500ml bottle of DMEM [Invitrogen] was warmed to 37°C and, under 
a  laminar  flow  cabinet,  poured  bit  by  bit  onto  the  autoclaved 
methylcellulose, stirring all the time with a sterile pipette to disperse 
clumps.  The bottle was then mixed on a heated magnetic stirrer for 30 
minutes-2 hours, to make sure the powder was dispersed evenly into a 
cloudy solution. 
3)  The  bottle  of  semi-dissolved  methylcellulose  was  next  placed  in  a 
bucket of ice overnight to dissolve completely. 
4)  Methylcellulose  medium  was  kept  at  4°C  and  poured  out  to  use  as 
needed.  Serum, antibiotic etc. were added just before use, as for normal 
culture medium.  
 
To seed cells in suspension,  
1)  The required volume of methylcellulose medium was warmed to 37°C, 
serum and factors were added as in section 2.1.1, and the gel poured into 
tubes as needed.  10ml methylcellulose suspension in a 50ml centrifuge 
tube was used for cell counts, and scaled up to 50ml suspension in a 
250ml tube for larger samples e.g. for Western blotting.   
2)  Cells were trypsinised and resuspended in a small volume of medium (1-
5ml depending on size of tube) and squirted into the centre of the gel 
using a sterile pipette under the surface of the methylcellulose.  800,000 
cells were seeded in 10ml, or 4 million in 50ml suspension. 
3)  The lid was closed and the tube slowly inverted at least 20 times to 
ensure  cells  were  evenly  mixed.    Tubes  were  kept  upright  in  the   80 
incubator  in  a  rack  or  beaker,  with  lids  loosely  attached  to  allow 
equilibration with the CO2-controlled atmosphere. 
4)  Suspension cultures were maintained in this way for a maximum of 72 
hours, as there was no way of replacing the medium without disturbing 
the cells. 
 
To retrieve cells:  
1)  Methylcellulose suspension was diluted first 1:2 with warm DMEM + 
1%  serum,  mixing  thoroughly,  then  the  tube  was  filled  with  further, 
cold, DMEM + 1% serum (to 50 or 250ml), inverted to mix, and the 
tubes placed on ice.   
2)  Tubes  were  centrifuged  [Beckman  Coulter  J6-M]  at  500  g  for  10 
minutes at 4°C. 
3)  Dilute medium was aspirated to the 5ml mark.  Usually there was no 
compact pellet at this stage, and cells were spread around the sides of the 
conical base of the tube.   
4)  Cells were resuspended in 10ml ice-cold PBS, carefully dislodging them 
from the walls of the tube, and transferred to a clean 15ml tube. 
5)  The suspension was centrifuged again at 500 g for 5 minutes at 4°C.  
After this, a more compact pellet usually appeared. 
6)  (a) For counting, supernatant was aspirated down to the pellet, and 500µl 
trypsin was added to dissociate cells.  The suspension was pipetted up 
and down either very gently once or twice using a 1ml Gilson tip (for 
anchorage-dependent  cells),  or  5-10  times  fairly  vigorously  using  an 
18G  needle  and  syringe  (for  colony-forming  cells).    4.5ml  normal 
medium containing serum was added to inactivate the trypsin, and the 
resulting suspension was counted in isotonic solution [Beckman Coulter 
Isoton®  II  diluent]  using  a  Coulter  counter.  Only  one  tube  was 
processed in trypsin at a time. 
6)  (b) For replating, supernatant was aspirated and the pellet resuspended    
gently in warm medium, and the cells plated straight away. 
6)  (c) For freezing a pellet for lysis, supernatant was aspirated thoroughly 
and the pellet was re-washed in 1ml ice-cold PBS to remove residual   81 
methylcellulose. The washed cells were transferred to a 1.5ml tube and 
centrifuged for 3 minutes at 3500 g in a cooled minifuge at 4°C. The 
pellet was then snap frozen in liquid nitrogen. (N.B. For cyclin IP or 
kinase assay, pellets were only used ‘fresh’ and lysed directly without 
snap freezing.)  
 
2.1.6 Harvesting attached cell pellets 
Medium  was  removed  from  cells  to  be  harvested  and  the  dishes 
immediately placed on ice.  Cells were washed twice in ice-cold phosphate-
buffered saline (PBS), and excess PBS removed.  Each dish was tilted and the 
cells scraped quickly downwards using a clean rubber policeman.  The collected 
cells were then taken up using a 1ml pipette and transferred to a 1.5ml tube 
placed on ice.  500µl extra ice-cold PBS was used to wash off any remaining 
cells and transferred to the same tube.  Cell samples were centrifuged at 3500 g 
in a cooled minifuge at 4°C for 3 minutes, all supernatant was removed and 
pellets were snap frozen in liquid nitrogen. (N.B. For cyclin IP or kinase assay, 
pellets were only used ‘fresh’ and lysed directly without snap freezing.) 
 
2.1.7 Flow cytometry 
BrdU was added to medium or methylcellulose suspension 1 hour before 
cell harvesting, and mixed thoroughly.  Samples to which BrdU had not been 
added were processed in parallel with the test samples for all conditions.  Upon 
retrieval,  the  cell  pellets  were  washed  in  ice-cold  PBS  +  1mM  EDTA, 
resuspended in 200µl of the same and then fixed in 2ml 80% ice-cold ethanol 
while vortexing.  Ethanol-fixed samples were kept at 4°C for up to two weeks 
until needed.  Samples were then washed in ice-cold PBS + 1mM EDTA to 
remove ethanol, and treated with 2M HCl for 30 minutes at room temperature 
(RT) to denature DNA, followed by 2 washes in PBS + 1mM EDTA and one in 
PBS-T (PBS + 0.1% BSA + 0.2% Tween 20).  The washed cell pellet was 
incubated for 20 minutes with 2µl anti-BrdU antibody [Roche 11170376001, 
clone 9318] at room temperature in the dark.  After two more washes with PBS-
T, the pellet was incubated with 50µl AlexaFluor® 488 fluorescent secondary 
antibody [Molecular Probes] at 1:250 in 0.1% BSA/PBS for 20 minutes at room   82 
temperature in the dark.  The stained cells were then washed once more in PBS 
+  1mM  EDTA  and  resuspended  in  300µl  propidium  iodide  (PI)  solution 
(50µg/ml PI [Sigma P-4864], 100µg/ml RNase A [Qiagen], 0.1% BSA [Sigma], 
in PBS + 1mM EDTA).  BrdU- and PI-stained cells were analysed the following 
day using a FACSCalibur flow cytometer [Becton Dickinson] and Cellquest Pro 
software.  10,000 events were collected for each sample, gated either to include 
only single cells with a DNA content between 2N and 4N (Chapter Three), or 
all single cells with >2N DNA content (see Figure 5-1). 
 
2.1.8 Roscovitine treatment 
For FACS analysis 
Attached  cells  were  treated  with  the  CDK  inhibitor  Roscovitine 
[Calbiochem 557360] added to the medium as a 10mM stock in DMSO.  Final 
concentrations of drug ranged from 5-50µM, and the treatment was left on for 
24 hours.  For the last hour of treatment, BrdU was added to the medium, before 
harvesting, fixing and staining cells as above. 
 
For analysis of giant nuclei 
Cells  were  cultured  on  PLL-coated  glass  coverslips  for  3  days,  with 
Roscovitine added to the medium as above, and replenished every 24 hours.  
After  72  hours’  treatment,  cells  were  fixed  for  20  minutes  in  4% 
formaldehyde/PBS at room temperature, washed twice in PBS, and incubated 
with Hoechst [Bisbenzimide H 33342, Fluka 14533] at a final concentration of 
170ng/ml in 0.1% BSA/PBS for 1 hour.  Coverslips were then washed 6 times 
by dipping sequentially into small containers of PBS, and mounted on glass 
microscope  slides  using  Prolong  Gold  [Invitrogen  P36930].    Slides  were 
examined using a Zeiss Axioplan 2 fluorescence microscope.  Using hand-held 
counters to keep tally, 100 nuclei were counted using the Hoechst channel, and 
the number of “giant” nuclei – that is, with an area approximately twice that of 
the majority of nuclei in the field, was noted. 
 
2.1.9 Soft agar colony formation assays 
For standard Schwann cell and MEF assays:   83 
Cells were seeded in 6-well plates at 4000 cells per well, in a top layer 
of  0.6%  agarose  [Seaplaque®,  Lonza  50101]  over  a  bottom  layer  of  0.8% 
agarose in 5:6 normal MEF or Schwann cell medium: PBS.  PBS was added 
initially to the agarose powder and autoclaved, followed by dilution of the warm 
melted agarose in medium.  MEF colonies were counted after 1 week in 10 
fields per well, using a 4x objective phase contrast microscope.  Schwann cell 
colonies were stained with MTT [Calbiochem 475989] after 2 weeks, by adding 
100µl of a 10mg/ml solution to each well and incubating overnight. 
 
To test for rare oncogenic transformation in Schwann cells (see section 5.6): 
      Cells  from  either  attached  or  replated  (2  passages  on  normal  dishes 
following 72 hours in methylcellulose suspension) cultures were used.  500 000 
cells per 15cm plate were seeded in a layer of 0.5% agarose on top of a bottom 
layer of 1% agarose [Seaplaque®, Lonza 50101] dissolved in normal medium.  
The following day, the plates were overlaid with 5ml fresh culture medium and 
fed with another 5ml each week.  Colonies were counted after 4 weeks, in 30 
fields per plate, using a 4x objective phase contrast microscope [Olympus]. 
  
Soft agar for time-lapse: 
4000 NSLT cells per well of a 12-well plate were seeded in 500µl 0.6% 
agarose.  When set, the thin layer of agar was overlaid with fresh medium and 
the plate humidified by filling unused wells with sterile water.  The plate was 
incubated  in  a  37°C  chamber  under  a  phase  contrast  microscope  and 
photographs of individual cells were taken every 15 minutes. 
 
2.1.10 Use of kinase inhibitors on NSLTRas suspended cells 
Following  NSLTRas  cell  seeding  into  methylcellulose,  the  MEK 
inhibitor U0126 [Promega V1121] or the PI3K inhibitor LY294002 [BioMol 
ST-420] were added to the suspension at 20µM final concentration in DMSO.  
Tubes were inverted slowly 20 times to mix cells with inhibitor.  DMSO was 
added at 1:1000 as a vehicle control.  Cells were then retrieved and counted in 
duplicate shortly after seeding, and a day later. 
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2.2 Protein Analysis 
2.2.1 Western blotting 
Harvested cell pellets were lysed in RIPA buffer (1% Triton X100, 0.5% 
sodium deoxycholate, 50mM Tris pH 7.5, 100mM NaCl, 1mM EGTA pH 8, 
20mM NaF, 100µg/ml PMSF, 14µg/ml aprotinin, 1mM sodium orthovanadate).  
Samples were vortexed and incubated on ice for 15 minutes, vortexing every 5 
minutes.  Lysates were then centrifuged at 12000 g in a cooled minifuge at 4ºC 
for 15 minutes before transferring the cleared supernatant to a fresh 1.5ml tube.  
Protein concentration was measured against standard BSA solutions using the 
BCA microplate assay [Pierce] and extra RIPA added as needed to equalise 
protein concentration in all samples. 4x Laemmli sample buffer (200mM Tris-
HCl  pH  6.8,  8%(w/v)  SDS,  40%  glycerol,  0.4%  (w/v)  bromophenol  blue, 
400mM DTT) was then added and samples boiled at 95°C for 5 minutes to 
denature protein.  Samples were loaded onto polyacrylamide gels (see below), 
resolved  by  SDS  gel  electrophoresis  (SDS-PAGE),  and  transferred  to 
nitrocellulose membranes [Millipore Immobilon-P].  Membranes were blocked 
for 1hr at RT in 5% milk powder/TBST (Tris-buffered saline + 0.05% Tween 
20),  or  according  to  the  antibody  directions.    Blocked  membranes  were 
incubated overnight in primary antibody diluted in block solution, with rolling 
agitation, before washing in TBST and incubating for one hour in horseradish 
peroxidase-conjugated secondary antibody diluted in block.  Membranes were 
then  washed  4  times  in  TBST  and  once  in  TBS  before  chemiluminescent 
detection using ECL Plus™ reagent [GE Healthcare].  
 
Recipe for discontinuous polyacrylamide gels: 
Resolving gel:   Acrylamide/Bis  30%/0.8%  solution  to  required  final 
polyacrylamide concentration (5-15%) 
  373mM Tris pH 8.8 
  0.1% sodium dodecyl sulphate (SDS) 
  0.04% tetramethylethylenediamine (TEMED) 
  0.04% ammonium persulphate (APS) 
 
Stacking gel:  5% acrylamide/bis   85 
  125mM Tris pH 6.8 
  0.5% SDS 
  0.12% TEMED 
  0.06% APS 
 
Antibodies used for Western: 
Protein  Antibody  Dilution  Species 
Cyclin D1  sc-450  1:5000  Mouse 
Cyclin E  sc-481  1:200  Rabbit 
Cyclin A  sc-596  1:5000  Rabbit 
Cyclin B1  sc-595  1:500  Rabbit 
CDK4  sc-260  1:1000  Rabbit 
CDK6  Neomarkers Ab-3  1:1000  Mouse 
CDK2  sc-163  1:2000  Rabbit 
CDK1  sc-747  1:500  Rabbit 
p21  sc-397-G  1:500  Goat 
p27  sc-1641  1:500  Mouse 
ß-tubulin  Sigma T4026  1:10,000  Mouse 
 
All  antibodies  are  from  Santa  Cruz  Biotechnology  if  not  otherwise  stated.  
Secondary antibody dilutions were 1:2000, except for ß-tubulin, for which a 
1:5000 dilution was used.  For immunoblotting following immunoprecipitation 
(IP)(see below), double the stated antibody concentration was used.  
 
2.2.2 Antibody-sepharose cross-linking 
Cyclin A antibody [Cancer Research UK clone E72] was stably cross-linked 
to protein G-sepharose beads [Sigma P3296] in order to avoid interference of 
the  precipitating  antibody  heavy  and  light  immunoglobulin  chains  with  the 
pulled-down proteins visible by Western blot. 
1)  1mg  antibody  was  diluted  to  5ml  in  Borate  buffer  (200mM  sodium 
tetraborate decahydrate, pH 9.0) and added to 500µl of packed beads.  
2)  The mixture was rotated at RT for 1 hour to bind antibody to sepharose.   86 
3)  Beads were pelleted (5 minutes at 50 g in bench-top centrifuge), then 
washed  for  2  minutes  rotating  in  Borate  buffer,  pelleted  and  washed 
again. 
4)  Beads  were  pelleted  once  more  and  diluted  to  5ml  in  Borate  buffer 
containing 20mM dimethyl pimelimidate (DMP) cross-linking agent. 
5)  The mixture was rotated at RT for 30 minutes to cross-link antibody to 
beads. 
6)  Beads  were  pelleted  and  resuspended  in  5ml  Ethanolamine  buffer 
(200mM ethanolamine, pH 8.0), rotating at RT for 5 minutes to stop the 
cross-linking reaction. 
7)  Beads were pelleted and resuspended in 5ml fresh Ethanolamine buffer, 
rotating for 1 hour at RT to quench unreacted DMP. 
8)  Beads were pelleted and washed in 5ml NP40 buffer (1% Nonidet P40, 
150mM NaCl, 50mM Tris pH8, 20mM NaF, 100µg/ml PMSF, 14µg/ml 
aprotinin, 1mM sodium orthovanadate, 10mM sodium pyrophosphate), 
and kept as a 50:50 bead: buffer slurry for experiments. 
 
2.2.3 Immunoprecipitation and kinase assays 
Freshly  harvested,  unfrozen  cell  pellets  were  used  to  help  preserve 
protein complex integrity.  Pellets were lysed in NP40 buffer (see above) and 
the  protein  concentration  measured  using  the  BCA  assay  as  for  Western 
blotting.  1000µg protein was used for immunoprecipitation (IP) followed by 
Western blot; for kinase assays, 100µg protein was used for cyclin B IPs, 150µg 
protein for cyclin A IPs, and 300µg protein for cyclin E IPs.  Lysates were made 
up to 1ml in NP40 buffer and pre-cleared with either protein A- or protein G-
sepharose beads [Sigma P9424 or P3296] rotating for 2 hours at 4°C, before 
incubating for 1 hour with either: 
•  cyclin E antibody (10µl Santa Cruz sc481) for 1 hour followed by the 
addition of 50µl protein A bead slurry for 1 hour; 
•  cyclin B antibody (3µl Santa Cruz sc245) for 1 hour followed by the 
addition of 50µl protein G bead slurry for 1 hour; 
•  protein G beads cross-linked to cyclin A antibody [Cancer Research UK 
clone E72], for 1 hour.   87 
Beads were washed 3 times in ice-cold NP40 buffer and either boiled in 50µl 1x 
Laemmli buffer before using for Western blot as above, or further washed twice 
in ice-cold kinase assay buffer (50mM Tris pH 7.5, 10mM MgCl2, 1mM DTT) 
plus 1mg/ml BSA for kinase assay.  Kinase assay samples were incubated with 
γ-
32P ATP [Amersham AA068-250µCi] at 1:100 in kinase assay buffer plus 
200µg/ml  purified  histone  H1  substrate  [Sigma]  at  37°C  for  30  minutes.  
Radioactive samples were run on polyacrylamide gels as for Western blot, and 
the gels were then fixed for 10 minutes in 40% methanol + 10% acetic acid, 
vacuum dried and exposed to film or phosphor screen.  Screens were scanned 
and densitometry was used to determine the intensity of the bands.  To compare 
between experiments using slightly different levels of radioactivity (due to the 
half-life of the γ-
32P ATP), the intensity of each band was quantified relative to 
the NSLT attached sample. 
 
2.2.4 p27 immunodepletion 
250µg of protein lysate from NSLT attached and suspended cells was 
either pre-cleared using 50µl protein A-sepharose beads, or immunodepleted 
using 20µl p27 antibody [Santa Cruz sc-528] together with beads, rotating at 
4ºC for 1 hour. Beads were pelleted and discarded, while the cleared/depleted 
supernatant  was  subjected  to  2  more  rounds  of  clearing  or  depletion, 
respectively.  Samples of lysate were taken before and after each depletion to 
monitor the decreasing p27 levels by Western blot.  The final control (non-
specifically cleared) and p27-depleted (lacking all p27-bound protein) samples 
from both attached and suspended cell lysates were then immunoprecipitated 
with  50µl  cyclin  A-crosslinked  beads  (see  section  2.2.2),  and  the 
immunoprecipitate blotted for CDK2 [Santa Cruz sc-163, 1:1000].   
 
2.3 Microscopy 
2.3.1 Immunofluorescence 
BrdU immunofluorescence 
Cells were seeded the day before staining, on 13mm diameter poly-L-
lysine coated glass coverslips in 4-well plates at densities ranging from 15,000   88 
to 30,000 cells/well.  BrdU was added for 4 hours before fixing the cells with 
4%  formaldehyde  in  PBS  for  20  minutes  at  room  temperature.    If  assaying 
suspended cells, BrdU was added to the methylcellulose and mixed thoroughly 
by inversion before incubating for 4 hours, retrieving the cells as normal and 
seeding them on coverslips as above.  Previously suspended cells were allowed 
to attach to the coverslips (30mins-1hr) before fixing.  Fixed cells were then 
washed twice in PBS and permeabilised for 30 minutes at room temperature 
(RT) in 0.5% TritonX100 + 2M HCl to denature DNA.  After 2 more PBS 
washes, cells were blocked for 15 minutes at RT in 3%BSA/PBS.  Blocked 
coverslips were incubated with primary antibody to BrdU [Roche clone BMC 
9318] at 1:300 in 0.1% BSA/PBS, for 1 hour at RT.  Coverslips were then 
washed 6 times by dipping sequentially into containers of PBS, and incubated 
with the secondary antibody, AlexaFluor® 488 anti-mouse [Invitrogen] diluted 
at 1:300 in 0.1% BSA/PBS, plus 1:6000 Hoechst.  Following antibody staining, 
coverslips were washed again 6 times in PBS, finally rinsing in water before 
mounting  inverted  on  glass  slides  with  ProLong  Gold  [Invitrogen].    BrdU 
staining was viewed using an Axioplan 2 fluorescence microscope [Zeiss].  
 
LT immunofluorescence 
20,000 cells were seeded per coverslip.  The following day, cells were 
fixed in 4% formaldehyde/PBS for 15 minutes at RT and washed twice in PBS.  
Cells were then permeabilised in 0.5% TritonX100/PBS for 15 minutes at RT, 
before blocking for 1 hour at RT in DMEM/10% FCS.  Coverslips were washed 
in PBS and incubated for 1 hour at RT in the dark with primary antibodies to 
SV40  [Fitzgerald Industries  International,  pAb419]  at  a  1:50  dilution  in  3% 
BSA/PBS.  After washing 6 times in PBS, coverslips were again incubated for 1 
hour at RT in the dark, with secondary antibodies (FITC-conjugated anti-mouse 
1:300) diluted in 3% BSA/PBS + 1:5000 dilution Hoechst.  Coverslips were 
finally washed 6 times in PBS and once in water before mounting on glass 
microscope slides in ProLong Gold [Invitrogen]. 
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2.3.2 Hoechst/ CellTracker 
Cells were either grown on coverslips overnight at approximately 20,000 
cells  per  well,  or  cultured  in  methylcellulose  for  24  hours,  then  retrieved, 
washed and allowed to settle onto coverslips.  CellTracker Red stock was added 
to the medium at 5µM final concentration and the cells incubated at 37ºC for 30 
minutes before washing once with medium, replacing with fresh medium and 
incubating for a further 30 minutes.  CellTracker-stained cells were then fixed 
for 20 minutes in fresh 4% formaldehyde/PBS at RT, washed twice in PBS, and 
incubated with Hoechst at 1:6000 in 0.1% BSA/PBS for 1 hour.  Coverslips 
were then washed 6 times by dipping sequentially into small containers of PBS, 
and  mounted  on  glass  microscope  slides  using  ProLong  Gold  [Invitrogen].  
Slides  were  examined  using  a  Zeiss  Axioplan  2  fluorescence  microscope  as 
before, and two counts were made using hand-held counters: (1) Count 100 
whole cells using the CellTracker channel, and note how many are binucleate by 
switching  to  the  Hoechst  channel;  (2)  Count  100  nuclei  using  the  Hoechst 
channel,  and  note  how  many  appear  “giant”  –  that  is,  have  an  area 
approximately twice that of the majority of nuclei in the field.  Blind labelling 
of slides was used to eliminate bias between samples. 
 
2.3.3 Metaphase spreads 
1)  Cells  were  seeded  on  10cm  dishes,  either  passaging  normally  for 
attached  cells,  or  immediately  after  retrieval  from  methylcellulose 
suspension.  
2)  After  48  hours,  or  directly  after  plating  for  cells  retrieved  from 
methylcellulose  suspension,  demecolcine  was  added  (Sigma  D1925, 
final conc. 0.05µg/ml) to the medium to block cells at metaphase. 
3)  After  2  hours  in  demecolcine,  cells  were  trypsinised  into  tubes  and 
centrifuged for 10 minutes at 30 g (the low speed is essential to keep 
cells intact). 
4)  Supernatant was removed. Cells were gently resuspended in 2ml warm 
0.075M KCl solution. 
5)  Tubes were incubated at room temperature for 12 minutes to swell the 
cells.   90 
6)  Tubes were centrifuged for exactly 5 minutes at 30 g, in order to pellet 
swollen cells without bursting them. 
7)  Supernatant was removed.  3ml fresh, ice-cold Carnoy's fixative (3:1 
dried methanol: glacial acetic acid) was gently added down the side of 
the tube, pipetting gently but rapidly to prevent cells from clumping.  
8)  Tubes were left to fix at room temperature for 30 minutes. 
9)  Tubes were centrifuged again for 5 minutes at 30 g. Supernatant was 
removed and cells resuspended in fresh fixative. 
10) Steps 8 and 9 were repeated, finally resuspending cells in 300µl fixative.  
11) 20µl  cell  suspension  was  dropped  onto  ultra  clean  microscope  slides 
from a height of 40cm. Slides were held vertically at an angle so that the 
drop spread out rapidly upon impact, and left propped at an angle to dry. 
12) Slides were washed in 70% acetic acid and left to dry. 
13) Vectashield mounting medium with DAPI was used to mount spreads 
under large square coverslips. 
14) Chromosomes  were  observed  under  a  fluorescence  microscope 
[Axioplan 2, Zeiss].  
 
Several metaphase spreads were photographed for each sample and then the 
chromosomes counted using the CellCounter application for ImageJ.  Spreads 
with well-separated chromosomes were preferentially chosen, but some had one 
or two overlapping, which meant that counts were only accurate to within ±2 
chromosomes. 
 
2.3.4 Live/dead staining 
To  quantify  viability  of  cells  in  suspension,  a  Live/Dead®  kit 
[Invitrogen  L3224],  containing  two  reagents,  was  used.    The  first  reagent, 
calcein AM, is cell permeable and produces the fluorescent green dye calcein 
when exposed to intracellular esterase activity, ubiquitously present in live cells.  
Calcein  is  polyanionic  and  so  is  well  retained  within  cells  when  produced 
intracellularly.  The second reagent, ethidium homodimer-1, is excluded from 
intact cells, but will  enter cells whose membranes have been disrupted, and 
fluoresce bright red when bound to DNA.  When reagents are at the optimum   91 
concentrations, all cells incubated with a mixture of the two will appear either 
green or red under a fluorescence microscope. 
Since  we  wanted  to  determine  the  viability  of  cells  within  the 
methylcellulose suspension culture, and not any effects which may be due to the 
retrieval procedure, the reagents were incubated directly with the cells in a 50µl 
aliquot of methylcellulose removed from suspension culture, using a cut tip to 
minimise shearing.  Both reagents were prepared at 1µM final concentration in 
PBS, and 100µl of the mixture was added on top of the cells in methylcellulose 
on a standard microscope slide.  The slides were incubated in a Petri dish at 
37°C  for  30  minutes,  then  samples  were  covered  with  large  coverslips  and 
viewed immediately under the fluorescence microscope.   
 
2.4 p27 knockdown approaches 
2.4.1 p27 siRNA design and transfection 
Four different commercially designed siRNA duplexes were used [HP 
GenomeWide siRNA, Qiagen].  These have been designed to specifically target 
the rat sequence of the p27 gene CDKn1b.  
 
1) Target sequence:   CAG CTC CGA ATT AAG AAT AAT 
siRNA duplex:               G CUC CGA AUU AAG AAU AAU 
        | ||| ||| ||| ||| ||| ||| 
        C GAG GCU UAA UUC UUA UUA 
 
2) Target sequence:   CAG TTA ATT GTT TAG CGG TAA 
siRNA duplex:    G UUA AUU GUU UAG CGG UAA 
        | ||| ||| ||| ||| ||| ||| 
        C AAU UAA CAA AUC GCC AUU 
 
3) Target sequence:  CTG AAT TCT TAG AAT TGA CTA 
siRNA duplex:    G AAU UCU UAG AAU UGA CUA 
        | ||| ||| ||| ||| ||| ||| 
        C UUA AGA AUC UUA ACU GAU 
   92 
4) Target sequence:  TCG GTG AGA ACT GAT CCT TTA 
siRNA duplex:    G GUG AGA ACU GAU CCU UUA 
        | ||| ||| ||| ||| ||| ||| 
        C CAC UCU UGA CUA GGA AAU 
 
siRNA stocks were kept at 20µM in Qiagen’s proprietary ‘siRNA suspension 
buffer’,  as  aliquots  frozen  at  -20ºC,  and  thawed  as  needed.    Duplexes  were 
incubated for 10 minutes at room temperature in DMEM [Gibco 11880] with 
HiPerfect  Reagent  [Qiagen]  added  at  1:18  dilution  to  form  siRNA/lipid 
complexes for delivery to cells.  Different final concentrations of siRNA, from 
0.5nM to 10nM, were used, either a single sequence or a mixture of two.  After 
adding  siRNA  complexes  to  cells  growing  on  6-well  plates  and  leaving 
overnight, the medium on cells was changed, and 24 hours later, samples were 
harvested for Western blot.  p27 levels were compared in cells that had received 
targeted siRNA to those that had been transfected with an equal amount of non-
targeted negative control siRNA [Qiagen cat. no. 1022076]: 
 
Negative control siRNA:    UUC UCC GAA CGU GUC ACG U 
        ||| ||| ||| ||| ||| ||| | 
        AAG AGG CUU GCA CAG UGC A 
 
This sequence has no known homology to any mammalian gene according to 
the  manufacturer,  and  so  controls  for  non-specific  effects  on  cells  such  as 
siRNA toxicity. 
 
 
 
2.4.2 p27 shRNA design and generation of cell lines 
Selection of target sequences and vector cloning: 
Three  different  short  hairpin  RNAs  (shRNAs)  were  designed  using 
Clontech’s ‘RNAi target sequence selector’ online tool, and a fourth was taken 
from the literature (Itoh et al. 2007), having been successfully used to target p27 
in mouse cells (in a region where the target sequence is conserved between   93 
mouse and rat), using a similar vector.  The p27 gene sequence used to design 
targets can be found at: 
 
http://www.ensembl.org/Rattus_norvegicus/Gene/Sequence?db=core;g
=ENSRNOG00000007249;r=4:171841696171846572;t=ENSRNOT00000049848;
time=1227634574090.09 
 
Of the ten possible target sequences given by the program, numbers 2, 3 and 7 
were chosen, on the basis that they are well separated from each other and thus 
will target different regions of the gene; and also that BLAST searches of each 
did not reveal sequence similarity to any other rat gene.  The target sequences 
were  used  to  design  shRNA  duplexes  suitable  for  cloning  into  a  retroviral 
expression  vector  using  Clontech’s  ‘shRNA  sequence  designer’  online  tool.  
This places the target sequence and its reverse complement arranged as a mirror 
image either side of the hairpin loop sequence TTCAAGAGA, and adds BamH1 
and  EcoR1  overhangs  for  insertion  into  the  pSIREN  vector,  plus  a  Mlu1 
restriction  site  for  insert  identification.    The  target  sequences  and  resulting 
shRNA  duplexes  are  shown  below,  with  the  target  in  pink,  its  reverse 
complement in green, and the Mlu1 site highlighted in yellow. 
 
Target “2”:    TGCCGAGATATGGAAGAAG 
 
5'-gatccGTGCCGAGATATGGAAGAAGTTCAAGAGACTTCTTCCATATCTCGGCATTTTTTACGCGTg-----3' 
3'-----gCACGGCTCTATACCTTCTTCAAGTTCTCTGAAGAAGGTATAGAGCCGTAAAAAATGCGCActtaa-5' 
 
 
Target “3”:    GCTTTAGTTCTGGGAGATC 
 
5'-gatccGCTTTAGTTCTGGGAGATCTTCAAGAGAGATCTCCCAGAACTAAAGCTTTTTTACGCGTg-----3' 
3'-----gCGAAATCAAGACCCTCTAGAAGTTCTCTCTAGAGGGTCTTGATTTCGAAAAAATGCGCActtaa-5' 
 
Target “7”:    GAGGTAGTGGGTTGATCAT 
 
5'-gatccGAGGTAGTGGGTTGATCATTTCAAGAGAATGATCAACCCACTACCTCTTTTTTACGCGTg-----3' 
3'-----gCTCCATCACCCAACTAGTAAAGTTCTCTTACTAGTTGGGTGATGGAGAAAAAATGCGCActtaa-5' 
   94 
Target “itoh”:   GTGGAATTTCGACTTTCAG 
 
5'-gatccGTGGAATTTCGACTTTCAGTTCAAGAGACTGAAAGTCGAAATTCCACTTTTTTACGCGTg-----3' 
3'-----gCACCTTAAAGCTGAAAGTCAAGTTCTCTGACTTTCAGCTTTAAGGTGAAAAAATGCGCActtaa-5' 
 
The shRNA duplexes were purchased from Sigma and cloned into the retroviral 
expression  vector  RNAi-Ready  pSIREN-RetroQ-ZsGreen  [Clontech  cat.  no. 
632455] between the BamH1 and EcoR1 sites as directed.  Preparation of the 
shRNA  expression  vectors  was  carried  out  according  to  the  manufacturer’s 
instructions: 
1)  shRNA  duplexes  were  annealed  by  mixing  100µM  of  each 
oligonucleotide  in  a  1:1 ratio  and  heating  to  95ºC  for  30  seconds  to 
disrupt the secondary hairpin structure, followed by gradual cooling over 
6 minutes. 
2)  Annealed  shRNAs  were  diluted  to  0.5µM  concentration  (a  1:100 
dilution) in TE buffer, and ligated to the linearised vector by incubating 
the following mixture at room temperature for 3 hours: 
 
2µl   pSIREN-RetroQ-ZsGreen vector (25ng/µl) 
1µl   shRNA oligonucleotide (0.5µM) 
1.5µl   T4 DNA ligase buffer (10x) 
0.5µl   BSA (10mg/ml) 
9.5µl   nuclease-free water 
0.5µl  T4 DNA ligase enzyme (400U/ml) 
15µl 
 
A  ligation  reaction  was  set  up  as  above  for  each  of  the  four  p27  target 
oligonucleotides, plus a vector-only control. 
3)  Each  completed  ligation  reaction  was  transformed  into  competent 
HB101 bacteria by adding 2µl ligation mixture to 50µl of bacterial cell 
suspension, incubating on ice for 5 minutes and then heat shocking at 
42ºC for 30 seconds in a water bath before replacing on ice. 
4)  Transformed bacteria were grown up in 250µl SOC medium shaking for 
1 hour at 37ºC, and then 30µl of each transformation was spread onto   95 
agar plates containing the selection antibiotic ampicillin under aseptic 
conditions, and incubated at 37ºC overnight. 
5)  3 or 4 well separated colonies from each selection plate were isolated 
and grown up in small starter cultures of LB medium + ampicillin for 8 
hours,  then  plasmids  were  purified  from  the  bacteria  and  digested  to 
check for the presence of the shRNA insert (see below). 
6)  Once the presence of an insert was confirmed by restriction digest, 0.5ml 
of the starter culture was inoculated into 250ml LB medium + ampicillin 
and grown up at 37ºC overnight with vigorous shaking.  Plasmid was 
purified from this large bacterial culture by maxi prep [Qiagen] and kept 
as a stock dissolved in TE and frozen at -20ºC. 
 
Diagnostic restriction digests to check for shRNA vector inserts: 
Restriction  digests  to  check  for  the  presence  of  an  Mlu1-containing 
insert were carried out on plasmid from 3-4 separate colony cultures for each of 
the four inserts, and also on the re-ligated vector alone (no insert) and a control 
plasmid  containing  a  negative  control  insert  [Clontech]  (half  the  hairpin 
sequence against a luciferase target gene):  
 
  5'   GAT CCG TGC GTT GCT AGT ACC AAC TTC AAG AGA TTT TTT ACG CGT G    3' 
       GC ACG CAA CGA TCA TGG TTG AAG TTC TCT AAA AAA TGC GCA CT TAA  
 
A representative diagram showing the relative positions of the restriction sites in 
the  vector  is  shown  below.    The  insert  is  located  between  the  BamH1  and 
EcoR1 sites, and all inserts used contained a unique Mlu1 site as shown.   96 
 
Five different restriction digests were set up: the first three single digests were 
only carried out as controls on one vector; the two double digests were carried 
out on all vectors as diagnostic for the presence of a Mlu1-containing shRNA 
insert. 
(i)  EcoRV single digest 
One predicted fragment: 6628bp 
(ii)  Sal1 single digest 
Two predicted fragments: 5927bp + 701bp 
(iii)  Mlu1 single digest 
One predicted fragment: 6628bp 
(iv)  Mlu1 + EcoRV double digest 
Two predicted fragments in vectors with an insert: 5301bp + 1327bp 
(only one 6568bp fragment if insert is missing) 
(v)  Sal1 + Mlu1 double digest 
Three predicted fragments in vectors with an insert: 5066bp + 861bp + 
701bp (only two 5867bp + 701bp fragments if insert is missing). 
 
The four p27 shRNA plasmid stocks from the maxi prep, having been checked 
at the mini prep stage for Mlu1 sites by restriction digest (see Figure 4-7), were 
further verified by sequencing.  The U6 promoter sequence  
5’-ATGGACTATCATATGCTTACCGTA-3’    97 
(located approximately 50bp upstream of the insert site) was used as a forward 
sequencing primer, as suggested in the instructions accompanying the pSIREN-
RetroQ-zsGreen  vector,  and  sequencing  was  carried  out  by  MWG  Biotech.  
Plasmids with insert targets “2”, “3” and “itoh” were 100% matched to their 
correct insert sequence, while insert target “7” was sequenced correctly for the 
first 18 nucleotides before the read failed – probably due to the confounding 
secondary structure of the hairpin. 
Diagnostic PCR to verify expression of correct vectors 
Genomic  DNA  was  purified  from  the  sorted  zsGreen  cells  using  the 
DNeasy spin-column protocol [Qiagen] and a diagnostic PCR was performed.  
Primers were designed to detect the presence of the control shRNA insert in the 
pSiren vector, using the Primer3 designer program:  
http://frodo.wi.mit.edu/ 
All options were kept at default, except that the reverse primer was obligatorily 
targeted to the negative control insert sequence (Figure 2- 4). 
 
2.5 In vivo tumourigenesis assay 
20  female  CD-1  nude  mice  at  35-41  days  old  were  obtained  from 
Charles River and housed in individually ventilated cages using sterile supplies.  
NSLT  cells  from  72-hour  suspension  culture,  which  had  been  replated  and 
passaged twice, were injected subcutaneously into 9 mice, once on each flank (2 
injections per mouse, performed under gas anaesthetic).  Injections were carried 
out using 21G sterile needles, and approximately 750,000-1 million cells in 150-
200µl sterile PBS were introduced per flank.   Another 9 mice were injected in 
the  same  way  with  NSLT  negative  control  cells,  which  had  been  briefly 
introduced to methylcellulose suspension in parallel with the test cells, but were 
immediately retrieved and replated.  2 mice were injected with NSLTRas cells 
as a positive control, and were sacrificed after 12 days due to the growth of 
subcutaneous tumours up to 10mm in diameter on both flanks.  The remaining 
mice were monitored for signs of tumour growth.  After 4 months, one negative 
control and one test mouse were culled due to sickness unrelated to tumour 
formation.  Injections and culls were carried out by Drs L. Noon and I. Napoli.  98 
 
LEFT PRIMER (1):        cccatgattccttcatatttgc 
LEFT PRIMER (2) [U6 promoter]:  atggactatcatatgcttaccgta 
RIGHT PRIMER (reverse complement):  tagcaacgcacggatcctc 
 
PRODUCT SIZES: (1) 248bp; (2) 92bp 
 
    1 
gaacctcctcgttcgaccccgcctcgatcctccctttatccagccctcactccttctcta 
                                                                   
 
   61 
ggcgccggaattgaagatctgggcaggaagagggcctatttcccatgattccttcatatt 
                                               
>>>>>>>>>>>>>>>>>>> 
 
  121 
tgcatatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaa 
      >>> 
 
  181 
agatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttt 
       
 
  241 
taaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatt 
                       >>>>>>>>>>>>>>>>>>>>>>>> 
 
  301 
tcttggctttatatatcttgtggaaaggacgaggatccgtgcgttgctagtaccaacttc 
                                    <<<<<<<<<<<<<<<<<<<            
 
  361 aagagattttttacgcgtg 
                          
 
KEYS: 
>>>>>> left primer 
<<<<<< right primer 
 
 
Figure 2- 4: Positioning of PCR primers to identify negative control insert 
in pSIREN-RetroQ-zsGreen vector. 
Reverse primer is obligatorily targeted to the negative control insert (highlighted in 
green).  The two alternative forward primers are expected to produce PCR products of 
248bp and 92bp respectively, only in genomic DNA from cells expressing the negative 
control  insert  (see  Figure  4-8B).    Diagram  copied  from  output  of  Primer3  online 
program. 
   99 
Chapter Three – Characterisation of a primary cell model 
showing loss of anchorage dependence for proliferation 
 
3.1 Chapter introduction 
A  key  property  of  transformed  cells  in  vitro  and  those  which  are 
malignant  in  vivo  is  the  ability  to  divide  regardless  of  support  from  the 
surrounding  matrix,  a  characteristic  known  as  anchorage-independent 
proliferation.  In order to investigate how the genetic changes associated with 
cancer can permit cells to proliferate in the absence of anchorage signals, we 
chose to use a Schwann cell model system in which a single genetic change is 
sufficient  to  switch  cells  between  anchorage  dependent  and  independent 
proliferation (Mitchell et al. 2003). 
Primary rat Schwann cells can be cultured under conditions in which 
they are immortal, yet with no loss of cell cycle checkpoints (Mathon et al. 
2001).  Use of the undifferentiated Schwann cell model enables us to introduce 
defined oncogenic changes step by step in a controlled way, with minimal risk 
of additional spontaneous mutation.  This property is of the utmost importance 
when studying cell cycle regulation, as spontaneous genetic changes leading to 
immortalisation  often  affect  the  cell  cycle,  and  this  could  lead  to  confusing 
results  in  a  less  genetically  stable  system.    We  chose  to  model  the 
transformation  process  using  (1)  the  viral  oncoprotein  Large  T  (LT),  which 
binds and inactivates both p53 and the Rb family of pocket proteins: pRb, p107 
and p130 (Lane and Crawford 1979; DeCaprio et al. 1988; Dyson et al. 1989; 
Hannon et al. 1993); and (2) the oncogenic Ras protein that harbours a G12V 
mutation,  which  traps  the  protein  in  its  active  GTP-bound  form  and  causes 
constitutive activation of its many downstream targets (McGrath et al. 1984).  
Expression of both LT and oncogenic Ras proteins together has been shown to 
be  sufficient  for  full  transformation,  including  anchorage  independence,  in 
mouse and rat cells (Michalovitz et al. 1987; Clark et al. 1988; Hirakawa and 
Ruley 1988; Ridley et al. 1988; Beachy et al. 2002); expression of hTERT is 
additionally  required  in  human  cells,  to  satisfy  the  requirement  for 
immortalisation (Hahn et al. 1999).  Normal Schwann cells expressing LT alone   100 
(NSLT)  remain  anchorage  dependent,  despite  losing  their  requirement  for 
mitogens. 
 
 
 
Since  previous  evidence  suggests  that  anchorage  signals  act  in 
combination with mitogens to alleviate the Rb-E2F checkpoint (see Introduction 
1.1.3.1) we might expect the inactivation of all the Rb family pocket proteins to 
remove  the  requirement  for  anchorage  signals  as  well  as  mitogens  for 
proliferation.  The fact that it does not, demonstrates that anchorage signals are 
also required downstream of Rb inactivation to drive cell cycle progression.  We 
previously showed that p53 inactivation is required to cooperate with oncogenic 
Ras to induce proliferation in these cells (Mitchell et al. 2003), consistent with 
studies  in  other  cell  types  (Hicks  et  al.  1991;  Fukasawa  and  Vande  Woude 
1997;  Azzoli  et  al.  1998),  but  this  was  not  sufficient  to  confer  anchorage 
independence.    NSLT  cells  therefore  appear  to  exhibit  a  novel  anchorage 
checkpoint, which is independent of both Rb and p53 function.  The ‘switch’ to 
anchorage independent proliferation upon additional expression of oncogenic 
Ras in these cells (NSLTRas) shows that only one genetic change is required to 
alleviate this secondary anchorage checkpoint, and the downstream effects of 
constitutive Ras activation may give clues to its mechanism.  New NSLT and 
NSLTRas cells were created in parallel, to ensure a carefully-controlled model 
cell  system,  and  initial  experiments  were  designed  (a)  to  set  up  optimal 
conditions  for  suspension  culture,  allowing  the biochemical  analysis  of  both 
attached and suspended cells, and (b) to characterise the cell cycle in normal 
Schwann cells (NS), NSLT, and NSLTRas cells, both when attached and in 
suspension.   101 
 
3.2 Genetic construction of model cell types 
3.2.1 Infection of cells 
It was considered important to use low-passage cells of equivalent ‘age’ 
to create stock populations of “NSLT” and “NSLTRas” that allow unbiased 
comparison  between  these  cell  types  in  subsequent  experiments.    Recently-
established, low passage rat Schwann cell cultures expressing LT Babe-Puro 
were infected in parallel  with either ‘empty’ LXSN retroviral vector or Ras 
LXSN,  containing  the  H-Ras
G12V  oncogene  (see  Materials  and  Methods).  
Retroviral infection of these cells is highly efficient, resulting in pools of cells 
that maintain a high complexity of vector expression, rather than clones.  The 
infected  NSLT  and  NSLTRas  populations  were  drug-selected  with  G418  to 
ensure all cells were expressing the vector.  Although normal Schwann and LT-
expressing Schwann cells are phenotypically relatively stable in culture under 
carefully-controlled conditions (Porter et al. 1986; Ridley et al. 1988; Mathon et 
al. 2001; Mitchell et al. 2003), cells drug-selected for LXSN expression were 
expanded and kept as low-passage stocks, which were then used at equivalent 
passage in experiments up to a maximum of 20 passages, to control for any 
inconsistency in cell behaviour in suspension culture that may occur after too 
many population doublings. 
 
3.2.2 Cell morphology and LT expression 
The  morphology  of  the  three  cell  types  in  normal  attached  culture 
conditions shows that while NSLT cells resemble normal Schwann (NS) cells, 
i.e. flattened, with an opaque nucleus; NSLTRas cells have a more elongated 
shape and appear refractive: a typical ‘transformed’ cell morphology indicative 
of oncogenic Ras expression (Figure 3- 1).  NS cells divide more slowly than 
the NSLT and NSLTRas cells, and are therefore seeded at a higher density in 
order to reach 80% confluence for passaging within three days.  All three cell 
populations  maintain  a  homogeneous  appearance  throughout  culture  and 
passaging.    102 
 
 
 
 
 
 
Figure 3- 1: Morphology of model cell types. 
Phase contrast micrographs of NS, NSLT and NSLTRas cell cultures on PLL-coated 
plates. NS and NSLT cells appear more rounded and flattened, while NSLTRas cells 
have a more elongated shape and appear highly refractive. X4 objective.  103 
In order to assess LT expression levels in the newly constructed cell stocks, cell 
samples  were  cultured  on  coverslips,  fixed,  and  stained  with  a  LT  antibody 
(Figure  3-  2A).    Observation  by  immunofluorescence  showed  nuclear 
expression  of  LT  protein  in  both  NSLT  and  NSLTRas  cells,  but  not  in  NS 
cultures.  Quantification of LT expression indicated that at least 99% of cells in 
both NSLT and NSLTRas populations were positive for LT staining (Figure 3- 
2B).    Moreover,  the  intensity  of  fluorescence  was  similar  in  NSLT  and 
NSLTRas nuclei, indicating similar expression levels in the two cell types.  
 
3.3 Cellular Characterisation 
3.3.1 Colony formation in soft agar 
To assess colony-forming ability in our newly constructed model cell 
types,  NS,  NSLT  and  NSLTRas  cells  were  seeded  into  soft  agar  to  assay 
anchorage-independent  proliferation.    Seeding  cells  in  6-well  plates  at  three 
different densities (2000, 4000 and 8000 cells/well) and staining cells with MTT 
after two weeks clearly showed that only NSLTRas formed colonies, and both 
NS and NSLT cells remained anchorage dependent (Figure 3- 3).  The average 
colony size correlated inversely with cell density, indicating that the availability 
of mitogens and growth factors was limiting after some days within the agar, 
despite  regular  additions  of  fresh  medium  to  the  top  of  the  plate.    Stained 
NSLTRas colonies were large enough to be seen with the naked eye, while 
microscopic inspection of the NS and NSLT plates revealed the persistence of 
single cells within the agar (Figure 3- 4A). 
In  order  to  more  closely  observe  the  anchorage-independent 
proliferation  leading  to  colony  formation,  and  to  see  what  happens  to  the 
anchorage  dependent  cell  types  while  existing  as  single  cells  in suspension, 
NSLT and NSLTRas cells were seeded in very thin (<3mm) layers of soft agar 
and viewed by time-lapse microscopy.  Cultures were viewed over a twenty-
four hour period, during which time 4-8 focus points were set up on individual 
cells  within  the  suspension  and  images  captured  every  15  minutes.    The 
resulting movies showed that these cells, though rounded and non-invasive,    104 
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Figure 3- 2: Nuclear SV40 LT antigen expression in NSLT and NSLTRas 
cells.   
(A) Fluorescence micrographs of NS, NSLT and NSLTRas cells seeded at 20,000 
cells/coverslip and immunostained the following day with polyclonal Ab419 (1:50) 
against the LT N-terminus, Alexa Fluor 488 anti-mouse fluorescent-conjugated 
secondary antibody (1:300) and Hoechst (1:5000). Left panels show Hoechst-stained 
DNA (blue); middle and right (magnified) panels show nuclear LT staining (green). 
X25 objective. 
(B) Quantification of LT-positive cells in each culture.  Nuclei were counted on 3 
coverslips per cell type.   105 
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Figure 3- 3: Soft agar assays of NS, NSLT and NSLTRas cells.   
(A) Cells were seeded in soft agar at 2000, 4000 or 8000 cells/well and incubated for 2 
weeks, fed weekly, before staining overnight with MTT [Calbiochem 475989, 
10mg/ml; 100µl/well].   
(B) Enlarged wells from the above photograph, showing the 2000-cell seeding density.  
NSLTRas (right) show colonies visible to the naked eye; no colonies are visible in 
either the NS (left) or NSLT (middle) cultures.  106 
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Figure 3- 4: NS and NSLT appear as single cells in soft agar suspension. 
(A) Cells were seeded in 0.6% soft agar suspension in 6-well plates and viewed by 
phase contrast microscopy after two weeks.  Individual NS and NSLT cells can be seen 
as round white dots, while MTT-stained NSLTRas colonies are black. X4 objective. 
(B) 4000 NSLT cells were seeded in 500µl 0.6% agar incubated in a thin layer in a 12-
well plate.  Shown are stills from time-lapse microscope photography of a single cell.  
Cell morphology changes from fully rounded and pale to collapsed and dark, indicating 
a cell death.  X25 objective.  107 
continually change shape while in soft agar suspension, strong evidence that 
they remain alive even when not dividing.  This finding was supported by one 
movie that appeared to show cell death – the NSLT cell in question changed 
from  a  shiny,  fully-rounded  morphology  to  a  collapsed,  dark-looking  speck 
within the space of 45 minutes (Figure 3- 4B).  Based on these and previous 
observations  of  cells  in  soft  agar  in  the  lab,  this  bright,  reflective  and  non-
‘blebbed’  appearance  was  taken  to  indicate  a  live  cell.    In  larger  soft  agar 
cultures, cells overwhelmingly maintain the ‘live’ morphology for at least four 
weeks if kept fed, and only started to appear blebbed and shrunken if medium 
was omitted.   
The  time-lapse  method  however  proved  unhelpful  for  observing 
NSLTRas cell division, as the optics of the medium were insufficiently sharp to 
reveal a clear cytokinesis, and cells tended to move out of the field of view as 
the agar contracted in the viewing chamber (despite humidifying the plate by 
overlaying the agar with medium and filling unused wells with sterile water).  
Following  these  observations,  this  technique  was  abandoned,  as  the  optical 
limitations  were  too  great  to  allow  more  detailed  imaging,  for  example  the 
staining of mitotic chromosomes. 
 
3.3.2 Optimisation of methylcellulose seeding and retrieval 
In  order  to  obtain  enough  cells  for  protein  analysis,  even  from 
anchorage-dependent samples in disperse suspension culture, an alternative to 
soft  agar  was  required,  as  retrieval  of  cells  from  soft  agar  cultures  would 
necessitate the isolation of individual colonies by pipette.  Methylcellulose gels 
have previously been used in suspension culture, and were not inhibitory to cell 
growth  and  proliferation  (Stoker  et  al.  1968;  Otsuka  and  Moskowitz  1975).  
This was confirmed in our system by overlaying an ordinary plate of NS cells 
with medium containing 2% methylcellulose - no change was observed in their 
morphology  or  proliferation  (judged  by  the  time  taken  for  a  plate  to  reach 
confluence).  The great advantage of using this type of gel over soft agar is that 
it  can  be  diluted  and  the  cells  retrieved  by  centrifugation.    Different 
methylcellulose concentrations and centrifugation speeds were tested in order to 
determine the conditions allowing the retrieval of most intact cells, while not   108 
allowing cells to sink to the bottom of the suspension culture.  Stoker et al. 
found that methylcellulose concentrations below 1% were too low to prevent 
cells  aggregating  in  suspension,  but  had  difficulty  pipetting  the  gel  at 
concentrations above 1.5%.  They settled on a methylcellulose concentration of 
1.3%, which allowed cells to remain discrete with acceptable ease of handling.  
However, they observed that cells close to the sides and base of the dish were 
able to adhere to and spread on the surface, and overcame this problem by 
coating  culture  ware  with  agar  before  adding  the  methylcellulose-cell 
suspension.  Despite this precaution, the authors reported that cells ‘fell slowly 
through the gel and eventually came to lie on the agar surface’, although this 
interface did not support cell spreading.   In order to retrieve cells for analysis 
the  methylcellulose  suspension  was  taken  up  into  a  wide-bore  pipette  and 
diluted with medium, washing the surface of the agar to retrieve all the cells 
(Stoker  et  al.  1968).    For  our  purposes,  we  used  the  simpler  method  of 
incubating the methylcellulose suspension directly in centrifuge tubes, allowing 
immediate addition of diluting medium without the need for pipetting of the 
viscous gel:   
 
This  method  has  previously  been  described  using  silicone-coated  test  tubes 
(Otsuka  and  Moskowitz  1975).    As  our  method  could  be  accomplished  by 
pouring and no longer required pipetting of the gel, higher concentrations of 
methylcellulose  medium  could  be  used  to  ensure  that  cells  were  adequately 
supported in suspension and did not sink or spread on the walls of the tube.  We 
tested  concentrations  of  1.5%  and  1.8%,  and  found  that  a  minimum 
concentration of 1.5% was sufficient to support cells - tested by taking small   109 
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Figure 3- 5: Cells remain evenly distributed in methylcellulose suspension.   
(A) NSLT cells were seeded in 1.5% and 1.8% methylcellulose suspension and mixed 
thoroughly by inversion.  Aliquots were taken from the top and bottom of the culture 
tube after 24 hours, to check for even cell distribution.  X4 objective. 
(B) NS, NSLT and NSLTRas cells were seeded in 1.8% methylcellulose suspension.  
Aliquots were taken from the cultures after 2 days and viewed by phase contrast 
microscopy.  NS and NSLT appear as single cells, and NSLTRas as 2-4 cell ‘colonies’. 
Cells all appear brightly refractive, indicating that they are viable.  X4 objective.  110 
aliquots from the top and bottom of the tube after 24 hours’ incubation and 
comparing the density of cells in each position (Figure 3- 5).   
Methylcellulose gel was made up at 1.8%, which following addition of 
trypsinised  cells  at  1:9  gave  a  final  dilution  of  1.62%.    After  2  days  in 
methylcellulose,  differences  in  cell  proliferation  could  be  seen  under  the 
microscope (Figure 3- 5), with NSLTRas cells visible as small colonies of 2-4 
cells, whereas NS and NSLT samples remained as single cells.  In preliminary 
retrieval  experiments  from  2%  methylcellulose,  centrifuging  at  650  g,  the 
number of intact cells recovered fell after 24 hours in suspension (Figure 3- 
6A), so we tested lower spin speeds of 500 and 250 g to see whether this would 
improve recovery.  Recovery numbers were in fact highest at 500 g, retrieving 
around 95% of cells immediately after seeding, and 75% 24 hours later, a figure 
that was not improved by varying the methylcellulose concentration (Figure 3- 
6B).   
Recovery procedures were further refined by varying the washing and 
trypsinising steps before cell counts were made.  Using relatively small volumes 
of methylcellulose (1/5
th the tube volume) allowed space within the tube for 
both equilibration with the CO2-controlled atmosphere within the incubator, and 
for addition of dilution liquid when retrieving.  DMEM plus 1% serum was used 
to dilute the suspension and helped stabilise the cells before washing with PBS.  
It  was  found  that  warm  methylcellulose  did  not  mix  uniformly  with  cold 
solution,  so  warm  DMEM  +1%  serum  was  initially  used  to  dilute  the 
suspension  1:2  before  addition  of  further  ice-cold  solution.    Samples  were 
incubated on ice while harvesting, to preserve the integrity of cells as far as 
possible.  After washing, trypsin was used to disperse cells before counting.   
However, it soon became clear that using the same procedure for the different 
cell  types  did  not  result  in  quantitative  recovery.    Simply  resuspending  the 
washed pellet in trypsin, before addition of serum-containing medium to quench 
the enzyme activity, was not sufficient to separate tightly aggregated NSLTRas 
cells, which showed up on the Coulter counter as large clumps.  Passing the 
suspension through an 18G needle was successful in separating these clumps 
and increased the effective NSLTRas count.  However, this treatment drastically 
reduced the counts from NSLT cells, which appeared on the Coulter counter as   111 
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Figure 3- 6: Optimisation of methylcellulose cell retrieval procedure. 
(A) 800,000 NS, NSLT and NSLTRas cells were seeded in 2% methylcellulose and 
retrieved by 650 g centrifugation on the day of seeding (day 0), and after 1 and 2 days.  
Graph shows mean of duplicate cell counts for each cell type.  Error bars indicate s.d. 
(B) NSLT cells were seeded in 1.5% or 1.8% methylcellulose and retrieved by 
centrifugation at either 250 or 500 g, aiming to improve efficiency of cell retrieval.  
Graph shows percentage recovery for each condition.  112 
debris, suggesting that not only were NSLT cells not dividing to form colonies, 
they are also less physically robust in suspension.  It was therefore decided to 
use  a  gentle  resuspension  by  pipette  for  NS  and  NSLT  cells,  and  a  more 
stringent resuspension using the 18G needle for NSLTRas cells, to ensure the 
production of a single-cell suspension for counting. 
 
3.3.3 NSLTRas proliferate in suspension, but NS and NSLT do not 
Counts  of  retrieved,  washed  and  dispersed  cells  pelleted  from 
suspension  culture  (Figure  3-  7)  showed  a  clear  increase  in  numbers  of 
NSLTRas cells over time, quadrupling in number over 48 hours.  This is similar 
to their normal 24-hour cell doubling time in attached culture, showing that 
NSLTRas  cells  proliferate  as  well  in  suspension  as  they  do  on  plates.    In 
contrast, NS and NSLT cells did not increase in number over 48 hours, and the 
number of NS cells retrieved decreased over time.  It was thought that this was 
partly  due  to  cells  being  less  robust  in  withstanding  the tough retrieval  and 
washing procedure, since NSLTRas could withstand fairly vigorous syringing 
through an 18G needle to disperse cells from their tight colonies, whereas even 
gentle resuspension of NS samples resulted in fragmentation of the cells.  This 
may account for the less than 100% retrieval rate of this cell type.   
 
3.3.4 The majority of cells survive in suspension 
To  quantify  the  cell  loss  that  occurred  due  to  cell  death  while  in 
suspension, rather than due to loss or breakage during retrieval, a commercial 
kit that identifies both live and dead cells was used to stain small samples of 
cells in methylcellulose.  Viability staining of suspended cells using this kit 
(Figure 3- 8A) revealed that a proportion of both NSLT and NSLTRas cells 
were dead in suspension, though most remained alive throughout the duration of 
the experiment (48 hours).  This is consistent with Schwann cells’ non-epithelial 
origin,  which  would  suggest  that  they  do  not  undergo  automatic  anoikis 
following detachment from the extracellular matrix (Frisch and Francis 1994).  
Expression of oncogenic Ras improved the NSLT cell survival rate from 74% to 
87%, which may be due to the activation of PI3K-Akt pathways downstream of 
Ras (Khwaja et al. 1997).  Early studies on the suspension of 3T3 fibroblasts  113 
 
 
 
 
 
 
 
Figure 3- 7: NSLTRas cells increase in number in methylcellulose 
suspension, while NS and NSLT do not. 
NS, NSLT and NSLTRas cells were seeded in 1.8% methylcellulose suspension and 
retrieved by centrifugation at 500 g.  Duplicate samples were counted shortly after 
seeding (day 0), and then at approximately 24-hour intervals (day 1, day 2).  NSLTRas 
cells roughly double in number every 24 hours (black bars), indicating anchorage-
independent proliferation, while numbers of NS and NSLT cells retrieved do not 
increase over the course of the experiment (grey bars).  Graph shows data combined 
from three similar experiments.  Error bars indicate s.e.m.  114 
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Figure 3- 8: Most cells remain viable in methylcellulose suspension and 
resume proliferating when retrieved and replated. 
(A) Quantification of cell viability in methylcellulose suspension. Aliquots containing 
cells were removed from culture at the stated times and incubated for 30 minutes with 
components of the Live/Dead Viability/Cytotoxicity kit [Invitrogen]. Green indicates 
live cells; red cells are dead. 
(B) Phase contrast micrographs of proliferating cells retrieved and replated from 
suspension culture. Left, NS cells replated after 30 hours; Right, NSLT cells replated 
after 36 hours in methylcellulose suspension.  115 
found that trypan blue exclusion, which indicates live cells, was over 99% for at 
least 3 days in suspension (Otsuka and Moskowitz 1975).  This is consistent 
with our observations of cells in soft agar.  It is possible that the relatively low 
viscosity of methylcellulose compared to soft agar contributes to the reduced 
cell survival in this medium.  This possibility will be discussed in Chapter Six.  
 
3.3.5 Cells replated from suspension culture resume proliferation 
Further  evidence  to  support  the  predominant  survival  of  cells  in 
suspension culture comes from the replating of cell samples recovered from 
suspension on ordinary culture plates (Figure 3- 8B).  The majority of retrieved 
NS and NSLT cells reattached and resumed proliferation after several hours in 
methylcellulose as soon as they were allowed to settle, indicating a temporary, 
reversible arrest in suspension rather than a permanent cell cycle exit.  This is 
consistent with the idea of a cell cycle ‘anchorage checkpoint’ in NSLT cells 
analogous  to  that  in  NS,  which  is  alleviated  when  the  requirement  for 
attachment is met.  NSLTRas cells likewise reattached as normal and continued 
their  proliferation  upon  replating.    This  is  consistent  with  previous  studies, 
which showed that 3T3 fibroblasts exhibited a reversible cell-cycle arrest in 
suspension (Otsuka and Moskowitz 1975). 
 
3.3.6 NSLTRas cells require Raf/ MEK to proliferate in suspension 
Expression of oncogenic Ras in NSLT cells is sufficient to overcome 
their anchorage dependence, but there has not so far been a consensus on the 
downstream effectors responsible for this aspect of transformation (Yang et al. 
1998; Repasky et al. 2004).  In order to determine the pathways responsible in 
our system, we investigated whether the PI3K or ERK pathways, key mediators 
of Ras signalling, are necessary for NSLTRas cell proliferation in suspension.  
The inhibitors LY294002 and U0126 were added to methylcellulose containing 
NSLTRas  cells.    LY294002  inhibits  PI3K,  and  U0126  inhibits  the  ERK 
upstream  activating  kinase  MEK.    As  shown  in  Figure  3-  9A,  cell  counts 
indicated that NSLTRas were able to proliferate in the presence of LY294002, 
but not U0126, indicating that the ERK pathway, but not the PI3K pathway, was   116 
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Figure 3- 9: Raf/MEK signalling is necessary and sufficient to overcome the 
anchorage checkpoint.  
(A) NSLTRas cells were seeded in methylcellulose suspension containing either the 
PI3K inhibitor LY294002 (20µM), the MEK inhibitor U0126 (20µM), or DMSO 
(1:1000) as a vehicle control.  Graph shows means of cell counts from two 
experiments.  Error bars indicate s.e.m.  * p >0.1, no significant difference; *** p 
<0.02, significant difference (2-tailed, unpaired t-test). 
(B) LT-expressing cells were infected with either control vector (left panels), or a 1 in 
1000 ratio of H-Ras
G12V- (middle) or c-Raf kinase domain-carrying vector (right 
panels) to control vector.  Soft agar wells (top) show colonies in both the H-Ras
G12V - 
and c-Raf- expressing cultures visible to the naked eye.  Phase contrast micrographs 
(bottom) show the morphology of H-Ras
G12V - and c-Raf-induced colonies.  
Experimental data from Davide Danovi.   117 
necessary for Ras-induced anchorage independent proliferation.  This result was 
supported by other studies (D. Danovi, personal communication), showing that 
the kinase domain of c-Raf (Ras-activated effector of the ERK pathway) was 
sufficient to induce colony formation in LT-expressing cells (Figure 3- 9B).  
 
3.3.7 FACS analysis shows an aberrant cell cycle profile in NSLT 
suspended cells 
Following  the  observations  that  NSLT  cells  do  not  proliferate  in 
suspension, but are quickly able to return to the cell cycle once reattached, we 
performed flow cytometric analysis to determine in which phase the cells arrest, 
since  this  could  give  important  clues  to  the  biochemical  mechanism  of  the 
anchorage checkpoint and how signals from the substratum feed into cell cycle 
control pathways.  BrdU was added to both attached and suspended cultures one 
hour prior to harvesting.  Samples were then fixed and stained with antibodies 
to BrdU, to mark cells actively progressing through S phase, and propidium 
iodide (PI), to indicate total DNA content.  The results were gated to exclude 
cell aggregates and debris (Figure 3- 10A).  Samples to which BrdU had not 
been added were fixed and stained in the same way, in order to define the BrdU-
negative population and determine the threshold for identifying BrdU-positive 
cells (Figure 3- 10B). 
Asynchronously  dividing  populations  of  attached  NS,  NSLT  and 
NSLTRas  cells  exhibited  a  characteristic  ‘horseshoe-shaped’  FACS  profile, 
showing largely BrdU-negative clusters in G1 and G2/M, linked by an arc of 
BrdU-positive S phase cells (Figure 3- 11A).  The relative proportions of cells 
in S and G2/M phases compared to G1 were increased in faster-cycling cells, 
reflecting a shortening of G1 phase (Figure 3- 11B).  This could be seen in both 
NSLT (38% S/G2/M phase) and NSLTRas cells (41% S/G2/M) compared to NS 
(25%).  Normal population doubling times in attached culture are around 24 
hours for NSLT and NSLTRas cells, and around 48 hours for NS (Lloyd lab 
unpublished data). 
After 24 hours in suspension, the FACS profile of NS cells showed a 
classical G1 arrest, with BrdU incorporation almost undetectable and nearly all    118 
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Figure 3- 10: Gates used for cell cycle analysis by flow cytometry. 
(A) Dot plot from typical attached, proliferating cell sample, indicating gate used to 
exclude cell aggregates and debris.  Attached cells were trypsinised, ethanol-fixed, and 
stained with propidium iodide (PI) to indicate DNA content.  Plot shows the area 
(vertical scale) vs. width (horizontal scale) of the PI signal. 
(B) Demonstration of the positioning of the BrdU+ gate on a plot of BrdU fluorescence 
intensity (vertical scale) vs. DNA content (horizontal scale), by delineating a boundary 
immediately above the dots which appear in a no-BrdU control sample (left panel).  
NSLT attached, proliferating cell samples were processed in parallel.  BrdU was added 
to the right sample for 1 hour before harvesting.  Both samples were harvested, ethanol-
fixed and stained with antibodies to BrdU, and propidium iodide (PI) to indicate DNA 
content as above.   119 
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% Cells in phase: 
(Attached) 
G0/G1  S  G2/M 
NS  74  11  15 
NSLT  62  18  20 
NSLTRas  59  24  17 
 
Figure 3- 11: Attached NS, NSLT and NSLTRas cells show normal 
proliferating cell cycle profiles when analysed by flow cytometry. 
(A) Attached NS, NSLT and NSLTRas cells were given a 1-hour BrdU pulse directly 
before harvesting, fixing, and staining for flow cytometry, with antibodies to BrdU, and 
propidium iodide (PI) to indicate DNA content.  Top panels: histograms of DNA 
content, with phases marked as indicated.  Bottom panels: dot plots of BrdU 
incorporation vs. DNA content, with BrdU+ gates defined as in Figure 3- 10B.  
Percentages indicate BrdU+ cells for each cell type. 10,000 events were collected per 
sample. 
(B) Quantification of the proportion of cells in each phase, as defined by markers on 
histograms above.  120 
cells appearing in the G0/G1 cluster (Figure 3- 12A, left panel).  Importantly, 
given  that  a  proportion  of  cells  would  have  been  mid-cycle  when  put  into 
suspension, this suggested that the majority of NS cells were able to complete 
the cycle and return to G1 within 24 hours even in the absence of anchorage 
signals.  
Consistent with the increase in cell numbers, NSLTRas cells after 24 
hours in suspension maintained a ‘proliferating’, horseshoe-shaped cell cycle 
profile (Figure 3- 12, right panel).  The accumulation of cells in G2/M phase 
(55% compared to 17% in attached cells) suggests that the process of mitosis 
and  cytokinesis  may  take  longer  in  suspension.    However,  there  was  little 
reduction in the BrdU-positive population (Figure 3- 13A), consistent with an 
overall proliferation rate similar to that in attached cells, as observed in the cell 
counts. 
   In contrast, NSLT suspended cells, although no longer proliferating, did 
not show a profile characteristic of cell-cycle arrest.  There were several points 
to note from the analysis (Figure 3- 12A, middle panel).  Firstly, the PI profile 
was similar to that of the proliferating NSLTRas cells, in that cells appeared in 
all phases including S phase, with some accumulation in G2/M phase (Figure 3- 
12B).  However, in contrast to NSLTRas, the rate of BrdU incorporation in 
NSLT was substantially inhibited compared to the proliferating, attached cells, 
with only half as many cells BrdU-positive in suspension (see also Figure 3- 
13A).    Although  BrdU  incorporation  in  NSLT  suspended  cells  was  much 
reduced,  it  was  not  completely  absent,  as  might  be  predicted  for  a  non-
proliferating cell sample.  Finally, and importantly, many cells in S phase (i.e. 
with  an  intermediate  DNA  content)  were  clearly  BrdU-negative,  giving  a 
triangular rather than horseshoe-shaped BrdU plot. 
Together,  these  observations  indicate  a  slower  cell-cycle  progression, 
with periods of stalling, rather than a phase-specific arrest in NSLT suspended 
cells.  The presence of cells that show an ‘S phase’ DNA content between 2N 
and  4N,  which  nevertheless  remain  BrdU-negative,  indicates  that  replication 
must have stalled for at least the duration of the one-hour BrdU pulse.  To 
confirm  the  FACS  data,  NSLT  cells  were  given  a  5-hour  BrdU  pulse  in 
suspension before retrieving, fixing within one hour, and antibody staining   121 
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% Cells in phase: 
(Suspended 24hrs) 
G0/G1  S  G2/M 
NS  87  6  7 
NSLT  46  13  41 
NSLTRas  32  13  55 
 
Figure 3- 12: Suspended NSLT cells show an unusual cell cycle profile. 
(A) NS, NSLT, and NSLTRas cells in methylcellulose suspension were given a 1-hour 
BrdU pulse directly before harvesting at 24 hours, fixing, and staining for flow 
cytometry, with antibodies to BrdU, and propidium iodide (PI) to indicate DNA 
content.  Top panels show histograms of DNA content.  Bottom panels show dot plots 
of BrdU incorporation vs. DNA content, with BrdU+ gates defined as in Figure 3- 10B.  
Percentages indicate BrdU+ cells for each cell type. 10,000 events were collected per 
sample. 
 (B) Quantification of the proportion of cells in each phase, according to the cell cycle 
profiles.   122 
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Figure 3- 13: Quantification of BrdU incorporation by flow cytometry, 
confirmed by immunofluorescence in NSLT cells from suspension. 
(A) BrdU incorporation in NS, NSLT, and NSLTRas attached cells, and those 
suspended for 24 or 48 hours, following a one-hour BrdU pulse.  Samples were 
analysed by flow cytometry and quantified by ‘gating’ dot plots as demonstrated in 
Figure 3-10B.  Graph shows mean of 4 separate experiments.  Error bars indicate s.e.m.  
* p>0.7, no significant difference; ***p<0.02, significant difference (2-tailed, unpaired 
t-test). 
(B) Immunofluorescence staining for BrdU in NSLT cells following a five-hour pulse 
in 24-hour suspension.  Cells were retrieved, washed to remove excess BrdU and 
methylcellulose and then plated on laminin and PLL-coated coverslips.  Immediately 
after settling (20 minutes after plating), cells were fixed and immunostained to show 
BrdU-positive nuclei (green).  123 
samples for immunofluorescence.  Any BrdU present in the methylcellulose was 
thoroughly washed away before attaching the cells to coverslips.  Quantification 
of  the  BrdU  staining  on  cells  after  24  hours  in  suspension  confirmed  the 
maintenance  of  low  levels  of  BrdU  incorporation  in  NSLT  suspended  cells 
(Figure 3- 13B). 
A  continued,  slow  rate  of  BrdU  incorporation,  coupled  with  an 
accumulation of cells in G2/M phase, raised the possibility that all NSLT cells 
would be able to complete S phase given enough time, and would then arrest 
somewhere in G2/M phase.  This would place the requirement for anchorage in 
NSLT cells at mitotic entry or exit.  The fact that the proportion of NSLT cells 
in G1 phase decreases from 62% to 46% when they are put into suspension 
suggests that cells are able to make the transition from G1 to S phase in the 
absence of anchorage.  To see whether this trend continues, we compared FACS 
analysis of NSLT cells suspended for 24-hour and 48-hour time periods (Figure 
3- 14A).  Cells in suspension for 48 hours were given a one-hour BrdU pulse, 
and processed by flow cytometry as before.  The PI profile and BrdU/PI plot of 
NSLT cells after 48 hours was similar to that of the 24 hour suspended cells.  
The  percentages  of  cells  in  each  phase  are  also  almost  identical,  with  little 
further  accumulation  of  cells  in  G2/M  phase,  suggesting  that  S  phase 
progression is extremely slow (Figure 3- 14B).  The absence of any further 
decrease in the proportion of cells in G1  suggests that perhaps cells do not 
maintain their ability to enter S phase in suspension.  Confirmation of whether 
all cells are competent to enter S phase would require samples taken after a 
much  longer  timescale,  beyond  the  scope  of  this  assay,  since  the 
methylcellulose medium cannot be replenished in these suspension cultures. 
 
3.4 Chapter summary and conclusions 
As  documented  in  this  first  results  chapter,  we  constructed  the 
NS/NSLT/NSLTRas  model  cell  system  and  optimised  the  methylcellulose 
method of suspension culture and retrieval, in order to investigate the novel 
p53-  and  Rb-independent  anchorage  checkpoint  mechanism  found  in  NSLT 
cells.    Counts  of  cells  retrieved  from  suspension  supported  the  results  from  124 
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% Cells in phase:  G0/G1  S  G2/M 
NSLT (attached/ 0 hrs suspended)  62  18  20 
NSLT (24 hrs suspended)  46  13  41 
NSLT (48 hrs suspended)  46  12  42 
 
Figure 3- 14: Comparison of attached and suspended NSLT cell cycle 
profiles after 0, 24 and 48 hours. 
(A) Cell cycle profiles from attached (left) and suspended NSLT cells after 24 hours 
(middle) and 48 hours (right) in methylcellulose.  Cells were given a one-hour BrdU 
pulse directly before harvesting, and stained with PI.  Histograms (above) indicate 
frequency of DNA content in each sample; dot plots (below) show BrdU incorporation 
against DNA content. Percentages indicate BrdU incorporation.  10,000 events were 
collected per sample. 
(B) Quantification of cells in each phase, according to the above histograms.  125 
colony-forming  assays  in  soft  agar,  in  showing  that  only  NSLTRas  cells 
increased in number and were able to form colonies in suspension, while NS 
and  NSLT  cells  were  both  strictly  anchorage  independent  with  respect  to 
proliferation. Cells that were retrieved were able to reattach to culture dishes 
and resume proliferation, indicating that suspension-induced mitotic arrest was 
reversible in these cells, although retrieval of NSLT cells from methylcellulose 
was not 100% due to a minor proportion of cells that die in suspension.  
NSLTRas  cells  showed  a  cell  cycle  profile  consistent  with  their 
observed  proliferation  in  suspension,  and  NS  cells  exhibited  a  classical  G1 
arrest, as seen in previous studies on NRK and NIH 3T3 fibroblasts (Guadagno 
and Assoian 1991; Zhu et al. 1996).  In contrast, the NSLT cells did not show a 
stable arrest.  Instead, flow cytometry analysis showed that suspended NSLT 
cells appeared in all phases of the cell cycle, and importantly, results from both 
FACS and fluorescence microscopy showed the maintenance of a low level of 
BrdU incorporation, suggesting that NSLT cells were able to progress through S 
phase  while  in  suspension.    This  was  unexpected,  since  the  absence  of  any 
increase in the total number of cells led us to expect a complete block to cell 
cycle progression.  DNA replication was slower in suspension, as shown by the 
reduced  proportion  of  BrdU-positive  cells  compared  to  the  attached  sample, 
with periods of stalling, shown by the proportion of S-phase cells that did not 
incorporate any BrdU during a one-hour pulse.  Analysis of cells in suspension 
culture  also  showed  an  accumulation  of  cells  in  G2/M  phase,  suggesting  a 
secondary  requirement  for  anchorage  in  G2/M  phase  of  the  cell  cycle,  in 
addition to the well-documented G1/S phase requirement seen in NS cells.  This 
novel anchorage checkpoint is only detectable in the NSLT cells, as they require 
little signal input for the G1/S phase transition.  The following chapter describes 
the  investigation  of  the  molecular  mechanism  inhibiting  normal  cell-cycle 
progression in suspended NSLT cells.   126 
Chapter Four – Biochemical characterisation of model 
4.1 Introduction 
In  the  previous  chapter  I  described  the  differences  in  cell  cycle 
behaviour between our three model cell types: NS, NSLT, and NSLTRas, and 
optimised  a  methylcellulose  suspension  culture  system  which  allows  both 
anchorage-independent culture and maximal retrieval of cells.  NSLTRas cells 
proliferate efficiently in suspension, while NS and NSLT cells do not increase 
in  number  at  all,  and  either  arrest  in  G1  or fail  to  complete  the  cell  cycle, 
respectively.  In this chapter we characterise the differences between anchorage 
dependent and independent cells biochemically, in particular the analysis of the 
composition  and  activity  of  the  key  drivers  of  the  cell  cycle,  the  cyclin-
dependent kinase complexes, since the mechanism responsible for the aberrant 
cell cycle progression seen in NSLT suspended cells is highly likely to be the 
result of altered CDK regulation. 
 
4.2 Biochemical characterisation 
4.2.1 NSLT cells maintain cyclin/CDK expression in suspension 
Protein samples were prepared from the three cell types: NS, NSLT and 
NSLTRas, from both attached and 24-hour suspended cell cultures, and the total 
levels  of  cyclins  and  cyclin-dependent  kinases  were  analysed  by  Western 
blotting (Figure 4- 1).  In NS cells, cyclins D, E and A and B are expressed in 
attached cells, but levels of cyclins D, E and A drop to barely detectable levels 
in suspension, indicating that anchorage signals are ordinarily required for their 
expression.  CDK2 levels also decrease substantially in suspension, and CDKs 4 
and 6 show a modest decrease, while levels of cyclin B and CDK1 in NS cells 
do  not  appear  to  change  in  suspension.    It  is  known  that  both  integrin  and 
mitogenic signals are required to produce the sustained ERK activation required 
to  induce  cyclin  D1  expression,  in  cells  with  an  intact  Rb-E2F  checkpoint 
(Roovers et al. 1999).  In the absence of cyclin D1 expression, cyclins E and A 
were also expressed at lower levels in NS suspended cells, since active cyclin   127 
 
 
 
 
 
Figure 4- 1: Expression levels of cyclins and CDKs. 
Western blot analysis of total lysate from attached (+) and suspended (-) NS, NSLT, 
and NSLTRas cells.  ß-tubulin is shown as a loading control.   128 
D-CDK4/6  is  required  to  inactivate  Rb  and  to  promote  E2F-mediated 
transcription (Johnson 1995).  
In contrast, LT-expressing cells (both NSLT and NSLTRas) expressed 
higher levels of many of the cyclins and CDKs in attached cells when compared 
to NS.  These included all four cyclins: D, E, A and B, and CDKs 1 and 2.  This 
is consistent with the E2F-mediated derepression of the cyclin E (Ohtani et al. 
1995), cyclin A (Schulze et al. 1995), CDK2 (Shiffman et al. 1996) and CDK1 
(Dalton  1992)  gene  promoters  owing  to  inactivation  of  Rb  by  LT,  and  has 
previously been reported in these cells (Lloyd et al. 1997).  Moreover, the high 
expression of each of these cell-cycle regulators was maintained in suspension 
in both the NSLT and NSLTRas cells (compare lanes 3-4 and 5-6).  This is in 
contrast to the NS cells, where the expression of the cyclins and CDK2 was 
dependent on the presence of attachment signals (compare lanes 1 and 2).  The 
minimal  expression  of  cyclin  B1  in  both  NS  attached  and  suspended  cells 
compared to NSLT may reflect the relatively small proportion of NS cells in 
G2/M phase at any one time in this asynchronous cell population, given that 
cyclin  B  levels  rise  towards  the  onset  of  mitosis  and  the  protein  is  rapidly 
degraded to signal mitotic exit.  The higher cyclin B levels in the more rapidly 
proliferating  NSLT  and  NSLTRas  attached  cells  could  be  due  to  the  higher 
proportion of cells in mitosis in these cultures.  The presence of cyclin B in the 
NSLT suspended sample is a further indication that these cells are found in all 
phases of the cell cycle and not accumulated in arrest, in agreement with the cell 
cycle profiles shown in Chapter Three.  
The levels of CDK4 in the three cell types were remarkably consistent, 
whether attached or in suspension, indicating that the levels of the CDK are not 
differentially regulated  in  the  different  cell  types,  or  by  cell  adhesion.   The 
related cyclin D1-associated kinase CDK6 is also detectable in all samples, and 
again levels do not seem to correlate either with cell type or adhesion status.  
The consistency of CDK4 expression in our cells is indicative of its regulation 
primarily  by  cyclin  binding  (Matsushime  et  al.  1994)  and  other  post-
translational mechanisms, rather than by control of its expression levels. 
Expression of the cyclins and CDKs in NSLT and NSLTRas cells does 
not seem to correlate with proliferation, as the protein levels were comparable in   129 
the  anchorage-dependent  NSLT  and  anchorage-independent  NSLTRas,  and 
expression  was  largely  maintained  in  suspension  in  both  cell  types.    This 
suggests  that  differences  in  cyclin-CDK  activation  may  be  responsible  for 
inhibiting proliferation in the suspended NSLT cells.   
 
4.2.2 CDK2 activity in anchorage-dependent cells is dramatically 
reduced in suspension 
As central regulators of cell cycle progression, cyclin-CDK complexes 
are likely to be the eventual targets of any anchorage-dependent mechanism 
preventing cell proliferation in suspension.  As seen in the previous section, 
cyclin  and  CDK  levels  were  unchanged  in  NSLT  suspended  compared  to 
attached  cells,  implying  that  anchorage-dependent  regulation  in  these  cells 
could be at the level of cyclin-dependent kinase activity, rather than at the level 
of protein induction, as in NS cells.  To assess this possibility, kinase assays 
were  carried  out  on  immunoprecipitated  cyclin  complexes,  to  measure 
endogenous CDK activity associated with cyclins E, A, and B1 in attached and 
suspended cells.  Cyclins E and A associate with CDK2, while CDK1 associates 
with cyclin A and cyclin B.  Activity of the endogenous cyclin complexes can 
be measured in vitro by monitoring phosphorylation of a histone H1 substrate 
with radiolabelled ATP.  Preliminary tests using previously frozen cell pellets 
showed a great deal of variability between experiments, and it was found that 
the consistency of results was markedly improved when unfrozen samples were 
used.  This is most likely due to the labile nature of regulatory modifications on 
the cyclin-CDK complexes, which may be disrupted by freezing and thawing.  
Experiments  were  therefore  designed  so  that  fresh  samples  of  both  attached 
cells and 24-hour-suspended cells of all three cell types would be ready for 
harvesting at the same time, and lysis, immunoprecipitation and kinase assays 
were carried out on unfrozen cell samples on the day of harvesting.  Tests using 
decreasing amounts of lysate in the kinase assay showed a linear relationship 
between protein added and the kinase activity produced, indicating that levels of 
substrate and ATP were not limiting. 
As shown in Figure 4- 2A, cyclin E-associated kinase activity was much 
higher  in  NSLT  and  NSLTRas  attached  cells  than  NS, reflecting  the  higher  130 
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Figure 4- 2: Cyclin-dependent kinase activity in attached (+) and suspended 
(-) cells. 
Autoradiograms show representative results for (A) cyclin E, (B) cyclin A and (C) 
cyclin B-associated kinase assays following cyclin immunoprecipitation from attached 
and suspended cell lysates.  IPs were carried out using 300, 150 and 100µg of protein 
per sample respectively in (A), (B) and (C).  Graphs show means from 4 similar 
experiments +/- s.e.m.  * p value >0.05, no significant difference; *** p value <0.002, 
significant difference using a 2-tailed, one-sample t-test (suspended relative to 
attached).   131 
expression of CDK2 and cyclin E as seen in Figure 4- 1.  Comparison of E 
kinase  activity  in  NS  attached  and  suspended  cells  was  difficult  because 
phosphorylation levels were so low as to be barely above background levels.  
Kinase activity was highest in the NSLTRas attached cells, and did decrease 
somewhat in NSLTRas suspended cells.  However, in NSLT cells, there was a 
much more pronounced decrease in CDK activity in suspension (>3 fold), with 
kinase  activity  close  to  basal  levels.    However,  the  reduced  cyclin  E-CDK 
activity seen in NSLT suspended cells was not less than that of the NS attached 
cells,  which  are  proliferating,  suggesting  that  other  factors  may  be  limiting 
NSLT proliferation in suspension. 
Measurements of cyclin A-CDK activity (Figure 4- 2B) in attached cells 
were also consistent with the levels of cyclin A, CDK2 and CDK1 expression: 
much higher in LT-expressing cells than in NS cells.  In NS cells, cyclin A-
associated  kinase  activity  was  reduced  to  basal  levels  in  suspension,  also 
consistent with the lack of cyclin-CDK protein expression.  In contrast, while 
levels of cyclin A, CDK1 and CDK2 protein were maintained in NSLT cells in 
suspension, there was a dramatic decrease in cyclin A-associated kinase activity 
in  the  suspended  cells  (>5  fold),  to  levels  lower  than  those  in  proliferating 
attached NS cells.  There was also an approximately 2-fold reduction in cyclin 
A-CDK activity in NSLTRas suspended cells, but in this case the kinase activity 
was still considerably higher than in the NS attached cells, and had little effect 
on cell proliferation.  The relative cyclin A-CDK activity, above or below the 
putative ‘threshold’ level in NS attached cells, therefore correlates with whether 
cells proliferate, for both NSLT and NSLTRas samples. 
Cyclin B-CDK1 activity (Figure 4- 2C) was much higher in NS attached 
cells  compared  to  NS  suspended  cells,  consistent  with  the  lack  of  CDK1 
expression in suspension, and the G1 arrest seen in the previous chapter.  Levels 
of  cyclin  B-CDK1  activity  were  higher  in  LT-expressing  cells  than  in  NS, 
consistent  with  their  higher  CDK1  expression.    However,  the  reduction  in 
kinase activity in suspended NSLT and NSLTRas cells was less pronounced 
than for other cyclin-CDKs.  In NS cells, cyclin B-associated kinase activity 
clearly correlates with cell proliferation, but in NSLT and NSLTRas cells this is 
not the case.  This pattern of cyclin B-CDK1 activation was perhaps due to   132 
variations in the proportion of cells in M phase, given the relatively narrow 
period of cyclin B-CDK activation, rather than correlation with proliferation per 
se (Sherr 1996). 
The overall reduction in CDK activity when NSLT cells were suspended 
indicates  that  CDK  activity  is  predominantly  anchorage  dependent  in  these 
cells,  and  that  the  level  of  inhibition  of  cyclin-CDK  activity  is  likely  to 
contribute to aberrant cell cycle progression in suspension.   
 
4.2.3  Composition  of  cyclin-CDK  complexes  in  suspension 
indicates increased association of p27 
Since the results in Figure 4- 1 showed that total cyclin and CDK protein 
expression  does  not  decrease  in  NSLT  suspended  cells,  we  examined  the 
composition of the cyclin-CDK complexes further to discover how their activity 
was inhibited.  CDK activity is regulated by at least three mechanisms: cyclin 
binding, activating and inhibitory phosphorylations, and the binding of small-
molecule CDK inhibitors, including p21 and p27 (Morgan 1995).  To analyse 
the  mechanism  responsible  for  inhibiting  cyclin-dependent  kinase  activity  in 
NSLT cells, we first determined the total levels of these CDK inhibitors in our 
attached and suspended cell lysates. 
Western blots of total CDK inhibitor levels (Figure 4- 3A) showed that 
in NS cells, p27 levels were induced in suspension, as has been observed in 
previous studies in anchorage-dependent fibroblasts (Zhu et al. 1996; Carrano 
and Pagano 2001).  Surprisingly, p21 levels were decreased in NS suspended 
cells,  in  contrast  to  previous  studies  suggesting  that  both  p27  and  p21  are 
induced following loss of cell anchorage (Fang et al. 1996; Zhu et al. 1996).  In 
NSLT  and  NSLTRas  cells,  p21  levels  were  unchanged  in  suspension,  most 
likely due to the LT-mediated inhibition of p53 (el-Deiry et al. 1993; Lloyd et 
al.  1997;  Wu  and  Schönthal  1997).    NSLTRas  cells  maintained  barely 
detectable  levels  of  p27  as  well  as  p21,  consistent  with  Ras-induced 
upregulation of Skp2-mediated degradation (Kawada et al. 1997; Bornstein et 
al. 2003; Bhatt et al. 2007).  In contrast, p27 levels were strongly induced in 
NSLT cells in suspension.  The expression pattern of p27 suggests a potential   133 
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Figure 4- 3: Composition of cyclin A-CDK complexes. 
(A) Total expression levels of CDK inhibitors in NS, NSLT and NSLTRas attached (+) 
and suspended (-) cells.  20µg of protein sample was loaded per lane. 
(B) Immunoprecipitated (IP) cyclin A complexes, showing levels of cyclin A and 
bound CDK2 and p27 by immunoblot (IB).  IP was carried out starting with 800µg of 
total protein for each sample.  134 
mechanism  for  anchorage-dependent  regulation  of  cyclin-CDK  activity  in 
NSLT cells. 
In  order  to  investigate  the  activation  status  of  CDK  complexes  in 
attached  and  suspended  cells,  we  analysed  their  composition,  to  determine 
levels of potentially active cyclin-bound CDK, as well as the levels of CDK 
inhibitors bound to the complex.  In preliminary experiments, cyclin A was 
immunoprecipitated  from  cell  lysates  and  associated  proteins  blotted  to 
determine levels of cyclin-bound CDK.  However, the levels of pulled-down 
proteins were obscured by the heavy and light chains of the IP antibody, which 
are present at high levels in the precipitate.  To avoid this, we used cyclin A 
antibody  chemically  cross-linked  to  protein  G  beads,  which  successfully 
removed the interference of heavy and light immunoglobulin chains with the 
pulled-down proteins.   
Blotting the separated complexes (Figure 4- 3B) showed that cyclin A 
and  CDK2  were  co-immunoprecipitated  from  NS  attached  cells,  while  no 
protein was pulled down in  NS suspended cells, consistent with the lack of 
cyclin A in these conditions.  In contrast, almost equal amounts of CDK2 was 
present bound to cyclin A in NSLT suspended as in attached cells.  Thus, the 
levels of cyclin A-CDK2 complex are not responsible for the loss of kinase 
activity in these cells.  A similarly equal amount of cyclin A-CDK2 was co-
immunoprecipitated  from  NSLTRas  attached  and  suspended  cell  lysates.  
Strikingly however, blotting for p27 in cyclin A complexes showed that the 
amount  of  CDK-bound  inhibitor  was  increased  in  NSLT  suspended  cells  in 
parallel  with  the  increase  in  total  p27  protein,  suggesting  that  p27  may  be 
responsible  for  the  CDK  inhibition  seen  in  NSLT  cells  in  suspension.    In 
NSLTRas cells, no p27 was detected bound to cyclin A complexes, consistent 
with the low p27 levels in Ras-expressing cells presumably due to its oncogene-
induced degradation (Kawada et al. 1997; Bhatt et al. 2007; Grimmler et al. 
2007).   
The evidence presented thus far supports a role for p27 in suspension-
induced CDK inhibition and anchorage dependence in NSLT cells.  To assess 
the  importance  of  p27  in  inhibiting  CDK  activity,  we  investigated  the 
proportion  of  CDK  complexes  that  were  bound  by  p27  in  attached  and   135 
suspended cells.  To do this, NSLT attached and suspended cell lysates were 
subjected  to  p27  immunodepletion  using  a  polyclonal  anti-p27  antibody.  
Blotting for p27 after successive depletions (removing protein-bound beads and 
adding fresh beads and antibody to the sample each time) indicated that three 
rounds  of  depletion  were  sufficient  to  remove  detectable  p27  in  the  lysates 
(Figure 4- 4A).  Non-specific ‘clearing’ by incubating with protein A-sepharose 
beads was used as a control.  The immunodepletion should also remove all p27-
bound protein, including any bound cyclin-CDK complexes, from the lysate.  
To determine the amount of unbound cyclin-CDK complex remaining, cyclin A 
complex was immunoprecipitated from p27-depleted and control supernatant, 
and blotted for CDK2 (Figure 4- 4B).  Depletion of p27-bound protein had little 
effect on the amount of cyclin-CDK complex retrieved from attached NSLT 
samples, whereas it almost completely removed CDK from suspended samples, 
indicating  that  nearly  all  cyclin  A-CDK2  complexes  were  p27-bound  in 
suspension.  Since p27 molecules bind and inhibit cyclin A-CDK2 with a 1:1 
stoichiometry  (Russo  et  al.  1996;  Bienkiewicz  et  al.  2002),  this  strongly 
suggests that the binding of p27 to cyclin-CDK complexes is responsible for the 
inhibition of CDK2 activity in suspended cells.  
 
4.2.4  p27  loss  cooperates  with  LT  in  inducing  anchorage 
independence 
To  confirm  the  role  of  p27  in  preventing  anchorage-independent 
proliferation, we took a genetic approach to knock down p27 expression in our 
cell system.  We used a siRNA protocol that had been previously tested in the 
lab and used against other gene targets in Schwann cells with high knockdown 
efficiency.  Sequences of the four designed siRNA duplexes, negative control 
(“scrambled”) duplex and procedures used are described in Chapter 2.  Briefly, 
siRNA was mixed with transfection reagent and added to cells overnight (17-19 
hours), before replacing with fresh medium.  Samples for Western blotting were 
harvested 24 hours after this medium change.  Initial experiments to test each 
siRNA  duplex  on  NSLT  attached  cells,  alone  and  in  combination,  at 
concentrations between 0.5 and 2nM, gave little if any knockdown as judged by 
Western blotting (Figure 4- 5A).  Different mixtures of two siRNAs, applied to  136 
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Figure 4- 4: Depletion of p27-bound complex shows most cyclin A-CDK2 
complex is inhibited by p27 in suspension. 
(A) p27 depletion of NSLT lysates, showing p27 levels initially (0) and after 1, 2 and 3 
rounds of p27 immunodepletion (1-3) in samples from attached (att) and suspended 
(susp) cells. β–tubulin (Btub) is shown as a loading control.  
(B) Immunoblot (IB) shows uninhibited CDK2 remaining in control (c) and p27-
depleted (d) lysates, by cyclin A immunoprecipitation (IP).  IP was carried out starting 
with 250µg of total protein for each sample. 
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Figure 4- 5: Testing of p27 siRNA. 
(A), (B) and (C): Cells were transfected with the indicated duplex(es), 1, 2, 3, 4, or 
negative control siRNA, ‘scr’, overnight at various nanomolar (nM) concentrations, 
and harvested the indicated number of hours (hrs) after medium change the following 
morning.  If no time is given, samples were harvested at 24 hours post-medium change.  
(A) and (C) blots used NSLT cells, (B) is of NS cell samples. All blots indicate total 
p27 levels, and each lane represents the protein from one well of a 6-well plate.   138 
NS  cells  at  higher  concentrations  up  to  4nM  produced  a  more  efficient 
knockdown (Figure 4- 5B).  The (1+4) combination was subsequently tested on 
NSLT cells at 3-5nM and cell samples were harvested over a time course of 48 
hours (Figure 4- 5C).  The ‘time zero’ samples all had very low levels of p27, 
which was attributed to the medium change immediately before their harvesting.  
Knockdown was most efficient at 5nM (compare right-hand lanes on (1+4) with 
those on the ‘scr’ blot), although treatment of cells with control siRNA at this 
level also had a small reducing effect on p27 levels.  There was little difference 
between the knockdown efficiencies at 24 and 48 hours, meaning this protocol 
could be used in time course experiments up to two days in suspension.   
The optimised siRNA procedure, using a mixture of duplexes 1 and 4 at 
a combined concentration of 5nM, was then scaled up for use on NSLT cells 
both attached and in suspension.  As before, attached, proliferating cells were 
transfected with siRNA overnight, followed by replacement with fresh medium.  
After  6  hours,  half  the  cells  were  transferred  to  methylcellulose  suspension 
culture, and 24 hours post-medium change, both attached and suspended cells 
were  harvested.    Western  blotting  of  the  total  cell  lysates  shows  efficient 
knockdown in attached cells, consistent with the preliminary data, but a weaker 
knockdown effect in suspended cells (Figure 4- 6A, top blot).  Cyclin A was 
also immunoprecipitated from samples of the lysate to determine the levels of 
p27 specifically bound to cyclin-CDK complexes.  Here the results showed a 
moderate reduction in bound p27 in attached cells, but little change in cyclin-
bound p27 in suspended cells (Figure 4- 6A, lower blot).  Cell counts from 
control and target siRNA-transfected suspension cultures were similar over 2 
days,  consistent  with  the  failure  to  deplete  p27  efficiently  (Figure  4-  6B).  
Perhaps the stabilisation of p27 protein following loss of anchorage was able to 
increase p27 levels in suspension even after knockdown, or the knockdown did 
not last long enough for levels to remain suppressed for 24 hours in suspension.  
It is also possible that the increased binding of p27 to cyclin A complexes in 
suspension protected it from degradation, further undermining the effect of the 
knockdown on p27 function. 
Given the initial success of the siRNA approach in reducing p27 levels 
in attached cells, it was hypothesised that a more long-lasting knockdown might   139 
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Figure 4- 6: p27 siRNA in attached and suspended cells 
(A) p27 siRNA knockdown in NSLT attached (att) and suspended (susp) cells. 
Attached cells were transfected with negative control (scr) or p27-targeted (1+4) 
duplexes at 5nM concentration.  Suspended cells were seeded into methylcellulose 6 
hours post-medium change; all cells were harvested at 24 hours.  Upper blot shows 
total p27; 25µg protein was loaded per lane.  Lower blot shows cyclin A-bound p27; 
cyclin A immunoprecipitation was carried out using 300µg of protein per sample.   
(B) Cell counts from siRNA-treated cells seeded into methylcellulose at medium 
change, and retrieved immediately (day 0) or after 1-2 days.   140 
allow time for complete elimination of p27 in attached cells before transferring 
them to suspension, thereby overcoming the problem of protein stabilisation and 
preventing p27 accumulation in suspended cells.  To effect stable knockdown, 
short hairpin RNA constructs (shRNAs) targeting the p27 sequence were cloned 
into pSiren-RetroQ-zsGreen (see Materials and Methods).  This retroviral vector 
plasmid should allow both constitutive expression of the shRNA construct, and 
identification of the knockdown cells via the coexpression of a green fluorescent 
tag.    Three  different  shRNAs  were  designed  using  Clontech’s  ‘RNAi  target 
sequence selector’ and ‘shRNA sequence designer’ online tools, targeting three 
different regions of the rat p27 gene at sequences unique to the rat genome 
(confirmed by BLAST searches).  A fourth shRNA sequence was taken from 
the literature (Itoh et al. 2007), having been successfully used to target p27 in 
mouse cells (at a target sequence conserved between mouse and rat) using a 
similar  vector.    Once  ligated  into  pSiren-RetroQ-zsGreen,  the  four  shRNA 
vectors were transformed into bacteria and isolated colonies were grown up, 
from  which  plasmid  DNA  was  purified.    The  presence  of  an  insert  was 
confirmed in all four cases by restriction digest at an Mlu1 site unique to the 
shRNA sequences (Figure 4- 7A).  After expansion of the constructs in bacteria 
and extraction of plasmid DNA by maxi prep, the identity of each insert was 
verified  by  sequencing.    The  U6  promoter  sequence,  located  approximately 
50bp upstream of the insert site, was used as a forward sequencing primer, as 
recommended by the vector manufacturer.  Plasmids with insert targets “2”, “3” 
and “itoh” were 100% matched to their correct insert sequence, while insert 
target “7” was sequenced correctly for the first 18 nucleotides before the read 
failed, probably caused by the confounding secondary structure of the hairpin. 
Each construct was transfected into the Phoenix retroviral packaging cell 
line and the virus used to infect populations of NSLT cells.  Following retroviral 
infection, cells were sorted by flow cytometry to purify the most highly green-
fluorescent cells expressing each shRNA vector (Figure 4- 7B).  p27 expression 
was assessed in the sorted cell lines by Western blotting of both attached and 
suspended cells, and cells were also seeded into soft agar suspension to assay 
colony formation.  Western blots of both attached and suspended shRNA cells 
gave puzzling results.  In attached samples (Figure 4- 8A), cells infected with   141 
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Cell sorting by FACS  No. of zsGreen cells retrieved  % zsGreen 
LT p27 shRNA 2  723000  11% 
LT p27 shRNA 3  412400  16% 
LT p27 shRNA 7  673100  21% 
LT p27 shRNA “itoh”  1231000  16% 
LT shRNA neg. control  646700  28% 
 
Figure 4- 7: Verification of shRNA constructs and cell sorting 
(A) Restriction digests of shRNA constructs. All are double digests with Mlu1 except 
for the controls indicated. ‘e’= EcoRV, ‘s’= Sal1, ‘m’= Mlu1.  All give the expected 
band pattern for vectors containing an Mlu1 insert (see Materials and Methods). 
(B) Table showing percentage of cells obtained after sorting for the highest-fluorescing 
green cells expressing each construct.   142 
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Figure 4- 8: p27 knockdown in purified shRNA-expressing NSLT cells. 
(A) p27 protein in attached shRNA cells by Western. ‘2’, ‘3’, ‘7’ and ‘itoh’ are the four 
shRNA constructs.  ctrl= identical vector containing a ‘half-hairpin’.  X=blank lane. 
Un= uninfected control (NSLT suspended cells).  30µg protein was loaded per lane. 
(B) PCR products from genomic PCR using primers specific to the negative control 
(ctrl) insert. Only genomic DNA from the control cells produces PCR product.  See 
Materials and Methods for primer positions. 
(C) p27 protein in suspended shRNA cells by Western. 7.5µg protein was loaded per 
lane.  Labels as above.   143 
the control vector express the lowest levels of p27, with shRNA populations ‘3’, 
‘7’ and ‘itoh’ expressing similar low levels, and sample ‘2’ showing the highest 
p27 levels.  This was so unexpected that we wanted to verify that the control 
and  target  shRNA  cell  populations  were  expressing  the  correct  construct.  
Genomic DNA was purified from the sorted cells, and PCR was performed, 
using primers we designed to detect the presence of the control shRNA insert in 
the pSiren-RetroQ-zsGreen vector (see Materials and Methods).  The reverse 
primer was obligatorily targeted to the negative control insert sequence, and two 
alternative forward primers were used in the PCR reaction.  Running the PCR 
products on a gel (Figure 4- 8B) demonstrated that the cell lines did contain the 
expected  constructs.    We  seeded  each  shRNA  cell  population  into 
methylcellulose suspension, and analysed p27 expression and cell number in the 
suspended cells.  p27 knockdown did not reduce protein levels in any of the 
shRNA-expressing cells more than in those expressing the control vector, and in 
some cases p27 levels were higher than in the uninfected NSLT control (Figure 
4- 8C).  The pattern of p27 expression between the four cell pools also differed 
from that in the attached cells: here, the ‘itoh’ sample had the lowest p27 levels, 
and ‘7’ the highest.  Cells expressing the p27-targeted shRNA constructs were 
seeded into soft agar suspension, and no colonies were observed after 5 weeks.  
At  this  point,  the  shRNA  approach  was  abandoned,  reasoning  that  RNA 
interference  may  not  be  appropriate  for  use  in  situations  where  post-
translational regulation is so important in determining the levels of the target 
protein. 
An alternative, genetic approach to assess the role of p27 in anchorage 
dependent proliferation was to use cells from a germline p27-deficient mouse.  
Instead of using cells from p27-null mice, we obtained frozen MEFs from mice 
whose  p27  gene  had  been  disrupted  by  targeted  insertion  of  a  neo  cassette, 
thereby truncating the protein.  This mutant p27 is missing the binding site for 
CDKs,  and  results  in  a  protein  unable  to  inhibit  cyclin-CDK  complexes 
(Kiyokawa et al. 1996).  Use of this p27 mutant would therefore clarify whether 
it  is  specifically  the  CDK  inhibition  activity  of  p27  that  is  necessary  for 
preventing anchorage-independent proliferation, rather than any other property 
of the protein.  Mice expressing only this “p27∆51” truncation mutant exhibit   144 
hyperplasia,  and  an  enlarged  body  phenotype,  that  resembles  the  p27-null 
mouse (Fero et al. 1996; Nakayama et al. 1996). 
Since  MEFs  are  extremely  prone  to  culture-induced  senescence  and 
spontaneous transformation, we cultured both p27∆51 and equivalent wild-type 
MEFs in physiological (3%) oxygen conditions in which they have been shown 
not to senesce (Parrinello et al. 2003).  We also used them at passage 1, to 
minimise the effect of culture shock on the cells, and the chance of unscheduled 
mutation.  Retroviral infection of both cell types was performed one day after 
thawing the cells at passage 1, with either pBabe-puro empty vector or pBabe-
puro containing Large T (see Materials and Methods).  Immediately following 
infection, without subjecting the cells to potentially damaging drug selection, 
cells were seeded into soft agar at 4000 cells per well.  Both wild type and 
p27∆51 cells remained strictly anchorage dependent after infection with pBabe-
puro, with less than one colony identified in these cultures on average (Figure 4- 
9).  Most wild-type MEFs expressing LT also remained anchorage dependent 
(<1% colony formation), but those lacking functional p27 formed colonies in 
soft agar at more than twice this rate, with over 8 colonies visible on average in 
each field of view.  Considering that the rate of LT infection in these cells may 
be low due to the lack of drug selection, the cooperation of p27 loss with LT in 
inducing colony formation is striking.  The loss of anchorage dependence in LT-
expressing  p27  mutant  cells,  in  combination  with  the  measurements  of  p27 
induction and CDK inhibition described above, was strong evidence that p27 is 
required  to  prevent  anchorage-independent  proliferation  in  cells  lacking 
functional p53 and Rb checkpoints. 
 
4.3 Chapter summary and conclusions 
In this chapter we have investigated the mechanism mediating anchorage 
dependence  in  NSLT  cells,  and  have  shown  that,  while  the  cyclin/CDK 
expression profile of these cells is similar to that of the anchorage-independent 
NSLTRas,  the  activity  of  the  CDKs  is  substantially  reduced  in  suspension.  
Both cyclin E and A-associated kinases show a significant reduction in activity 
in  NSLT  suspended  cells.    This  differs  from  the  inhibition  of  cyclin  E-
dependent kinase activity and lack of cyclin A expression previously observed  145 
  
 
 
 
 
 
 
Figure 4- 9: Colony formation in wild type (WT) and p27-deficient (p27-) 
MEFs. 
Soft agar assay of wild type (WT) and p27-deficient (p27Δ) MEFs, expressing either 
SV40LT (+LT) or empty vector.  p27Δ MEFs express a truncation mutant (p27Δ51) 
unable to bind and inhibit CDKs.  Cells were seeded in soft agar and colonies counted 
after a week in 10 microscope fields per well and at least 2 wells per cell type.  Graph 
shows counts from 5 similar experiments.  *** p<0.005, significant difference (2-
tailed, unpaired t-test).   146 
in human and rat fibroblasts due to E2F repression in suspension (Guadagno et 
al. 1993; Carstens et al. 1996; Fang et al. 1996; Schulze et al. 1996).  In NSLT 
cells, cyclin levels were unchanged in  suspension, and inhibition was at the 
level of CDK activation.   
It  is  clear  that  the  reduction  in  cyclin-CDK  activity  in  NSLT  cells 
correlates with a strong upregulation of the CDK inhibitor p27, making p27 a 
good candidate for the inhibition of NSLT cell proliferation in suspension.  This 
hypothesis is supported by the results in this chapter, showing that the majority 
of CDK2 is p27-bound in NSLT suspended cells.  Expression of LT in cells 
lacking functional p27 results in colony formation, indicating that loss of p27 is 
able to cooperate with LT in inducing anchorage independence.  p27 is therefore 
responsible  for  inhibiting  cell  proliferation  in  checkpoint-deficient  cells 
following loss of substrate adhesion.   147 
Chapter Five –Genomic instability 
5.1 Introduction 
In the previous chapter I identified the mechanism by which NSLT cells 
fail  to  proliferate  in  suspension.    I  showed  that  anchorage  dependence  in 
checkpoint-deficient cells (lacking p53 and Rb activity) is the result of CDK 
inhibition  by  p27,  and  that  loss  of  this  inhibition  results  in  anchorage-
independent proliferation, as measured by colony formation in soft agar (Figure 
4-9).    However,  the  results  presented  in  Chapter  3  showed  that  suspension-
induced arrest in NSLT cells is only partial, in that proliferation is inhibited but 
DNA replication continues, albeit slowly, in the absence of anchorage.  In this 
chapter, we analyse the effects of this aberrant cell cycle progression on the 
genomic  stability  of  these  cells,  and  the  functional  consequences  for  their 
tumourigenic potential. 
 
5.2 NSLT suspended cells develop >4N DNA content 
In  initial  experiments,  we  looked  for  evidence  of  rereplication  in 
suspension, generating cells with a DNA content greater than 4N.  The FACS 
data for cell cycle profiles shown in Chapter 3 used a ‘gate’ on the PI channel of 
the flow cytometer, in order to analyse only single cells with a DNA content 
between  2N  and  4N,  thus  excluding  both  debris  and  cell  aggregates  in  the 
sample.  This gate (R1) is defined on a dot plot of area versus width of the PI 
signal (FL2-A vs. FL2-W), as shown in Figure 5- 1A.  Gates R8 and R9 were 
not used to exclude cells from analysis, but are indicated to show the likely 
location  of  debris  and  cell  clumps  respectively.    Single  cells  with  a  DNA 
content greater than 4N would appear in the top left corner of the plot, so we re-
examined flow cytometric profiles of attached NS and NSLT cells by extending 
the R1 gate to detect these (Figure 5- 1A). 
Quantification  of  the  percentage  of  cells  with  >4N  DNA  content 
revealed firstly that neither the NS nor NSLT attached cells had a significant 
>4N DNA population (Figure 5- 1), indicating that LT expression did not in 
itself cause genomic instability in these cells, despite the inactivation of Rb and 
p53.  This may seem surprising, as p53 and Rb have previously been found to  148 
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Figure 5- 1: NSLT cells over-replicate in suspension. 
(A) Left: Example dot plot from attached, proliferating cell sample stained with PI.  
Vertical scale indicates increasing DNA content; horizontal scale indicates increasing 
width of signal, allowing doublet discrimination.  R1 ‘gate’ delineates data included in 
initial cell cycle profile; R8 shows position of cell debris (below 2N DNA content); R9 
shows position of cell aggregates (above 4N DNA content, but signal width indicates 
more than one cell).  Right: Example dot plot from suspended NSLT cell sample 
stained with PI.  Vertical scale indicates increasing DNA content; horizontal scale 
indicates increasing width of signal, as before.  The R1 ‘gate’ has been extended 
upwards to define data included for the >4N DNA profile: this gate was used to draw a  
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histogram for each sample like the one in (B), from which the % >4N DNA was 
calculated. 
(B) Quantification of >4N DNA content from FACS profiles of attached (0hrs) and 
suspended (24/48hrs) cells.  Cells were fixed and stained with PI to indicate DNA 
content, and the percentage of  >4N DNA cells was quantified on histograms as shown, 
using the extended R1 gate defined in (A) to exclude cell aggregates and debris.  Graph 
shows the mean of at least three samples, each consisting of at least 10,000 cell events.  
Inset is the extended PI profile from NSLT cells after 48 hours in suspension.   150 
prevent  rereplication  and  double-strand  break  accumulation  (Almasan  et  al. 
1995; Vaziri et al. 2003; Pickering and Kowalik 2006; Srinivasan et al. 2007), 
so  their  combined  loss  might  be  expected  to  lead  to  genomic  instability.  
However,  the  culture  conditions  used  for  our  Schwann  cells  are  likely  to 
contribute  to  their  stability:  the  use  of  minimal  amounts  of  serum  in  cell 
medium (3%) prevents mitogen over-stimulation and replication stress leading 
to DNA damage (Loo et al. 1987; Mathon et al. 2001; Fikaris et al. 2006).  The 
importance  of  the  correct  extracellular  conditions  for  maintaining  genomic 
stability  is  exemplified  by  the  normal  development  of  p53-deficient  mice, 
demonstrating relatively low levels of genetic instability in cells (Donehower et 
al. 1992), in contrast to the highly unstable genomes of p53-deficient mouse 
embryo fibroblasts in culture (Harvey et al. 1993). 
NS  suspended  cells  rarely  appeared  with  a  DNA  content  over  4N, 
consistent with their tight G1 arrest.  In contrast, the NSLT suspended cells 
showed a cell cycle profile with 4 clear peaks, indicating a substantial degree of 
over-replication (Figure 5- 1).  Almost 50% of cells had a DNA content greater 
than 4N after 48 hours, suggesting that the majority of NSLT cells overreplicate 
when placed into suspension.   The gradual emergence of this profile was likely 
due to the general slowing of cell cycle progression, indicated by the low levels 
of BrdU incorporation seen in suspended cells (Figure 3-12). 
The  observation  that  the  >4N  DNA  profile  appeared  as  two  discrete 
peaks and not a continuous spread would indicate that in the majority of cells, 
DNA replication origins were re-licensed and all re-fired to initiate a second S 
phase without an intervening mitosis (endoreduplication).  Uncoordinated re-
firing of replication origins (re-replication) would instead result in cells with a 
continuous range of DNA contents, rather than a multiple of the whole genome 
(Porter  2008).    The  possibility  of  origin  re-licensing  in  suspension  will  be 
discussed in Chapter Six. 
   151 
5.3  Metaphase  spreads  show  genomic  instability  in  NSLT 
suspended as well as NSLTRas cells 
To further investigate the over-replication phenotype seen in suspension, 
metaphase spreads were prepared from both attached cells and those recovered 
from  methylcellulose  culture.    Recovered  cells  from  suspension  were  plated 
straight  into  the  colchicine-related  microtubule  poison  Demecolcine  for  two 
hours (see Materials and Methods), thus allowing them to enter mitosis while 
attached, but blocking them in metaphase.  This treatment selects for those cells 
that rapidly enter mitosis when replated. 
The  chromosome  counts  for  NSLT  cells  were  striking  (Figure  5-  2). 
While attached cells, and those which had been in suspension for 24 hours, 
predominantly  had  a  normal  diploid  chromosome  number  (42  in  rat  cells), 
NSLT cells in suspension for 48 hours showed a significant minority of nuclei 
with more than the usual number of chromosomes (10%; median chromosome 
number  78.5).    In  agreement  with  the  DNA  profiles,  these  nuclei  most 
commonly  contained  about  double  the  usual  number  of  chromosomes, 
suggesting an 8N DNA content.  However, there were also nuclei that contained 
an aneuploid number of chromosomes between diploidy and tetraploidy.  This 
suggested  that  perhaps  endoreduplication  cycles  did  not  occur  in  all 
chromosomes, or that chromosomes had been lost or fused.  Aneuploidy has 
been reported to arise via a tetraploid intermediate, notably in p53-null cells 
(Fujiwara  et  al.  2005;  Ganem  et  al.  2007),  suggesting  that  intermediate 
chromosome numbers could have emerged from tetraploid cells that had then 
lost chromosomes.  The technique of chromosome painting could clarify these 
intermediate karyotypes, by identifying the exact complement of chromosomes 
together with any breakages or fusions (Buwe et al. 2003).  
NS  attached  cells  had  a  stable  diploid  complement  of  chromosomes 
(Figure 5- 2A, left), and the protocol employed for preparing metaphase spreads 
did not produce any from NS suspended cells, presumably because G1-arrested 
cells  did  not  have  time  to  reach  metaphase  following  their  retrieval  from 
methylcellulose.  Since the rate of BrdU incorporation in suspended NS cells 
was essentially zero, their chromosome complement would not be expected to 
differ  from  the  diploid  attached  cells.    NSLTRas  cells,  meanwhile,  had  a  152 
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Figure 5- 2: NSLT suspended cells develop both aneuploid and tetraploid 
nuclei. 
(A) Chromosome counts from metaphase spreads of attached (0) and suspended (24, 
48) NS, NSLT and NSLTRas cells.  Each vertical black bar represents one spread 
count; between 23 and 52 spreads were counted per sample.  Diploid chromosome 
complement is 42.  
(B) Fluorescence micrographs show example diploid (left) and tetraploid (right) 
metaphase spreads, from NSLT cells after 24 and 48 hours in suspension respectively.  
DNA is stained with DAPI.   153 
 
variable chromosome number even when attached, consistent with the known 
cooperation between p53 loss and Ras activation in inducing genomic instability 
(Hundley et al. 1997).  This inherent instability did not change in suspension, 
unlike the NSLT cells, whose unstable chromosome number only developed 
following loss of anchorage (Figure 5- 2). 
The relatively low percentage of cells with extra chromosomes detected 
in NSLT samples compared to those with a >4N DNA content may be due to 
the metaphase spread protocol, using cells recently retrieved from suspension.  
The  method  used  is  very  selective  for  cells  which  (a)  survive  the 
methylcellulose retrieval process, (b) are able to reattach quickly in the presence 
of  a  drug,  and  (c)  enter  mitosis  and  reach  metaphase  within  two  hours  of 
reattachment.    The  second  two  points  in  particular  would  be  expected  to 
seriously limit the number of metaphase spreads produced from cells which had 
undergone  aberrant  DNA replication  in  suspension,  which  could  explain  the 
discrepancy  between  the  metaphase  spread  and  FACS  data  estimates  of 
abnormal  DNA  content.    It  is  unlikely  that  adding  demecolcine  to  cells  in 
methylcellulose would be more representative, as unless they actually entered 
(abortive) mitosis in suspension then spreads of metaphase chromosomes could 
not be made, and it would be difficult to ensure that cells received the drug in 
appropriate concentrations within the gel.  The short period of replating allowed 
cells that had undergone DNA replication in suspension to reach metaphase, but 
the  presence  of  the  microtubule-depolymerising  drug  demecolcine  prevented 
cells dividing while attached, meaning that this reattachment should not alter the 
chromosome complement of retrieved cells. 
 
5.4 Giant nuclei only appear in NSLT suspended cells 
To clarify whether the tetraploid cells detected by our experiments had 
arisen through failure to enter or complete mitosis (resulting in a single ‘giant’ 
nucleus), or from cytokinesis failure following a successful mitosis (resulting in 
a binucleate cell), attached and suspended cells were stained with CellTracker™ 
cytoplasmic dye, fixed on coverslips, and stained with Hoechst to visualise the 
nuclei.  Suspended cells were allowed to reattach only during the CellTracker™   154 
treatment, for a total of one hour, to minimise any effect attachment could have 
on nuclear size.  In agreement with the previous results, NS and NSLT attached 
samples,  as  well  as  NS  replated,  showed  neither  binucleate  cells  nor  giant 
nuclei, consistent with their stable genotype (Figure 5- 3A).  In contrast, the 
NSLT  cells  replated  from  suspension  had  10%  abnormal  nuclei.    The  vast 
majority of abnormal cells had giant nuclei rather than being binucleate.  This 
suggested  either  that  cells  were  unable  to  enter  mitosis,  and  eventually  re-
entered S phase, or that there was a failure to complete mitosis, resulting in re-
fusion of the daughter nuclei.  Aborted cytokineses can also result in fusion of 
the newly formed nuclei, as well as formation of binucleate cells (Fujiwara et al. 
2005).   The  proportion  of  abnormal  nuclei  detected  was  consistent  with  the 
metaphase-spread data.  In agreement with this, the number of abnormal nuclei 
only increased in suspended NSLT cells.  This reaffirms our observation that 
loss of p53 and Rb checkpoints alone does not result in genomic instability, but 
that loss of anchorage precipitates its development in these checkpoint-deficient 
cells. 
Surprisingly, NSLTRas cells did not have a high percentage of abnormal 
nuclei in this assay even though the chromosome numbers were so variable.  
This could be due to the distinct morphology of NSLTRas cells compared to NS 
and NSLT (see Figure 3-1), making comparisons between normal and abnormal 
nuclei difficult.  However, it is clear that in contrast to NSLT cells, and in 
agreement  with  the  metaphase  spread  results,  the  proportion  of  abnormal 
NSLTRas cells did not increase in suspension.  This underlines the anchorage 
independence of the NSLTRas cell cycle. 
 
5.5  CDK  inhibition  in  attached  cells  can  reproduce  the 
suspended cell phenotype 
Our  results  indicate  that  the  failure  of  proliferation  seen  in  NSLT 
suspended cells is due to CDK inhibition (Chapter Four).  To determine whether 
the  inhibition  of  CDK  activity  in  suspension  was  sufficient  to  cause  the 
observed loss of anchorage-induced over-replication and instability in NSLT 
cells,  we  examined  whether  inhibiting  CDK  activity  in  attached  cells  could 
induce genomic instability.  We used the CDK  inhibitor Roscovitine, which  155 
A 
 
B 
 
 
Figure 5- 3: NSLT cells replated from suspension show an increase in giant 
nuclei. 
(A) Percentage of giant nuclei and binucleate cells in attached (att) and recently 
replated suspension (susp) cultures, stained with CellTracker™ and Hoechst.  Giant 
nuclei were judged by eye, being at least twice the size of normal nuclei.  Binucleate 
cells were identified using the cytoplasmic stain to define cells containing two nuclei, 
as shown below.  Each sample count was from at least 100 cells on 2 coverslips.  Graph 
shows the mean results from 3 experiments. Error bars indicate s.e.m.  *** p<0.02, 
significant difference (2-tailed, unpaired t-test). 
(B) Example micrographs of a binucleate cell (left) and a giant nucleus (right).  DNA is 
stained with Hoechst (blue), and the cytoplasm is stained with CellTracker™ Red or 
Green.   156 
  
potently and selectively inhibits CDK2, CDK1 and CDK5, by competing for the 
CDK’s ATP-binding site (De Azevedo et al. 1997; Meijer et al. 1997).  Initially, 
Roscovitine was tested on NS, NSLT and NSLTRas attached cells on coverslips 
at concentrations of 1, 2, 5, 10, 20, 50 and 100µM, and BrdU incorporation was 
quantified by immunofluorescence following a 4-hour BrdU pulse. 10µM was 
sufficient to inhibit BrdU incorporation in NS cells, while 50µM was required 
for a comparable inhibition in NSLT and NSLTRas cells, consistent with their 
higher levels of CDK2 and CDK1 activity (see Figure 4-2).  However, to imitate 
the partial inhibition of DNA replication seen in NSLT suspended cells, a lower 
inhibitor concentration would be required.  A second titration was then carried 
out using Roscovitine  concentrations up to 45µM, and the effects on NSLT 
nuclei were analysed.  Attached NSLT cells were treated every 24 hours with 
the inhibitor, and observed after 72 hours (Figure 5- 4A).  Hoechst staining 
showed that a large proportion (15-22%) of NSLT cells had giant nuclei after 
25-45µM  Roscovitine  treatment,  suggesting  overreplication  similar  to  that 
occurring  in  NSLT  suspended  cells.    The  effects  peaked  at  35µM,  higher 
concentrations  having  a  lesser  effect  due  to  the  inhibition  of  cell  cycle 
progression.  Figure 5- 4B shows an example of a ‘giant’ nucleus as seen in 
NSLT cells treated with 30µM Roscovitine. 
The  35µM  concentration  of  Roscovitine  was  then  tested  on  cells 
analysed  by  flow  cytometry.    FACS  profiles  supported  the  idea  of  CDK 
inhibition inducing similar effects in attached cells as it does in suspension: 
profiles  of  both  NS  and  NSLT  attached  cells  treated  with  Roscovitine  were 
similar  to  those  of  suspended  cells  (Figure  5-  4C).    NS  cells  arrested 
predominantly in G1 phase, although Roscovitine treatment also arrested a few 
attached cells in G2, probably because CDK1 activity was insufficient to allow 
completion  of  mitosis.    NSLT  suspended  cells  instead  had  an  aberrant 
‘proliferating’ cell cycle profile, with a proportion of BrdU-incorporating cells 
and a significant minority which have an intermediate ‘S-phase’ DNA content 
but are BrdU-negative.  The Roscovitine-treated attached NSLT cell profile was 
comparable to that of the untreated, suspended cells.  Importantly, the dose of 
Roscovitine was crucial: while concentrations above 35µM effectively inhibited  157 
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Figure 5- 4: CDK inhibition in NSLT attached cells produces a phenotype 
similar to that in suspended cells. 
(A) Percentage of giant nuclei in NSLT cells treated for 72 hours with the indicated 
concentrations of the CDK1/CDK2 inhibitor Roscovitine, and stained with Hoechst.  
Inhibitor was dissolved in DMSO and added to medium.  Medium containing inhibitor 
or DMSO control (0µM) was changed every 24 hours.  Counts represent the mean of 
two treated coverslips, with at least 100 nuclei counted per coverslip.   
(B) Fluorescence micrograph represents Hoechst-stained nuclei from NSLT cells 
treated with 30µM Roscovitine, showing one ‘giant’ nucleus, distinguishable by eye 
(centre right). 
(C) FACS profiles of attached, Roscovitine-treated cells compared to untreated cells 
from 24-hour suspension culture for NS (left two panels) and NSLT (right two panels). 
Cells were stained with PI to indicate DNA content and BrdU incorporation measured 
to indicate DNA replication.  158 
BrdU  incorporation,  lower  concentrations  had  little  effect  on  the  cell  cycle 
profile and all cells in S phase were able to actively incorporate BrdU during the 
one-hour pulse as in untreated cells.  This raises the possibility that it is the 
partial inhibition of CDK activity that gives rise to the over-replication of DNA 
in suspended NSLT cells. 
 
5.6  Genomic  instability  in  NSLT  suspended  cells  leads  to 
oncogenic transformation 
Variable chromosome number in a cell population is a sign of genomic 
instability.  Genomic  instability  is  considered  to  be  a  key  factor  in  the 
progression  of  many  cancers,  acting  to  increase  the  frequency  of  oncogenic 
changes in cells (Loeb et al. 2008; Chandhok and Pellman 2009).  A population 
of  cells  including  both  aneuploid  and  tetraploid  chromosome  complements 
would therefore be expected to exhibit a higher rate of oncogenic transformation 
than  cells  with  a  stable  genome.    We  wanted  to  ask  whether  the  genomic 
instability seen in our NSLT cells after prolonged periods in suspension was 
sufficient  to  induce  full  oncogenic  transformation,  including  anchorage 
independence. 
To test this, we took NSLT cells that had been in suspension for 72 
hours,  and  cells  that  had  been  cultured  in  parallel  under  normal  attached 
conditions, and put them into soft agar suspension to assay spontaneous colony 
formation.  In preliminary experiments, neither cell type formed colonies after 3 
weeks in soft agar, indicating that simply transferring cells from one form of 
suspension  culture  to  another  is  not  sufficient  to  induce  oncogenic 
transformation.  However, it would be predicted that some cell division would 
be required for genomic instability to produce the genetic changes required to 
drive oncogenic transformation.  The simplest way to achieve this would be to 
replate  cells  following  a  period  in  suspension  and  allow  them  to  resume 
proliferation  with  an  abnormal  genome  for  a  time  before  assessing  their 
transformation state.  To test this, the soft agar experiment was repeated, using 
suspended cells cultured in attached conditions (“replated”) for approximately 6 
population doublings after retrieval from methylcellulose.  NSLT attached cells 
passaged in parallel with those put into methylcellulose were used as a control.    159 
Both  “attached”  and  “replated”  NSLT  cells  were  put  into  soft  agar  culture.  
Strikingly,  while  the  background  from  spontaneous  mutation  of  “attached” 
NSLT cells remained negligible, the “replated” NSLT now formed colonies in 
suspension  (Figure  5-  5A).    Despite  the  colonies  formed  from  the  replated 
NSLT  being  rare,  around  1  in  100,000  cells,  there  was  a  clear  difference 
between these ‘destabilised’ cells and those passaged normally (Figure 5- 5B).  
An additional control population of NSLT cells was seeded into methylcellulose 
suspension  and  retrieved  immediately,  before  passaging  in  parallel  with  the 
other cultures and seeding into soft agar.  Colony formation in this population 
was  as  low  as  the  attached  cell  control,  indicating  that  it  is  the  time  in 
suspension, allowing aberrant genome replication, which is important for future 
oncogenic transformation and not the methylcellulose procedure itself. 
To test the tumourigenic capacity of these unstable “replated”  NSLT 
cells directly, they were injected subcutaneously into the flanks of nude mice.  
NSLT cells that had not been subject to a period in suspension, and NSLTRas 
cells,  were  used  as  negative  and  positive  controls,  respectively.    While  the 
positive  control  mice  quickly  developed  subcutaneous  tumours,  and  were 
sacrificed within two weeks, the NSLT-injected mice have not to date shown 
any signs of tumour development (5 months), and the experiment is ongoing. 
 
5.7 Chapter summary and conclusions 
In  this  chapter,  we  have  investigated  the  development  of  genomic 
instability in NSLT cells following loss of anchorage.  Quantification of >4N 
DNA content by flow cytometry indicated that DNA over-replication occurred 
in NSLT cells in the absence of anchorage, with up to 50% of cells having an 
above-diploid  DNA  content  after  48  hours  in  suspension.    Moreover,  when 
replated and subjected to metaphase spread or Hoechst staining, at least 10% of 
these cells were aneuploid and a similar proportion had giant nuclei.  Loss of 
anchorage was clearly responsible for these effects on the genome: >4N DNA 
content, giant nuclei and an aneuploid chromosome complement only appeared 
in suspended NSLT and not in attached cultures.  Attached cells treated with the 
CDK  inhibitor  Roscovitine  showed  a  similar  overreplication  phenotype, 
indicating  that  the  reduced  CDK  activity  in  NSLT  suspended  cells  is  likely  160 
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Figure 5- 5: NSLT cells passaged from suspension have an increased rate of 
oncogenic transformation 
(A) Soft agar assay of colony formation: in NSLT cells after 72 hours in 
suspension, followed by replating (centre), compared with NSLT (left) and 
NSLTRas (right) passaged normally, as negative and positive controls respectively. 
(B) Quantification of combined results from six similar soft agar experiments. a = 
attached cells passaged normally; c = control cells passaged normally that have 
undergone the methylcellulose seeding and retrieval procedure; r = replated cells 
after 72-hour methylcellulose suspension, plus two additional passages on ordinary 
culture plates. Error bars indicate s.e.m.  *** p<0.0005, significant difference (2-
tailed, unpaired t-test).  161 
responsible  for  development  of  the  observed  genomic  abnormalities.  These 
results  indicate  loss  of  anchorage  in  checkpoint-deficient  cells  as  a  novel 
contributor to the development of genomic instability.  
   We would expect a low rate of colony formation in genetically unstable 
cells from suspension, because, from the 10% of aneuploid NSLT cells detected 
after  48  hours,  only  a  few  may  have  survived  the  reattachment  and  been 
successfully  expanded.    They  may  have  aborted  cell  cycle  re-entry  due  to 
resumption  of  better  genome  controls  in  the  presence  of  anchorage  signals 
(Lewis et al. 2002; Truong et al. 2003), or the extra chromosomes may simply 
be too much of a burden for efficient proliferation (Torres et al. 2007; Weaver et 
al. 2007).  In addition, of those that did resume proliferation with an unstable, 
aneuploid chromosome complement, not all changes would result in oncogene 
activation or loss of further cell cycle controls.  The fact that colonies do form 
following expansion of genomically unstable cells, but not others, indicates an 
effective increase in the spontaneous mutation rate in unstable cell populations, 
thereby  raising  the  likelihood  of  progression  to  a  fully  transformed  and 
tumourigenic  state.    This  result  shows  that  a  period  without  proper  cell 
anchorage, which allows aberrant genome complements to develop, precipitates 
future transformation in checkpoint-deficient cells.   
Ordinary  NS  cells,  with  functional  p53  and  Rb  networks,  are  not 
susceptible  to  instability,  since  they  arrest  stably  in  G1  phase  and  do  not 
undergo  any  DNA  replication  in  suspension.    NSLTRas  cells,  which  can 
proliferate equally well in suspension as when attached, appear constitutively 
unstable, so loss of anchorage does not contribute to genomic instability in these 
cells.  However, partly transformed cells such as NSLT, i.e. those lacking cell 
cycle  checkpoints,  are  susceptible  to  increasing  genomic  instability  in 
suspension.  This shows that although the secondary, p27-mediated “anchorage 
checkpoint”  induced  in  p53-  and  Rb-deficient  cells  prevents  anchorage-
independent  proliferation,  the  fact  that  aberrant  DNA  replication  is  possible 
means that cells may develop an unstable genome more prone to oncogenic 
transformation.  The checkpoint mechanism therefore acts as a “double-edged 
sword”.  Maintenance of anchorage dependence acts as a tumour suppressor in 
the  short  term,  by  inhibiting  cell  division,  but  the  concomitant  S  phase   162 
progression leads to the accumulation of genomic abnormalities, which can act 
to increase the rate of oncogenic transformation. 
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Chapter Six – Discussion 
The  maintenance  and  propagation  of  a  stable  genome  through 
generations  of  cells  is  the  major  objective  of  the  cell  cycle  process.    To 
coordinate  DNA  replication  with  cell  division,  ensure  proliferation  is 
appropriate to the cellular context, and allow scope for repair to the genome 
following  insult,  mammalian  cells  have  developed  a  range  of  cell  cycle 
checkpoints  which  pause  or  arrest  cell  cycle  progression  in  response  to 
unfavourable  conditions,  such  as  insufficient  mitogens  or  DNA  damage 
(Elledge 1996).  The failure of many of these checkpoint mechanisms has been 
shown  to  adversely  affect  genome  stability  and  predispose  to  oncogenic 
transformation  (Hartwell  1992;  Bartek  and  Lukas  2001;  Kastan  and  Bartek 
2004; Kops et al. 2005).  A key characteristic of transformed cells is their ability 
to proliferate anchorage independently.  In this thesis I have analysed a primary 
cell model of transformation, to investigate how sequential loss of cell-cycle 
checkpoints results in anchorage independence.  This model consists of three 
cell types:  
•  Normal Schwann cells (NS), which are anchorage dependent;  
•  NS  cells  expressing  SV40  Large  T  antigen  (NSLT),  which 
inactivates p53 and Rb.  Cells proliferate mitogen-independently, 
but remain anchorage dependent; 
•  NS  cells  expressing  SV40  Large  T  plus  oncogenic  Ras 
(NSLTRas),  which  are  fully  transformed,  and  therefore 
proliferate anchorage-independently. 
Using  this  model  I  have  found  that  although  NSLT  cells  fail  to 
proliferate  in  suspension,  they  become  genomically  unstable  after  prolonged  
periods  without  anchorage.    Importantly,  this  was  not  merely  due  to  the 
abrogation of p53 and Rb checkpoints - loss of anchorage signals was necessary 
to initiate these genomic changes, which resulted in the subsequent emergence 
of fully-transformed cells.  This indicates loss of anchorage as a novel trigger 
for the development of genome instability and transformation, in the absence of 
primary checkpoint mechanisms.  These findings, and their implications, are 
discussed in more detail below.   164 
 
6.1 Manifestations of the anchorage checkpoint in our system 
and role of p27 
It  is  well  established  that  adherent  cells  require  both  mitogens  and 
signals from the extracellular matrix to proliferate.  Epithelial and endothelial 
cells additionally require adhesion for survival, and these cell types respond to 
loss of anchorage signals by inducing a form of apoptosis, known as anoikis.  
Non-epithelial cell types, such as fibroblasts, do not die, but undergo a cell 
cycle arrest, following loss of anchorage (Otsuka and Moskowitz 1975; Frisch 
and Francis 1994).  Previous studies on anchorage dependence in fibroblasts 
have shown that attachment signals are required to induce cyclin D1, promote 
the expression of cyclins E and A, and the activation of CDK2, to allow cell 
cycle progression past the Rb/E2F checkpoint (Guadagno and Assoian 1991; 
Guadagno  et  al.  1993;  Fang  et  al.  1996;  Zhu  et  al.  1996).    Detached  cells 
therefore fail to enter S phase and undergo a G1 arrest, due to insufficient cyclin 
D1 induction.  Moreover, in the absence of anchorage, the CDK inhibitor p27 is 
stabilised, contributing to the maintenance of the arrest by direct inhibition of 
cyclin E-CDK2 activity and suppression of cyclin A transcription (Schulze et al. 
1996; Zhu et al. 1996).  
Although Large T antigen can transform some immortalised cell lines, 
expression  of  LT  is  rarely  sufficient  to  induce  anchorage-independent 
proliferation  in  primary  cells.    Full  transformation  of  human  cells  has  been 
shown to require SV40 small t antigen in addition to LT, hTERT and oncogenic 
Ras  (Hahn  et  al.  2002).    Small  t  was  found  to  be  necessary  for  p27 
downregulation (Porrás et al. 1999; Schüchner and Wintersberger 1999).  More 
recently,  small  t  was  reported  to  cooperate  with  cyclin  E  overexpression  to 
overcome p27-induced arrest, and to activate integrin signalling in human cells, 
leading to anchorage-independent proliferation in cooperation with LT (Moreno 
et al. 2004; Sotillo et al. 2008).  In rodent cells, which constitutively express 
telomerase, oncogenic Ras has been shown to cooperate with p53 and Rb loss to 
induce anchorage independence (Hicks et al. 1991; Serrano et al. 1997; Mitchell 
et al. 2003).  Previous reports have shown that Ras exerts its effect in part by 
promoting p27 degradation (Aktas et al. 1997; Kawada et al. 1997), as well as   165 
activating  the  ERK  pathway  needed  for  cyclin  D1  induction.  These  reports 
suggest  the  existence  of  a  secondary,  Rb-independent  anchorage  checkpoint 
mediated by p27 in LT-expressing cells. 
 
Consistent with previous findings in fibroblasts, NS cells in suspension 
did not undergo anoikis, but arrested with a G1 DNA content.  NS cells were 
able to return to the cell cycle upon replating, indicating that the arrest was 
reversible.  G1 arrest in suspension was characterised by loss of cyclin D1, 
cyclin  E,  and  cyclin  A  expression,  and  minimal  cyclin-dependent  kinase 
activity.    Moreover,  p27  was  also  strongly  upregulated  in  suspension,  in 
agreement with results in other cell types.  
As in other rodent cells, Ras cooperated with the inactivation of p53 and 
Rb by LT to promote proliferation of suspended NSLTRas cells.  Importantly, 
these cells failed to induce p27 in suspension, consistent with previous results 
suggesting  that  Ras-induced  p27  proteolysis  is  responsible  for  anchorage-
independent  proliferation  (Kawada  et  al.  1997).    Moreover,  data  from  our 
laboratory indicates that an active  Raf kinase domain is sufficient to induce 
anchorage-independent proliferation in LT-expressing cells, suggesting that Ras 
is  acting  through  Raf  to  overcome  the  anchorage  checkpoint  (D.  Danovi, 
unpublished).  However, we cannot rule out other Ras-induced mechanisms that 
might also be involved in promoting anchorage-independent proliferation, and 
these are discussed in section 6.3. 
As anchorage dependent cells, Schwann cells expressing LT alone failed 
to proliferate in suspension, and accordingly, cyclin-CDK activity was strongly 
inhibited.  This was found to be due to the upregulation of p27, as there was an 
increase in p27 bound to cyclin-CDK complexes in NSLT suspended cells.  In 
addition, inactivation of p27 in LT-expressing MEFs induced colony formation 
in soft agar, demonstrating directly that p27 mediates a secondary anchorage 
checkpoint  in  cells  where  Rb  is  inactivated.  These  results  reaffirm  p27’s 
importance  as  a  tumour  suppressor.    Many  studies  have  demonstrated  that 
downregulation, mislocalisation, and increased degradation of p27 via Skp2 are 
correlated with poor prognosis in a range of cancers (Catzavelos et al. 1997; 
Loda et al. 1997; Chu et al. 2008).  Notably, a mouse model of prostate cancer   166 
has shown that p27 deficiency accelerates progression to a poorly differentiated 
carcinoma  (PDCA)  in  animals  expressing  SV40  LT  in  the  prostate  gland 
(Shaffer et al. 2005).  This report is particularly interesting in the light of our 
results, since progression to PDCA is associated with loss of E-cadherin, and 
therefore a change in the adhesive microenvironment of the cell (Umbas et al. 
1992;  Perl  et  al.  1998).    It  is  tempting  to  speculate  that  the  prostate  cells 
expressing LT in the absence of p27 would be  anchorage independent, thus 
encouraging tumourigenesis. 
In contrast with NS and NSLTRas cells, NSLT cells also exhibited new 
and unexpected behaviour in suspension.  Although proliferation in these cells 
was inhibited, DNA replication was not completely blocked.  This indicated that 
in the absence of the Rb checkpoint, LT cells were able to overcome G1 arrest, 
consistent  with  previous  observations  (Mann  and  Jones  1996).    Moreover, 
overreplication occurred if suspension was prolonged more than a few hours, 
suggesting that p27 is not sufficient to fully arrest or control the cell cycle in the 
absence  of  the  Rb  checkpoint.  NSLT  suspended  cells  also  exhibited 
aneuploidy, and an increase in the rate of spontaneous transformation.  These 
findings  suggest  that  in  checkpoint-deficient  cells,  upregulation  of  p27  may 
indirectly act to promote tumourigenesis by causing genome instability. 
A few studies have already linked p27 to genomic instability, but reports 
have been conflicting.  For example, one study found that p27 accumulation 
resulted in overreplication, in conjunction with overexpression of cyclin E and 
A,  which  is  consistent  with  our  results  (Nakayama  et  al.  2000).    However, 
others suggest that overexpression of p27 inhibits the emergence of aneuploidy 
in cancer cells (Chen et al. 1996b), or that p27 deficiency leads to an increase in 
genomic instability (Payne et al. 2008).  How can this discrepancy be resolved? 
One possibility is that a balanced oscillation of CDK activity, rather than overall 
activation or inhibition, is crucial for correct control of DNA replication, and 
the effect of increasing p27 therefore depends on cellular context.  Our results 
additionally suggest that checkpoint status is key in determining the outcome of 
increased p27: in conjunction with the Rb checkpoint, p27 strengthens G1 arrest 
and therefore safeguards genome stability; in the absence of Rb function, p27   167 
may be counterproductive, due to the adverse effects of inhibiting CDK activity 
during S phase, as discussed below. 
   
6.2 How p27 might induce genome instability 
Our  results  suggest  that  aberrant  DNA  replication  in  NSLT  cells  is 
caused  by  p27  upregulation  in  suspension  inhibiting  CDK  activity,  in  the 
absence of Rb and p53 checkpoints.  This is supported by the analogous results 
obtained using the CDK inhibitor Roscovitine in attached NSLT cells.  How 
could  CDK  inhibition  give  rise  to  genomic  instability?    Two  potential 
mechanisms are origin re-licensing, and replication stress, as described below.  
 
6.2.1 Origin re-licensing 
Replication licensing is normally strictly confined to late mitosis and 
early G1 phase, to ensure that each section of DNA is replicated only once 
(Nishitani and Lygerou 2002).  Moreover, there is evidence that deregulation of 
replication  licensing  proteins  contributes  to  aneuploidy  and  instability  of 
chromosome structure in cancer cells  and mouse models (Hook et  al. 2007; 
Blow and Gillespie 2008).  CDK activity plays an important role in controlling 
origin licensing in mammalian cells, as well as in yeast (Itzhaki et al. 1997; 
Bates et al. 1998; Coverley et al. 1998; Nguyen et al. 2001; Ballabeni et al. 
2004; Liu et al. 2004a; Porter 2008).  Robust switching between states of high 
and low CDK activity minimises the time where activity is ‘intermediate’ and 
the cell is vulnerable to inappropriate origin licensing or firing (Diffley 2004).  
Completion of mitosis, with its associated drop in CDK activity, is normally 
required  to  ‘reset’  pre-replicative  complexes  at  replication  origins  (Stillman 
1996), suggesting that an unscheduled reduction in CDK activity may permit 
origin re-licensing before sister chromatids are separated at mitosis, resulting in 
overreplication.    Thus,  in  NSLT  suspended  cells,  partial  inhibition  of  CDK 
activity during S and G2 phases could cause inappropriate origin licensing and 
re-firing, leading to an increased, unstable DNA content.  An alternative and 
non-mutually  exclusive  possibility  is  that  anchorage  is  itself  required  for 
regulation  of  replication  licensing  components:  for  example,  cdc6  has  been 
shown to require anchorage for its expression in fibroblasts (Jinno et al. 2002).    168 
This could impair licensing control in detached cells such that origin firing is 
uncoordinated, leading to incomplete replication, again producing an unstable 
genome. 
   
6.2.2 Replication stress 
The  second  potential  link  between  loss  of  anchorage  and  oncogenic 
transformation  could  be  replication  stress,  and  consequent  activation  of  a 
chronic DNA damage response, in NSLT suspended cells.  Replication stress 
has been reported in cancer cells as a result of the conflict between oncogene 
stimulation  of  proliferative  pathways,  and  normal  cell  cycle  checkpoints 
(Bartkova et al. 2006; Di Micco et al. 2006).  Importantly, this stress has been 
shown to occur very early in the tumourigenic process, and it is associated with 
DNA  damage,  as  shown  by  characteristic  markers  such  as  γ-H2AX  and 
activated Chk2 (Bartkova et al. 2005; Gorgoulis et al. 2005).  Loss of anchorage 
in NSLT cells could result in replication stress due to a similar conflict between 
loss of Rb activity, promoting proliferation, and p27-induced CDK inhibition, 
acting to impede cell cycle progression.  CDK inhibition in S phase would be 
predicted to result in the stalling of replication forks, and activation of a DNA 
damage response due to collapsed forks and unreplicated DNA.  The irregular 
BrdU  incorporation  in  suspended  NSLT  cells  suggests  that  replication  forks 
may indeed be stalling in S phase in response to CDK inhibition. 
  
Several observations suggest that LT-expressing cells with inactive p53 
and  Rb  may  be  prone  to  genomic  instability  following  replication  stress.  
Firstly, the absence of functional p53 removes the p21 checkpoint in G2 phase, 
allowing progression into mitosis in the presence of DNA lesions.  Rb loss has 
been shown to impair DNA damage-induced arrest and promote DNA double-
strand break formation (Sage et al. 2000; Pickering and Kowalik 2006).  Cells 
lacking Rb activity will overreplicate in response to cell cycle inhibition by 
either p21 or nocodazole, suggesting that p27 could have the same effect in 
NSLT cells (Niculescu et al. 1998; Srinivasan et al. 2007).  p53 has been shown 
to prevent rereplication in response to cdt1 and cdc6 overexpression (Vaziri et 
al.  2003),  and  both  p53  and  Rb  have  been  shown  to  be  required  for  the   169 
‘tetraploidy  checkpoint’  arrest  following  mitotic  slippage  (Iida  et  al.  2004).  
Finally, SV40 LT alone has recently been shown to promote a DNA damage 
response  (Hein  et  al.  2009).   Although  we  have  not  directly  assessed  DNA 
damage  in  our  NSLT  cells,  the  chromosome  complement  was  stable  and 
overreplication did not occur in attached cells: loss of anchorage was required to 
induce these changes.  This suggests either that LT is not sufficient to induce 
DNA damage in our system, or more interestingly that any damage incurred in 
attached cells is repairable, but detachment of the cell from the substratum and 
consequent CDK inhibition triggers replication stress and chronic damage.  In 
support of this idea, adhesion is required for arrest or apoptosis following DNA 
damage in fibroblasts (Gadbois et al. 1997; Lewis et al. 2002; Truong et al. 
2003).  This suggests that loss of anchorage could impair the damage response, 
as well as causing replicative stress.  An impaired DNA damage response in the 
presence  of  CDK  inhibition  has  already  been  demonstrated  in  human  cells, 
using the inhibitor drug Roscovitine (Jazayeri et al. 2005).  
 
6.3  Alternative  mechanisms  of  Ras-induced  anchorage 
independence 
The  finding  that  p27  is  responsible  for  preventing  anchorage-
independent proliferation in LT-expressing cells is neatly balanced by previous 
observations  showing  that  oncogenic  Ras  signalling  downregulates  p27  via 
Skp2-mediated degradation, as shown by the lower p27 levels in NSLTRas cells 
(Kawada et al. 1997).  This provides a ready explanation for the mechanism by 
which  Ras  evades  the  anchorage  checkpoint  in  this  system.    However,  it  is 
unlikely that this is the whole story.  Our finding that CDK activity is somewhat 
inhibited  in  NSLTRas  suspended  compared  to  attached  cells,  despite  no 
upregulation  of  p27,  points  to  the  existence  of  an  alternative  anchorage-
dependent  mechanism  of  regulating  CDK  activity.    Moreover,  the  colony-
forming ability of cells expressing LT and oncogenic Ras is higher than that of 
cells  expressing  LT  in  the  absence  of  p27  inhibition.    These  observations 
suggest that Ras promotes anchorage-independent proliferation in other ways, in 
addition to downregulation of p27.  Two other effects of Ras that are likely to 
be relevant to anchorage independence are described below.   170 
 
6.3.1 p73 isoform switching 
The  p53-related  transcription  factor  p73  is  found  in  two  forms:  an 
oncogenic “ΔN” form which cooperates with Ras to transform cells in the same 
way  as  loss  of  p53,  and  the  tumour-suppressive  “TA”  or  transactivation-
competent form (Grob et al. 2001; Petrenko et al. 2003).  Importantly, although 
p53 and p73 are related, LT does not bind or inhibit p73 (Marin et al. 1998).  
Beitzinger  et  al.,  using  a  model  system  that,  like  ours,  employs  LT  and 
oncogenic  Ras,  found  that  the  Ras-mediated  switch  between  anchorage-
dependent  and  independent  proliferation  was  associated  with  a  switch  from 
expression  of  the  TA  form  to  the  ∆N  form  of  p73,  via  PI3K  signalling 
(Beitzinger et al. 2008).  This study further demonstrated that knockdown of the 
TAp73 isoform was sufficient to induce anchorage-independent proliferation in 
the  LT-expressing  cells,  and  either  re-expression  of  TAp73,  or  depletion  of 
ΔNp73  prevented  anchorage-independent  proliferation  in  the  Ras-expressing 
cells.    Since  the  obvious  difference  between  the  two  p73  isoforms  is  their 
transcriptional activity, Beitzinger et al. also attempted to define relevant p73 
target genes that would explain the maintenance of anchorage dependence in 
their cells, though none so far has yielded a plausible explanation.  Given the 
precedent set by p53 and its control of the CDK inhibitor p21, the possibility 
remains  that  an  important  functional  target  of  p73  involved  in  anchorage 
dependence will be found. 
Related to this, and highly relevant to our results, is the recent discovery 
that  TAp73  also  plays  a  role  in  maintaining  genomic  stability,  in  particular 
suppressing  aneuploidy,  especially  when  p53  is  absent  (Talos  et  al.  2007; 
Tomasini et al. 2008).  Furthermore, previous work has indicated that adhesion 
is required for the DNA-damage-induced stabilisation of p73 (Lewis et al. 2002; 
Truong et al. 2003).  These combined results have intriguing parallels with our 
findings, and suggest that p73 destabilisation may contribute to the genomic 
instability of NSLT cells in suspension. 
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6.3.2 Role of the cytoskeleton in successful cell division and 
survival 
A recent report suggests that normal human fibroblasts can complete 
mitosis but not cytokinesis in suspension, leading to binucleation of suspended 
cells,  and  that  Ras  acts  to  promote  cytokinesis,  rescuing  this  phenotype 
(Thullberg et al. 2007).  Although this did not seem to be the case in our system, 
since  we  did  not  observe  a  large  increase  in  binucleate  cells,  the  idea  that 
cytokinesis may be a problem for suspended cells is intriguing, and suggests a 
particular role for altered cytoskeletal dynamics in Ras-transformed cells.  Since 
oncogenic  Ras  counts  many  cytoskeletal  regulators  amongst  its  effectors, 
including Rho and Rac (Marshall 1996; Rodriguez-Viciana et al. 1997; Klein et 
al. 2008), it is not unreasonable to predict that altered cytoskeletal dynamics 
contributes to the anchorage-independent proliferation of Ras-expressing cells 
by supporting cell division in suspension.   
The differing cytoskeletal conformations in NSLT and NSLTRas cells 
are suggested by their different morphologies in attached culture (see Figure 3-
1).  Cell shape, as well as integrin ligation, has been shown to be important for 
cell-cycle  progression  in  anchorage-dependent  cells  (Huang  et  al.  1998; 
Mammoto et al. 2004).  Cytoskeletal changes are also well known to affect cell 
division.  For example, a stiffened actin cortex during cell rounding is required 
for correct formation and orientation of the spindle at mitosis (Kunda et al. 
2008).  Both attached and suspended cells are rounded when entering mitosis, 
but attached cells remain tethered at key opposing points by narrow cytoplasmic 
projections  (Mitchison  1992).    The  correct  positioning  and  stability  of  the 
mitotic spindle is dependent upon balanced forces being set up between these 
projections,  and  if  the  cell  shape  is  artificially  distorted,  cells  may  develop 
multipolar  spindles  and  suffer  unequal  chromosome  segregation  (Grill  and 
Hyman  2005;  Théry  et  al.  2007).    In  suspension  cultures  such  as 
methylcellulose and soft agar, the cell has lost these orientated connections, and 
therefore  the  spindle  positioning  may  be  aberrant,  leading  to  aneuploidy.  
Furthermore,  generation  of  the  forces  involved  in  pulling  chromosomes  to 
opposite spindle poles may require altered cytoskeletal organisation and tension 
in the absence of such substrate tethering.  This could result in mitotic arrest in   172 
cells lacking the required cytoskeletal dynamics for division in suspension.  If 
attempts to complete mitosis in suspension were not successful after a certain 
amount of time, similarly to the response to a delay induced by spindle poisons, 
the cell could either die, or undergo a mitotic ‘slippage’, returning to G1 with a 
tetraploid set of chromosomes (Verdoodt et al. 1999; Chen et al. 2003b).  This is 
an attractive explanation for both the increase in cell death seen in NSLT cells 
after  prolonged  periods  in  suspension,  and  the  emergence  of  tetraploid  and 
aneuploid  cells.    We  can  also  speculate  that  the  lower  the  rigidity  of  the 
surrounding  matrix,  the  lower  the  tension  in  the  cytoskeleton  and  the  more 
difficult it would be for a cell to complete mitosis.  This idea is supported by the 
increased survival of cells observed in soft agar, a more solid support compared 
to methylcellulose suspension. 
 
6.4 In vivo relevance and implications for cancer therapy 
To  our  knowledge,  this  is  the  first  report  demonstrating  that  loss  of 
normal anchorage signals can lead to genomic instability and promote cellular 
transformation.  Based on these results, it is conceivable that the detachment of 
a checkpoint-deficient but non-cancerous cell from its normal environment (or 
simply a change in cell adhesion) could precipitate tumourigenesis, due to the 
development of genomic instability.  Should the cell detach from the tumour 
mass completely, this effect could promote tumourigenesis in a new location.  
This concept is supported by the finding that metastasis of single cells is not 
always a late event in tumour progression, and can occur before the cell has 
fully transformed (Hüsemann et al. 2008).   
In  the  present  case,  genome  instability  was  triggered  in  checkpoint-
deficient  cells  by  the  induction  of  p27  following  loss  of  normal  anchorage 
signals.  However, it would be predicted that inhibiting CDK activity by other 
mechanisms would have a similar effect.  Consistent with this, we found that the 
addition  of  moderate  doses  of  the  CDK  inhibitor  Roscovitine  to  checkpoint 
deficient cells when attached, produced an impaired DNA replication phenotype 
similar  to  that  induced  in  our  suspended  cells.    These  inhibitors  have  been 
developed in part as potential cancer therapeutics, several of which are currently 
in  clinical  trials,  including  Roscovitine  itself  (Malumbres  et  al.  2008;   173 
Malumbres  and  Barbacid  2009).    Additionally,  a  novel  p27-stabilising 
compound,  argyrin  A,  has  recently  been  identified  as  a  potential  cancer 
therapeutic, which prevents p27 degradation by inhibition of the proteasome and 
so would also be predicted to inhibit CDK activity (Nickeleit et al. 2008).  Our 
results suggest that doses of CDK inhibitors insufficient to completely arrest 
cell-cycle  progression  may  have  deleterious  consequences,  particularly  in 
checkpoint-deficient cells, by promoting gross chromosomal instability, which 
can increase the chances of tumour progression.  This could have implications 
for the long-term outcome of drug treatment, especially in patients with primary 
tumours that lack key tumour suppressor genes. 
 
6.5 Further work 
The broad interpretation of the results presented in this thesis indicates a 
novel link between disruption of cell adhesion and increased transformation.  
Further work should aim to strengthen the mechanistic links between loss of 
anchorage  signals,  genome  instability  and  tumourigenesis.    For  example, 
extrapolating  the  results  showing  soft  agar  colony  formation  following 
temporary  disruption  of  anchorage,  to  show  that  a  period  in  suspension  is 
sufficient  to  cause  NSLT  cells  to  form  tumours  in  nude  mice,  would  more 
firmly establish this connection. 
More molecular detail for the mechanism linking CDK inhibition and 
aberrant DNA replication is also needed.  Analysis of proteins involved in the 
formation of the pre-replication complex, such as MCMs, Cdt1 and geminin, 
would help identify any abnormalities in DNA licensing, and also determine 
whether  the  expression  of  any  licensing  components  (other  than  cdc6)  is 
anchorage dependent.  Additionally, detection of markers of DNA damage, such 
as γ-H2AX or phosphorylated Chk2, would show whether the overreplication 
seen  in  LT-expressing  cells  in  suspension  triggers  a  DNA  damage  response 
consistent with replication stress, and whether any damage incurred is repairable 
on reattachment of the cells.   
The induction of DNA overreplication and aneuploidy upon suspension 
of LT-expressing cells should be demonstrated in other cell types, as although 
features of the Schwann cell model have been reproduced in other systems, loss   174 
of anchorage may not represent a general mechanism of producing genomic 
instability in all cells.  For example, it would be interesting to see whether an 
‘immortalised’ epithelial cell type would exhibit a similar incomplete arrest and 
overreplication in suspension.  As well as being a more accurate model for the 
majority of cancers, which usually arise in epithelial tissues, this would also 
enable studies correlating the loss of E-cadherin and p27 downregulation with 
anchorage-independent  proliferation,  as  has  been  done  for  contact  inhibition 
(Motti et al. 2005). 
  Our results implicating CDK inhibition in the development of genome 
instability used Roscovitine, which inhibits both CDK1 and CDK2 activity.  An 
inhibitor more specific to CDK2 could be used to clarify the role of particular 
CDKs in rereplication and aneuploidy.  Investigation of other cell cycle kinases 
important  in  mitosis  and  the  spindle  checkpoint,  for  example  Aurora,  could 
further  elucidate  how  aneuploid  NSLT  cells  arose  in  suspension.    A  more 
detailed time course assay of kinase activity in NS cells directly after seeding in 
suspension would show whether CDK activity is maintained following loss of 
anchorage, to allow completion of mitosis and return to G1.   
Finally, other mechanisms that have been shown to induce anchorage 
independence in LT-expressing cells, such as expression of the ΔNp73 isoform, 
could be analysed in our system in comparison with oncogenic Ras expression.   
This would help isolate genetic targets representing the minimum requirements 
for anchorage-independent proliferation in mammalian cells. 
In summary, the results detailed in this study have highlighted a wider 
role  for  anchorage  in  cell  cycle  control.    Further  work  should  establish  the 
effects  of  altered  cell  attachment  in  different  systems,  and  reveal  the  full 
implications for genomic stability and cancer. 
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